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Sorsby’s fundus dystrophy (SFD) is a rare autosomal, dominantly inherited, degenerative 
disease of the retina that results in a loss of central vision in middle age. The disease is a 
single-gene disorder caused by specific mutations in the tissue inhibitor of metalloproteinase-
3 (TIMP3) gene on chromosome 22. The SFD phenotype is very similar to age-related 
macular degeneration (AMD), a very common cause of blindness in the elderly. These 
phenotypic similarities include drusen, thickened Bruch’s membrane, atrophy of choroid and 
photoreceptors and neovascularisation. While AMD is a multifactorial disorder that is not 
associated with mutations in TIMP3, increased levels of TIMP3 protein are observed in the 
retina of both diseases indicating TIMP3 could still play a role in this disease.  
Although the disease mechanism responsible for the SFD phenotype is still uncertain, the 
evidence implies that the phenotype results from a toxic effect of the mutant TIMP3, rather 
than haploinsufficiency. At the start of this project, ten of the known mutations were 
localised to the coding sequence of exon 5 comprising most of the C-terminal domain of the 
molecule and demonstrated to result in dimeric TIMP3. There were also two exceptional 
mutations, including a mutation in exon 1 that encodes part of the N-terminal domain 
(Ser15Cys), and a splice site mutation caused by a single adenosine insertion at the 
intron4/exon5 junction. Recently, three additional mutations, including Tyr128Cys, 
Tyr154Cys and Tyr159Cys, were also identified in exon 5 but their effects on TIMP3 had not 
been examined. Thus, the consequences of these exceptional mutations and the newly 
identified C-terminus mutations on TIMP3 were still unknown.  
We hypothesised that both SFD and ageing result in cross-linking of TIMP3 leading to 
formation of a toxic molecule that may play a role in both diseases. The initial aim of this 
project was to investigate the consequence of the TIMP3 splice site mutation and these other 
recently described mutations on the TIMP3 protein. The second aim was to examine the 
effects of SFD mutation on a number of potential target molecules and downstream 
pathways.  These included the interaction with tumour necrosis factor α converting enzyme 
(TACE) and its consequence for retinal pigment epithelial cell apoptosis; with vascular 
endothelial growth factor receptor 2 (VEGFR2) and its role in angiogenesis; with epidermal 
growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1), mutations in 
which also cause an inherited retinopathy, and finally to examine potential activation of the 
receptor for advanced glycation end-products (RAGE). 
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This research project confirmed that all examined TIMP3 mutations expressed by human 
retinal cells formed dimers, including the novel splice site mutant, which resulted in the 
formation of several abnormally spliced truncated products. Dimerisation, therefore, almost 
certainly plays a crucial role in the SFD disease process.  
Retinal pigment epithelial cells expressing these mutant proteins were more sensitive to Fas-
induced apoptosis than those expressing the normal protein, although we were unable to 
confirm if this was mediated by increased avidity for TACE.  Moreover, mutant TIMP3 
proteins had a pro-inflammatory effect relative to the wild-type molecule, as determined by 
NF-κB activation, likely mediated by RAGE, although this still needs confirmation.  Mutant 
proteins were, however, less effective at inhibiting VEGF-induced endothelial cell invasion 
than their wild-type counterpart, almost certainly due to decreased ability to inhibit VEGFR2, 
and this could explain the choroidal neovascularisation that accompanies SFD, despite the 
high levels of TIMP3 protein present in the retina.  Mutations in TIMP3, responsible for SFD 
and in EFEMP1, responsible for Malattia Leventinese, did not appear to impair their mutual 
interaction and we speculate that increased deposition of TIMP3/EFEMP1 complexes are a 
common feature of SFD, Malattia Leventinese and age-related macular degeneration, and this 
may in turn lead to sequestration of complement factor H, a known binding partner for 
EFEMP1, impairing regulation of complement activation in the retina.  If this proves to be 
the case, targeting the interaction between these three molecules may provide a novel 
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1. Introduction  
Tissue inhibitor of metalloproteinases 3 (TIMP3) is named for its ability to inhibit the matrix 
metalloproteinase (MMP) family of extracellular matrix (ECM) enzymes.  However TIMP3 
has a number of unique features that are not shared by the three other members of this family, 
including binding to the ECM and inhibition of vascular endothelial growth factor receptor 2 
(VEGFR2). This complex functionality is reflected in the fact that specific mutations in 
TIMP3 give rise to Sorsby’s fundus dystrophy (SFD), a dominantly inherited degenerative 
disease of the retina that leads to blindness, usually in middle-age. The functional 
consequences of these mutations, and the possible role of TIMP3 in other retinopathies is the 
topic of this thesis. 
In order to begin to understand how these mutations may contribute to the disease phenotype, 
it is necessary to appreciate the complex nature of the ECM and the other molecules that 
TIMP3 interacts with in this environment and this will be the topic of the following sections.  
I will then discuss what is currently know about the role of TIMP3 in SFD and the potential 
role for TIMP3 in other retinopathies, specifically age-related macular degeneration and 
Malattia Leventinese (ML). 
 
1.1 The extracellular matrix (ECM)  
The extracellular matrix is a three-dimensional network of macromolecules that surrounds 
cells within tissues.  The ECM constitutes a microenvironment, which provides a mechanical 
and structural support for tissues and cells (Hubmacher and Apte 2013, Kim et al. 2011, Mott 
and Werb 2004) but it is also an important repository of a vast array of growth factors and 
other potent molecules that play important roles in tissue development and homeostasis 
(Mouw et al. 2014).  It is composed primarily of water and a complex mixture of insoluble 
macromolecules, primarily proteoglycans (PGs) and fibrous proteins such as collagen, elastin, 
laminins and fibronectins (Frantz et al. 2010, Ruoslahti et al. 1985).  
 
1.1.1 ECM Components  
1.1.1.1 Proteoglycans  
Proteoglycans (PGs) are extracellular matrix macromolecules composed of a specific core 
protein with covalently attached glycosaminoglycan chains (Theocharis et al. 2010, Velasco 
et al. 2010). The glycosaminoglycans (GAGs) are linear and negatively charged polymers of 
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repeated disaccharide and classified into two types including sulphated and non-sulphated 
GAGs which can be present either on the cell surface or in the surrounding ECM (Velasco et 
al. 2010, Gandhi and Mancera 2008). Hyaluronic acid (HA) is the only entirely non-
sulphated GAG, whereas there are many sulphated GAGs including chondroitin sulphate 
(CS), keratan sulphate (KS), dermatan sulphate (DS) and heparan sulphate (HS).  
In nature, all these sulphated glycosaminoglycan chains are covalently bound to a core 
protein to form the proteoglycan. Proteoglycans are produced by all mammalian cells and 
categorised into three major groups depending on their location including extracellular 
secreted PGs, cell-surface associated PGs and soluble PGs present in ECM and serum 
(Theocharis et al. 2010, Gandhi and Mancera 2008). PGs include heparan sulphate 
proteoglycans (HSPGs) such as syndecans and glypicans, chondroitin sulphate proteoglycans 
(CSPGs) such as aggrecan and veriscan, and small leucine-rich repeats (SLRPs) such as 
decorin and biglycan (Mouw et al. 2014, Theocharis et al. 2010). They play a major role in a 
variety of physiological and pathological functions including cell growth and tissue 
maturation, organisation of the extracellular matrix, modulation of growth factor activity, 
development of the nervous system, regulation of cell signalling and growth and metastasis of 
tumour cells (Iozzo 1998, Perrimon and Bernfield 2001, Velasco et al. 2010).  Their ability to 
bind water also plays an important role in maintaining tissue hydration in, for example, 
articular cartilage and the cornea. 
 
1.1.1.2 Fibrous proteins  
1.1.1.2.1 Collagens 
Collagens are the major insoluble fibrous protein found in the ECM and the most abundant 
proteins in eukaryotes. Although there are at least 28 types of collagens reported in the 
literature (Kim et al. 2011), only three types including I, II and III constitute 90% of the 
collagen in the body. The 28 reported collagens have different sizes, structure and function 
but they have common characteristics. For instance, they are either trans-membrane or 
extracellular molecules and consist of three α-chains comprising two α1-chains and one α2-
chain that form a triple helical structure that is a repetition of Gly-X-Y, with X or Y 
commonly being proline or hydroxyproline, respectively (Hubert et al. 2009, Mouw et al. 
2014). It is well known that the primary function of collagens is to provide support and 
binding partners for other proteins in the ECM, but they are also involved in a diversity of 
biological processes such as neural development and tumourigenesis (Hubert et al. 2009). 




1.1.1.2.2 Elastin  
Elastin is the dominant extracellular matrix protein in vertebrate connective tissues; for 
example, arterial blood vessels, skin and lungs (Daamen et al. 2007, Keeley et al. 2002). It is 
synthesised by a variety of cells, such as fibroblasts, smooth muscle and endothelial cells, and 
secreted into the extracellular space as a soluble precursor named tropoelastin and 
subsequently undergoes specific post-translation modifications, and becomes a highly cross-
linked molecule that binds to another molecules through lysines generating elastin fibres 
(Daamen et al. 2001, Daamen et al. 2007). Like collagens, elastin is a hydrophobic protein 
composed of uncommon amino acids including Gly, Val and Ala (around 75%), in which Gly 
account for 30% of the amino acids residues (Daamen et al. 2007, Vrhovski and Weiss 1998). 
Elastin plays an important role in supporting healthy cells and providing elastic tissues with 
the required resilience, allowing them to stretch and recoil (Almine et al. 2010). 
 
1.1.2 ECM in the eye  
All complex tissues such as cartilage, bones and teeth have their own specific ECM 
configuration and this is particularly apparent in the eye, which clearly contains some very 
specialised cell matrices in the cornea, lens and vitreous cavity, enabling light penetration 
through to the retina (Figure 1.1). The retina itself is an extremely complex structure 
containing several layers of highly specialised cell types (Figure 1.1).  These structures are 
supported by ECM, which is particularly predominant in the basement membranes of the 
inner limiting membrane (ILM) that forms the innermost layer of the retina adjacent to the 
vitreous body and Bruch’s membrane that separates the choroid from the retinal pigment 
epithelium.  Bruch’s membrane is of particular importance clinically as this structure is 
affected in age-related macular degeneration (AMD) and several other retinal diseases, 
including Sorsby’s fundus dystrophy (SFD) and Malattia Leventinese (ML).   
 
1.1.2.1   Bruch’s membrane 
Bruch’s membrane (BM) is a unique thin layer of tissue in the eye, occupying the space 
between the retinal pigment epithelium and the choroid. The BM was originally named the 
lamina vitrea due to its glassy appearance; and later renamed after the German anatomist Carl 
Ludwig Wilhelm Bruch who first isolated and described the membrane in his doctoral thesis 
in 1844. In the past, it was considered to be a simple sheet of extracellular matrix; however it 
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is now known to play crucial roles in retinal function, ageing and retinal diseases. The BM is 
a pentalaminar structure consisting of five layers: the basement membrane of the RPE, inner 
collagenous layer, elastin layer, outer collagenous layer and the basement membrane of the 
choriocapillaris (Figure 1.1 B, Table 1.1).  The pentalaminar membrane works as a single 
functional unit and is involved in the exchange of numerous biomolecules, nutrients, fluid, 
oxygen and waste products between its tissues and the general circulation. The properties of 
BM vary with factors such as genetics, age, environment, diseases and retinal location, and 
each human individual has unique BM properties affecting the development of normal vision 
and retinal disease. (Curcio and Johnson 2012, Booij et al. 2010) 
Bruch’s membrane undergoes significant structural and molecular age-related changes, and 
ageing is the strongest risk factor for developing AMD. However, those changes that have no 
direct clinical consequences and appear in the majority of individuals with time, are 
considered normal ageing. Currently, it is believed that AMD is a more severe form of the 
normal ageing process in RPE and Bruch’s membrane. RPE cells are responsible for the 
synthesis of the structural elements of Bruch’s membrane; for example, laminin, collagen 
type I and IV, metalloproteinases and their natural inhibitors (Alcazar et al. 2009, Nita et al. 
2014).  A high metabolic rate in RPE and photoreceptor cells; exposure to light and high local 
oxygen pressure lead to high levels of oxidative stress and participate in Bruch’s membrane 
changes (Booij et al. 2010). A proteomic analysis of the Bruch’s membrane and choroid from 
human post-mortem AMD patients was carried out by Yuan et al. (2010), who found that 99 
out of 901 proteins had significantly altered levels of expression compared to controls. 
Among the elevated proteins were several complement proteins and complement-associated 
proteins, damage associated molecular pattern proteins (DAMPs), inflammatory response 
proteins and regulatory protein such as TIMP3 and α1-microglobulin (Crabb et al. 2002, 
Crabb 2014, Sparrow et al. 2012, Yuan et al. 2010).  
  
























Figure 1.1: Illustration of different retinal layers in the human eye. 
(A) Anatomy of the normal eye. (B) A cross-section slice of the retina demonstrating 
detailed layers. The retina layers were drawn using Servier medical art website 










































Table 1.1: Protein components of regular human Bruch's membrane (BM). 
PGs: proteoglycans; HSPGs: heparan sulphate proteoglycans; E/N: 
entactin/nidogen; LAM: laminin. 
Retina Layers Compositions 
RPE basic membrane 
Collagen IV & V, laminins, fibulins, PGs (HSPGs), E/N, 
LAM 
Inner collagen layer Collagen I, III & V, fibronectin, fibulins, HSPGs 
Elastin layer Elastin collagen VI, fibronectin, fibulins, HSPGs, TIMP3 
Outer collagen layer Collagen IV, V & VI, fibronectin, fibulins, HSPGs 
Choriocapillaris basic 
membrane 




1.1.3 Extracellular matrix function and degradation  
As already documented, the ECM provides structural support, tensile strength and scaffolding 
for cells and tissues. Additionally it has diverse roles in most basic cell behaviour including 
proliferation, differentiation, adhesion, migration and apoptosis. Czyz and Wobus (2001); for 
example, demonstrated that the differentiation of embryonic stem cells is determined by 
various extracellular matrix components, while other studies showed that embryonic stem 
cells can be grown and differentiated into cells with retained fundamental characteristics on 
Matrigel, a commercial cell matrix material secreted by mouse sarcoma cells which contains 
various ECM components such as collagen VI, laminin-1 and growth factors as well as 
suitable growth medium (Guilak et al. 2009, Xu et al. 2001). The ECM also acts as a storage 
depot for cytokines, growth factors and chemokines that are released upon ECM degradation 
(Hubmacher and Apte 2013, Kleinman et al. 2003, Lu et al. 2011). Moreover cleavage of 
certain ECM components, such as collagen IV and laminin-5, exposes cryptic peptides that 
facilitate cell migration (Kessenbrock et al. 2010). 
ECM degradation is an important mechanism that regulates cell differentiation and tissue 
remodelling in embryonic development, bone remodelling, angiogenesis and wound repair. 
For example, in angiogenesis endothelial cells respond to changes in ECM composition such 
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as cleavage of fibrillar type I collagen and show increased expression of integrins that 
mediate attachment to ECM components such as collagens and laminins (Seandel et al. 2001, 
Stupack and Cheresh 2002). In contrast, abnormalities in the ECM dynamic lead to 
pathological conditions such as tissue fibrosis and cancer.  In cancer, for example, cleavage 
of ECM components by enzymes such as matrix metalloproteinases enables tumour growth, 
releases growth factors, facilitates angiogenesis and triggers endothelial to mesenchymal 
transition (EMT) promoting metastasis (Gialeli et al. 2011). 
 
1.1.4 Proteinases in ECM degradation and remodelling  
As the ECM contains a wide range of structurally and biochemically diverse components that 
undergo either degradation or modification processes during ECM remodelling, there are a 
large number of different proteinases to carry out these processes. Proteinases are classified 
into five main groups based on their chemical groups implicated in the hydrolysis of peptide 
bonds (Cawston and Young 2010). The five main proteinases groups include cysteine, 
aspartate, threonine, serine and metalloproteinases. Metalloproteinases including MMP 
(matrix metalloproteinases) and ADAM/ADAMTS (a disintegrin and metalloproteinases and 
a disintegrin and metalloproteinase with thrombospondin motifs, respectively) are considered 
the most significant extracellular enzymes in ECM remodelling (Cawston and Young 2010, 
Lu et al. 2011). Whilst serine proteinases such as cathepsin G and plasmin are extracellular 
proteinases working at neutral pH, cysteine, threonine and aspartate proteinases digest 
intracellular proteins at acidic pH (Cawston and Young 2010). However, some of the 
intracellular cysteine proteases, including cathepsins B and L, can be secreted and have the 
ability to digest ECM proteins (Burke et al. 2003, Guenette et al. 1994, Green and Lund 
2005).  The next section focuses on the extracellular metalloproteinases, specifically the 
MMP, ADAM and ADAMTS families, which are inhibited by TIMPs.  
 
1.2 The metzincin superfamily 
The metzincin proteinase superfamily are distinguished by containing a zinc ion and 
conserved methionine residue at their active site (Bode et al. 1993, Stocker et al. 1995) which 
comprises a conserved HEXXHXXGXXH...M amino acid sequence, where X can be any 
amino acid and the distance between the distal His and Met residues can vary. The Met 
residue forms a hydrophobic “seat” for the zinc ion which is chelated by the three His 
residues.  The family comprises MMP (also known as matrixins), ADAM, ADAMTS (known 
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collectively as adamlysins), astacin and pappalysin families, with the first three families 
being by far the most abundant in the ECM and these will be considered in more detail in the 
following section. 
 
1.2.1 Matrix metalloproteinases  
To date, there are 23 different MMPs found in humans and most vertebrates (Lu et al. 2011, 
Bonnans et al. 2014), which share many common structures and functions. Confusingly 
human MMPs are numbered up to MMP28, which is largely a result of some being named 
before their sequences had been verified, resulting in some duplication.  They have been 
categorised based on sequence similarities, domain organisation and substrate specificity 
(Table 1.2).  
 
1.2.1.1 MMP structure 
The mammalian MMPs share a common conserved structure that contains several domains 
including an autoinhibitory pro-domain, a catalytic domain, a flexible hinge motif and a 
haemopexin domain (Lu et al. 2011, Nagase and Woessner 1999, Page-McCaw et al. 2007) 
(Figure 1.2). The pro-domain at the N-terminus consists of a conserved cysteine residue 
coordinating to the zinc ion at the active site to inhibit catalysis. Destabilisation and cleavage 
of the pro-domain, usually by plasmin or other MMPs, uncovers the active site resulting in 
activation of the enzyme, a process known as the “cysteine switch”. The catalytic domain 
comprises a conserved methionine and specific zinc binding amino acids sequence, three α-
helices, five-stranded β-sheet and bridging loops. It also has calcium ions (two or three) and 
an extra zinc ion that provides structural stability required for enzymatic activity. The 
catalytic domain is linked to the haemopexin domain through a proline-rich linker peptide. 
The haemopexin domain is located at the C-terminus of MMP structure and contains a four-
bladed β-propeller structure, each of which consists of an α-helix and four antiparallel β-
strands, that function as a mediator for protein-protein interaction, which contributes to a 
variety of interactions such as enzyme activation, substrate recognition and protease 
localisation (Page-McCaw et al. 2007). However, MMP21 and 22 contain three different 
regions including cysteine-rich, proline-rich and IL-receptor like domains at their C-terminus 
instead of the haemopexin domain (Gururajan et al. 1998). 
  




Table 1.2: Members of matrix metalloproteinases family. 














Collagens type-I, -II, -
III, -VII & X; entactin; 
gelatines; tenacsin; link 
protein; perlecan and 
aggrecan. 
α1-antichymotrypsin; 
CTGF; IGFBP-2, -3 








Collagens type-I, -II & 
-III; aggrecan; gelatins 








Collagens type-I, II, III, 
IV, IX, X & XIV; 
osteonectin; perlecan; 












Gelatins; elastin; link 
protein; aggrecan; Ln; 
elastin; Fn; collagens 
type-IV, -V, -VII, -X 
and -XI. 
Galectin-3; IGFBP-5; 












entactin; aggrecan; link 
protin; elastin; N-
telopeptide of collagen 




3; α1-PI; kit-L; IL-2 








Type-III, IV, IX & X 
collagens; gelatins; 
tenascin; aggrecan; 
perlecan; decorin; link 




α2-M; CTGF; uPA; 
proIL-1β; IGFBP-3; 








Type-III, -IV & -V; Ln; 
Fn; link protein; 
aggrecan. 
Pro-1, -8 & -10. 
8 MMP11 Furin-activated Aggrecan; Fn; gelatins; α1-PI;  IGFBP-1;   
















gelatins; aggrecan; FN; 
link protein; tenascin; 





















11 MMP28 (Epilysin) 
Furin-activated 













13 MMP19   (RASI-1) 
Haemopexin 
domain 
Collagen type-IV; Fn; 








COMP; aggrean. Unknown. 
15 MMP-21 Haemopexin domain Unknown. Unknown. 
16 MMP27 Haemopexin domain Unknown. Unknown. 
No Membrane-anchored MMP 
17 






Type-I, -II & -III; 
aggrecan; Ln; Ln-5; 











Perlecan; nidogen; Fn; 















20 MMP24     Type I 
Transmembrane 
PG. ProMMP-2. 





MMP17   
  (MT4-
MMP) 
GPI-linked Gelatins; fibrinogen.  Unknown.  
22 
MMP25    
 (MT6-
MMP) 











                                     
  




















Figure 1.2: Domain structure of the metalloproteinases. 
The figure illustrates domain arrangement of MMP family members based on 
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1.2.1.2 MMP functions 
MMPs are produced as inactive zymogens that have a signal peptide allowing them to be 
either secreted to the extracellular space or anchored to the surface of the cell (Bonnans et al. 
2014, Carmeliet et al. 1997, Fanjul-Fernandez et al. 2010). As already mentioned, most 
MMPs are activated by proteolytic cleavage of the pro-domain extracellularly. However, 
there are some exceptional MMPs regarding their presence in the extracellular space and 
activation. For example, a number of MMP family numbers were also found in the 
intracellular space such as MMP-1, MMP-2, MMP-11 and MMP-13 (Cuadrado et al. 2009, 
Limb et al. 2005, Luo et al. 2002). Also, MMP-11, MMP-21 and MMP-28 are intracellularly 
activated by furin-like protease and then secreted as active forms.  
It is well known that MMPs function as ECM degradation enzymes; however, their 
proteolytic activities influence a variety of essential cellular and physiological processes. For 
instance, releasing cytokines and growth factors, cell adhesion, migration and proliferation, 
uterine and mammary involution, wound healing, bone development and angiogenesis 
(Fanjul-Fernandez et al. 2010, Page-McCaw et al. 2007, Rowe and Weiss 2008, Yamamoto 
et al. 2015). Numerous studies have shown that dysregulation of MMPs or their inhibitors 
result in a wide range of pathologies such as lung diseases, cardiovascular diseases, cancer, 
arthritis and different type of inflammatory diseases (Fanjul-Fernandez et al. 2010, Gaggar et 
al. 2011, Nagase and Woessner 1999).  
 
1.2.1.3 MMP regulation 
Under normal physiological conditions, MMPs activities are regulated at various levels 
including gene expression, precursor zymogen activation (the cysteine switch), binding to 
ECM components and specific inhibition (Tallant et al. 2010, Yamamoto et al. 2015). 
Although most MMPs are regulated transcriptionally and expressed in response to cytokines, 
hormones and growth factors, some are stored in inflammatory cell granules to restrict their 
action. Active MMPs are regulated by endogenous inhibitors such as α2-macroglobulin (α2M) 
for plasma associated MMPs and tissue inhibitors of metalloproteinases (TIMPs) for 
extracellular matrix MMPs (Brew and Nagase 2010, Yamamoto et al. 2015). 
 




In mammals adamalysins comprise two proteinase families, a disintegrin and 
metalloproteinase (ADAM) and a disintegrin and metalloproteinases with thrombospondin 
motif (ADAMTS) (Giebeler and Zigrino 2016). 
  
1.2.2.1 ADAM and ADAMTS  
ADAMs were originally also known as MDC proteins 
(metalloproteinase/disintegrin/cysteine-rich) (Giebeler and Zigrino 2016). To date 40 
members of ADAM family have been identified in the mammalian genome, of which 22 
ADAM genes have been described in humans (Table 1.3). In contrast to MMPs, only 12 of the 
human ADAMs encode proteolytically active proteins (Bode et al. 1993, Khokha et al. 2013, 
Reiss and Saftig 2009), with the remainder largely playing roles in cell adhesion via their 
disintegrin domains.  On the other hand all of the known ADAMTS genes in mammalian 
genomes are proteolytically active and generally target proteoglycans.  There are 19 known 
ADAMTS genes in humans, but these are named from 1 to 20 (Table 1.4), due to some, 
specifically ADAMTS11 and ADAMTS5, being assigned to the same gene that encodes the 
protein aggrecanase-2 (Abbaszade et al. 1999, Hurskainen et al. 1999, Kelwick et al. 2015, 
Porter et al. 2005).  
As their names suggest, ADAMs and ADAMTS share many structural features including 
metalloproteinases domain, pro-domain and disintegrin domain (Figure 1.3 & Figure 1.4). 
Despite the fact that they have common structural domains, there are also some significant 
differences, the most notable of these being ADAMs have transmembrane and cytoplasmic 
domains and are membrane bound molecules, although ADAM9 and ADAM12 have also 
been reported to have shorter, soluble variants (Gilpin et al. 1998, Hotoda et al. 2002), 
whereas ADAMTS proteinases lack a transmembrane domain but have varying numbers of 
thrombospondin-like repeats and are secreted proteinases (Lu et al. 2011).  
Several ADAMs have the ability to cleave transmembrane protein ectodomains, releasing 
adhesion molecules, growth factor receptors and cytokines, giving then the name 
“sheddases”. The ADAMTS are secreted proteinases and include aggrecanases and pro-
collagen-N-propeptidases that cleave matrix proteoglycans and collagens (Type I, II, and III), 
respectively (Bonnans et al. 2014, Kelwick et al. 2015). The disintegrin domain of the 
adamalysins is implicated in cell/cell cell/matrix interactions through binding integrins, while 
the Cys-rich domains bind to heparan sulphate proteoglycans. 
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ADAMs play important physiological roles in spermatogenesis, sperm-egg fusion, heart 
development, neurogenesis and morphogenesis in pancreas, kidney and lung. They have been 
also been implicated in playing pathological roles in diseases such as Alzheimer’s, asthma, 
chronic inflammatory diseases, cancer, Duchenne muscular dystrophy and cone-rod 
dystrophy (Dreymueller et al. 2015, Giebeler and Zigrino 2016, van Goor et al. 2009). 
Similarly, ADAMTS plays an important role in a wide range of physiological processes; for 
instance, maintenance and development of tissues, extracellular matrix turnover, ovulation 
and blood coagulation. In addition, their dysregulation and mutations have been implicated in 
several pathologies such as arthritis, atherosclerosis, cancer, central nervous system disorders 
and thrombotic thrombocytopenic purpura (TTP) (Cal and Lopez-Otin 2015, Gottschall and 
Howell 2015, Kumar et al. 2012, Levy et al. 2001, Rocks et al. 2008).  




Table 1.3: Members of the ADAM family. 































Pseudogene Unknown • Similar to ADAM1 
ADAM5 tMDC II Pseudogene Unknown • Production and development of sperm 
ADAM6 tMDC IV Pseudogene Unknown • Similar to ADAM5 
ADAM7 GP-83, EAP 1 
Non-
proteinase Unknown • Similar to ADAM5 




• Sheddase; fertilised egg 
implantation; neurogenesis 











• Sheddase; organ 
development such as heart; 
pancreas and nervous 
tissue; cell migration 
• Alzheimer’s disease; breast 
cancer  








• Sheddase; development of 
pancreas and nervous tissue 
• Inflammation; Alzheimer’s 
disease; cancer  
ADAM 11 MDC Non-proteinase Unknown 














• Sheddase; fertilised egg 
implantation; adipogenesis; 
myogenesis  
• Breast cancer; cardiac 










• Implantation of fertilised 
egg 
• Inflammatory bowel 
disease; atherosclerosis; 
cardiac hypertrophy and 
failure; glomerulonephritis; 
angiogenesis; cancer  
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• Sheddase; neurogenesis; 
organ development 
including heart, lung, 
pancreas 
• Inflammation including 
arthritis, inflammatory 
bowel disease, and 
psoriasis; atherosclerosis; 
cardiac hypertrophy and 
failure; Alzheimer’s 
disease; breast and 
pancreatic cancer; 
Glomerulonphritis  





ADAM19 FKSG34, Meltrin-β Proteinase 
RANKL, 
proneurgulin 
• Sheddase; fertilisation and 
spermatogenesis; 
development of 
cardiovascular, kidney and 
neuron organs 
• Ventricular septal defect; 
valvular stenosis; brain 
cancer; glomerulonephritis; 
allograft nephropathy 
ADAM20 P Proteinase Unknown  • Similar to ADAM18 
ADAM21 ADAM31 Proteinase Unknown  • Neurogenesis; sperm-egg fusion; Sperm formation 
ADAM22 MDC2 Non-proteinase Unknown  
• Neurogenesis 
• Cancer  










• Spermatogenesis; Teeth 
development; Growth 
factor metabolism  
• Breast cancer  
ADAM29 svph 1 Non-proteinase Unknown  
• Cancer and similar to 
ADAM20  
ADAM30 Svph 4 Proteinase Unknown  • Similar to ADAM20  
ADAM32 AJ131563 Non-proteinase Unknown  • Similar to ADAM20  




• Lung development 
• Genetically implicated in 
bronchial asthma 











































Figure 1.3: Structure of ADAM family members. 
Demonstration of ADAM domain organisation was drawn according to Giebeler and 
Zigrino (2016) and Khokha et al. (2013). Dis-RGD: contains a RGD amino acid 
sequence, only ADAM15; Dis-xCD: contains a conserved consensus-binding motif. 
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Table 1.4: Members of ADAMTS family.  
Based on Dubail and Apte (2015), Kelwick et al. (2015), Kumar et al. (2012) and van 





names Substrates Function in health and disease 




• Ovulation; implantation of fertilised 
egg; bone development 







III & -V 
fibrillar 
procollagens 
• Dermatosparaxis type VIIC, Ehlers-












• Development of bone and adipose 
tissue 









• Implantation of fertilised egg; bone 
and adipose tissue formation 
• Brain cancer; anti-angiogenic and 
anti-tumorigenic; arthritis 
ADAMTS6 - - • Unknown  
ADAMTS7 - COMP • Coronary artery disease 
ADAMTS8 METH-2 Aggrecan • Unknown  
ADAMTS9 KIAA1312 Versican, aggrecan • Anti-angiogenic in cancer 
ADAMTS10 - Fibrillin-1 • Weill-Marchesani syndrome  
ADAMTS12 - COMP • Asthma; Pro- and anti-tumorigenic 
ADAMTS13 vWFCP vWF 







• Multiple sclerosis  
ADAMTS15 - Verican, aggrecan 
• Anti-angiogenic; anti-tumorigenic; 
metastatic 
ADAMTS16 - Aggrecan • Hypertension 
ADAMTS17 LOC123271, FLJ32769 - • Weill-Marchesani-like syndrome 
ADAMTS18 HGNC:16662, ADAMTS21 Aggrecan 
• Microcornea, myopic chorioretinal 
atrophy and telecanthus (MMCAT) 
ADAMTS19 - - • Unknown  
ADAMTS20 - Versican • Unknown  
  




Figure 1.4: The ADAMTS family members.  
Illustration of ADAMTS structure depending on their domain organisation into groups 
including aggrecanase/proteoglycanase, procollagen N-propeptidase, von wilbrand 
factor cleaving protease (ADAMTS13), and those cleaving cartilage oligomeric 
matrix protein (COMP), and those ADAMTS ungrouped. (Kelwick et al. 2015, 
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1.3 The TIMP Family  
A variety of cell types, such as fibroblasts and macrophages, epithelial and endothelial cells, 
secrete small proteins termed tissue inhibitors of metalloproteinases (TIMPs) into the 
extracellular matrix. They are considered to be the major inhibitors of MMPs. TIMP1 was the 
first TIMP identified as a protein in human fibroblast culture medium and human serum and 
shown to inhibit collagenases (Bauer et al. 1975, Woolley et al. 1975). Three other TIMPs 
have been recognised in vertebrates and named TIMP2, TIMP3 and TIMP4. Genes for human 
TIMP1, TIMP2, TIMP3 and TIMP4 were mapped to the X-chromosome Xp11, 3-Xp11.23 by 
Willard et al. (1989), chromosome 17q25 by De Clerck et al. (1992), chromosome 22q12.1-
q13.2 by Apte et al. (1994) and 3p25 by Olson et al. (1998), respectively.   
 
1.3.1 TIMP structure  
The four mammalian TIMPs have molecular weights between 21 to 29 kDa and comprise 184 
to 195 amino acids excluding their signal sequences. Each TIMP contains 12 cysteine 
residues and two distinctive domains comprising the N-domain (about 125 amino acids) and 
the C-domain (about 65 amino acids), each of which is stabilised by three disulphide bonds. 
(Figure 1.5)  
While all TIMPs have a similar three-dimensional structure, constrained by the six disulphide 
bonds and a shared ability to inhibit MMPs, sequence conservation between family members 
is fairly low with only about 40% identity (Brew and Nagase 2010) (Figure 1.6). In contrast, 
sequence conservation of each family member between species is very high, with TIMP3 
being exceptional in this respect with, for example, human and chicken TIMP3 being 82% 
identical (Figure 1.7). The N-terminal domain of the TIMPs alone has been shown to be a 
completely active inhibitor of MMPs. In contrast, the C-terminal domain seems to give rise to 
the individual differences between TIMPs. For these reasons, each TIMP is believed to have 
a unique physiological role. (Li et al. 2005)  
  





Figure 1.5: TIMP primary structure. 
N-terminus is represented by pale blue circles including loop 1, 2 and 3 while the C-
terminus is represented by pale green including loop 4, 5 and 6, and disulphide 
















Figure 1.6: Multiple sequence alignment of human TIMP proteins. 
Sequence alignment of human TIMP proteins in which the dark grey shaded letters 
refer to identical residues, pale grey to similar residues and the khaki coloured to 
cysteine residues. 
  





Figure 1.7: Alignment of TIMP3 protein sequence from various species.  
Identical residues are highlighted in dark grey and similar residues in light grey. 
There is 100% identity between primate sequences, 96% identity between 
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1.3.2 TIMP function  
TIMPs participate in numerous biological phenomena; for instance, cell proliferation, 
invasion and migration of cells, angiogenesis, apoptosis and synaptic plasticity, some of 
which are independent of their main inhibitory function against MMPs. (Olson et al. 1998, 
Stetler-Stevenson et al. 1992)  
 
1.3.3 MMP inhibition  
As described earlier, TIMPs are defined as natural inhibitors of MMPs. Most MMPs are 
inhibited by all TIMPs; however, different specificities and binding affinities have been 
noticed. For instance, MMP-3 and MMP-7 are weakly inhibited by TIMP-2 and -3 whereas 
TIMP-1 is a better inhibitor (Hamze et al. 2007). TIMPs inhibit MMPs through a 1:1 non-
covalent binding at the active site. The binding involves the N-terminal Cys residue of the 
TIMP co-ordinating with the Zn²+ (Nagase et al. 2006) in a similar manner to the Cys residue 
of the pro-domain of the latent enzyme. Some TIMPs also have a broader inhibitory action 
that encompasses inhibition of ADAM and ADAMTS enzymes.   
 
1.3.4 Cell growth promotion  
Sequencing of TIMP1 cDNA revealed that it was identical to an erythropoietin potentiating 
factor sequence involved in erythroid progenitor cell proliferation (Brew and Nagase, 2010). 
TIMP1 also stimulates the growth of other cell types such as keratinocytes, chondrocytes and 
fibroblasts (Bertaux et al. 1991, Hayakawa 1994). TIMP2 has also been seen to have 
erythroid potentiating activity (Stetler-Stevenson et al. 1992) as well as promoting cell 
growth in many cell types including metanephric mesenchyme cells (Barasch et al. 1999, 
Hayakawa et al. 1994). 
 
1.3.5 Cell growth inhibition  
In contrast to the above, several studies suggest that both TIMP1 and TIMP2 are able to 
reduce the growth rate of some cells. For instance, Taube et al. (2006) showed that TIMP1 
reduced the growth rate of human breast epithelial (MCF10A) cells via inducing cell cycle 
arrest at G1. In addition, TIMP2 was shown to have a suppressive effect on the mitogenic 
response to tyrosine kinase-type receptor growth factors through activation of adenylate 
cyclase and increase the level of intracellular cAMP (Hoegy et al. 2001).  




1.3.6 Inhibition of angiogenesis 
Angiogenesis (see section 1.4.1.4.1) requires the activity of MMPs to enable endothelial cell 
migration and vessel remodelling and so it is assumed that TIMPs will play a role in 
regulating this process.  However TIMP2 and TIMP3 have also been shown to inhibit 
angiogenesis independently of their ability to inhibit these enzymes.  For TIMP2 this appears 
to be mediated by interaction with α3β1 integrin (Seo et al. 2003). For TIMP3 it is mediated 
by direct binding to vascular endothelial growth factor receptor 2 (VEGFR2) (Qi et al. 2003) 
(see section 1.4.1.4). 
 
1.4 TIMP3 
The third member of the TIMP family was firstly identified in chicken and designated 
ChIMP3. Pavloff et al. (1992) described ChIMP3 cDNA as encoding a mature protein that 
consists of 212 amino acids with a molecular mass of 21 kDa, comprising a signal peptide 
(24 a.a) followed by 188 a.a. mature protein sequence. Whilst ChIMP2 was found in the 
media produced by chicken embryonic fibroblasts, ChIMP3 was observed as a component of 
the extracellular matrix. Mouse and human TIMP3 genes were subsequently cloned (Leco et 
al. 1994) and shown to display the same ECM binding ability.  
The TIMP3 gene maps to the long arm of chromosome 22, specifically to the q12.1-q13.2 
region (Apte et al. 1994). The organisation of the human TIMP3 gene was described by Stohr 
et al. (1995) who reported that the gene is encoded by 5 exons, which span approximately 55 
kb of human genomic DNA (now shown to be 61.3kb) and lacks a TATA box region. As a 
result of using alternative polyadenylation signals, the TIMP3 gene gives rise to three 
different mRNAs encompassing 2.4, 2.8 and 5 kb transcripts but all with identical open 
reading frames. The TIMP3 gene has a promoter region in which the first 112 bases were 
found to have the ability to give high basal level expression in growing cells. (Wick et al. 
1995) (Figure 1.8) 
The expression of murine TIMP3 mRNA was observed by Apte et al. (1994) in many tissues 
including the placenta, heart, kidney, liver and the brain, with the highest expression level in 
the placenta and the lowest level was in the brain. Human and mouse TIMP3 were expressed 
in mouse NSO myeloma cells and produced an N-glycosylated 27 kDa protein which was an 
efficient inhibitor of MMPs. In addition, Ruiz et al. (1996) showed that TIMP3 mRNA was 
expressed by human retinal pigment epithelium. A later study was conducted to investigate 
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the ocular site of TIMP3 expression using in situ hybridization of albino mouse eyes and 






Figure 1.8: Gene structure of human TIMP3. 
5’ and 3’ flanking regions are indicated by lilac lines, coding exons by solid coloured 
boxes, non-coding exons by narrow boxes and introns by solid lines in blue. 




























                                                                                                                                   
49 
 
1.4.1 Novel properties of TIMP3  
As outlined in section 1.3.1, TIMP3 is extremely highly conserved across species and this 
probably reflects that it has been shown to engage in a number of interactions, in addition to 
MMP inhibition, and these will be discussed in more detail in the following sections. 
 
1.4.1.1 Localisation to the ECM   
TIMP1, TIMP2 and TIMP4 are all soluble proteins whereas TIMP3 is strongly bound to the 
ECM. Leco et al. (1994); for example, observed the expression of TIMP3 in the COS-1 cell 
line which gives rise to a 24 kDa protein that localised to the ECM.  
Langton et al. (1998) investigated the functional domains of TIMP3 by expression in COS-7 
cells. This showed that TIMP3, either in its unglycosylated (24 kDa) or glycosylated (27 
kDa) forms, was completely localised to the ECM, whilst a carboxyl terminal domain deleted 
TIMP3 lost its ECM localisation properties. A chimeric TIMP containing the amino terminal 
domain of TIMP2 and the carboxyl terminal domain of TIMP3 showed ECM binding.  
TIMP3 binds to heparin sulphate and sulphated glycosaminoglycans and it is likely that this 
characteristic is largely responsible for TIMP3 binding to the ECM (Yu et al. 2000). More 
recently, Lee et al. (2007) carried out a more detailed analysis of the interaction of TIMP3 
with the ECM and found it to be mediated by residues in both the N-domain and the C-
domain. The ECM binding motifs were identified as all basic amino acids, encompassing 
lysine residues at 26, 27, 30 and 76 of the N-terminal domain and arginine 163 and lysine 165 
of the C-terminal domain. Mutation in these residues to glutamine or glutamate was shown to 
result in a soluble TIMP3 molecule lacking its ECM binding ability. These findings were 
supported by TIMP1 mutated to lysine at residues 26, 27, 30 or 76, which was seen to give 
rise to a TIMP1 molecule capable of ECM binding. (Lee et al. 2007) 
 
1.4.1.2 Inhibition of ADAM/ADAMTS proteinases  
Amongst the mammalian TIMPs, TIMP3 is a distinct member with a broader inhibitory 
action toward metalloproteinases. This inhibitory action encompasses members of the ADAM 
(a disintegrin-metalloproteinase) and ADAMTS (a disintegrin-metalloproteinases with 
thromospondin motifs) families. For example TIMP3 inhibits the sheddases, ADAM10 and 
ADAM17 (Amour et al. 1998, Amour et al. 2000) and is an effective inhibitor of ADAMTS 
1, 2, 4 and 5 (Brew and Nagase 2010, Wang et al. 2006, Wayne et al. 2007). ADAMTS 4 and 
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5 are known as aggrecanases 1 and 2, respectively and appear to play a critical role in 
cartilage degradation in arthritis (Huang and Wu 2008, Tortorella et al. 1999).  
TACE (ADAM17) was reported by Amour et al. (1998) as the first non-MMP 
metalloproteinase to be inhibited by TIMP3.  The importance of TACE inhibition by TIMP3 
is illustrated by TIMP3 knockout studies in which many of the symptoms result from 
increased activity of TACE and subsequently increased release of TNF-α. For example 
Mohammed et al. (2004) showed that mice lacking the TIMP3 gene displayed chronic hepatic 
inflammation and Kassiri et al. (2005) demonstrated that T3 knockout mice developed dilated 
cardiomyopathy due to increased level of TNF-α. The crystal structure of TACE in complex 
with the N-domain of TIMP3 has been resolved to 2.3 Å, Wisniewska et al. (2008) 
demonstrating that the N-terminus of TIMP3, particularly Phe34, Leu94 and Leu67, binds to 
the hydrophobic surface of the TACE-catalytic domain.  Xu et al. (2012) conducted a study 
to examine TACE activation and binding to TIMP3 and found that TACE is present on the 
cell surface in a dimeric form that favours the binding of TIMP3, thus maintaining it in an 
inactive state.  Activation of the ERK/p38MAPK pathways resulted in a shift to monomeric-
TACE and the dissociation of TIMP3 (Figure 1.9).    
  






Figure 1.9: TACE domain organisation and activation.  
(A) Domain organisation of TACE. S: Signal peptide (17 aa); Pro: pro-domain 
(196aa); Catalytic: catalytic domain (258aa); Dis; disintegrin domain (98aa); Cys-
rich: cysteine-rich domain (98aa); TMI: transmembrane (23aa); Cyt: cytoplasmic 
domain (129aa). (B) Illustration of TACE activation. Upon activation of MAPK or 
ERK pathways, the balance between TACE dimer and monomer shift to monomer 
form, which is associated with increased TACE presentation on the cell surface 


























































































































































1.4.1.3 Apoptosis   
Several studies have demonstrated that apoptosis of various cell types, including cancer cell 
lines, is induced by increased expression of TIMP3. For example, TIMP3 overexpression was 
demonstrated to increase apoptosis of HeLa, HT1080 and MCF-7 cells (Baker et al. 1999) 
and retinal pigment epithelial cells (Majid et al. 2002). 
Full length TIMP3 and N-terminal domain TIMP3 were found to promote apoptosis whereas 
a TIMP2-TIMP3 chimera that had the N-terminal domain of TIMP2 and the C-terminal 
domain of TIMP3 did not (Bond et al. 2002). It was concluded that the pro-apoptotic effect of 
TIMP3 is located in the three loops of the N-terminal domain of TIMP3 and that TIMP3 
inhibition of metalloproteinases is associated with the induction of apoptosis.  This appears to 
be due to increased inhibition to TACE leading to decreased shedding of death receptors such 
as TNF-RI (tumour necrosis factor receptor-1), FAS and TRAIL-RI (TNF-related apoptosis 
inducing ligand receptor-1) (Ahonen et al. 2003). Recently, however, Qi and Anand-Apte 
(2015) showed that overexpression of TIMP3 induced apoptosis in endothelial cells through 
an MMP- and caspase-independent mechanism.  
In contrast to the evidence that over-expression of TIMP3 induces apoptosis, evidence from 
knockout mice suggests that TIMP3 inhibits apoptosis in the mammary gland (Fata et al. 
2001) and this appears to be due to loss of TIMP3 resulting in increased shedding of TNFα, 
which plays a role in epithelial apoptosis (Hojilla et al. 2011). 
 
1.4.1.4 Inhibition of VEGFR2    
TIMP3 is unique among the TIMP family in specifically binding to vascular endothelial 
growth factor receptor-2 (VEGFR2) (Qi et al. 2003), resulting in inhibition of angiogenesis 
and this will be considered in more detail below. 
 
1.4.1.4.1 Angiogenesis  
Vasculogenesis is the de novo development of blood vessels that plays a vital role in 
embryonic vascular network formation.  This is also accompanied by angiogenesis, the 
sprouting of capillaries from pre-existing vessels (Risau et al. 1988). While there is some 
evidence for vasculogenesis in adult tissues (D'Alessio et al. 2015), the new blood vessel 
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formation that occurs in adulthood, largely in the repair of injured tissue and the ovarian 
cycle, is primarily mediated by angiogenesis. Angiogenesis occurs in response to an initial 
stimulus such as ischemia, hypoxia and inflammation leading to upregulation of angiogenic 
stimuli. 
A diverse group of proteins have been identified to regulate the different stages of 
angiogenesis. These proteins are classified into angiogenic stimulators, inhibitors and 
extracellular matrix-bound cytokines. Angiogenic stimulators include soluble growth factor 
such as vascular endothelial growth factor (VEGF) and fibroblast growth factor 1 (FGF-1, 
acidic) and fibroblast growth factor 2 (FGF-2, basic); the inhibitors (antiangiogenic) comprise 
pigment epithelium derived factor (PEDF), angiogenin, transforming growth factor β (TGF-
β) and other small molecular weight molecules; and cytokines are also released by proteolysis 
and contribute to angiogenesis regulation. Among all these growth factors, VEGFs are 
considered the major mediators of angiogenesis and are described in more details in section 
1.4.1.4.2. Deregulated angiogenesis plays a role in a number of disease processes, including 
retinopathies, haemangiomas, tumour growth and peripheral and myocardial ischemia 
(Dawson et al. 1999, Ferrara 1995, Patan 2000, Yoo and Kwon 2013).  
 
1.4.1.4.1.1 Angiogenesis in retinopathies  
In normal physiological conditions the blood vessels in the eye remain in a quiescent state, 
which is maintained by the balance between angiogenic and anti-angiogenic factors. In 
response to pathological conditions such as inflammation and hypoxia, angiogenic factors are 
activated and the balance may shift to angiogenesis. Ocular angiogenesis, the formation of 
new blood vessels from the existing vascular network in the eye is a major cause of severe 
vision loss and can occurs in different layers such as the cornea, choroid and retina.  
Choroidal neovascularisation (CNV) is exemplified by neovascular (wet or exudative) AMD 
and is also a common feature of SFD.  The principle mediator of choroidal neovascularisation 
is VEGF. 
 
1.4.1.4.2 VEGF  
Vascular endothelial growth factors are essential for blood vessel formation in development 
and also for the growth of new vessels from existing vasculature. VEGFs are a family of six 
polypeptides including VEGF-A to -D (endogenous), VEGFE (viral) and PIGF, which 
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regulate the development of blood and lymphatic vessels. VEGFs are dimeric glycoproteins 
with a molecular weight of approximately 40 kDa. They were firstly discovered as vascular 
permeability factor.  
Among the VEGF family, VEGF-A has been extensively studied due to its function in cell 
signalling, angiogenesis and cancer. VEGF-A was firstly described as the main player in 
angiogenesis (Ferrara and Henzel 1989, Keck et al. 1989, Senger et al. 1983). The VEGF-A 
gene is localised to the short arm of chromosome 6 consisting of 8 exons that are 
differentially spliced to give rise to multiple isoforms. These VEGF-A isoforms encode 12 
polypeptides with variable amino acid length and numbers of heparin binding motifs that 
result in varying affinities for the ECM (Harper and Bates 2008, Nagy et al. 2007) (Figure 
1.10). These 12 isoforms are further divided into two subfamilies termed pro-angiogenic and 
anti-angiogenic with isoforms designated with a b suffix, such as VEGF165b, being anti-
angiogenic.  However the actual existence of these anti-angiogenic isoforms in vivo has 
recently been questioned and may be an artefact of the detection method (Harris et al. 2012). 
VEGF is expressed in several types of cell such as fibroblast, cancer cells, vascular 
endothelial and smooth muscle cells; and it regulates endothelial cell functions through auto 
and paracrine pathways (Barleon et al. 1997, Brogi et al. 1996, Chua et al. 1998, Lamalice et 
al. 2007). As outlined above, VEGF has been shown to play a role in several retinal diseases 
including age-related macular degeneration disease (AMD) and diabetic retinopathy. VEGF 
is expressed by various retinal cells, including retinal pigment epithelial cells, astrocytes and 
ganglion cells. (Penn et al. 2008)  
  





Figure 1.10: Protein isoforms of human vascular endothelial growth factor A 
(VEGF-A). 
The figure illustrates VEGF-A family members divided into angiogenic (1-7) and anti-
angiogenic (8-12) subfamilies. VEGF-A protein structures were drawn based on 
(Grunewald et al. 2010, Harper and Bates 2008, Penn et al. 2008).  
  







































1.4.1.4.3 VEGF receptor  
While the effects of VEGF are mediated through several receptors including VEGFR1, 2 and 
3 and neuropilins 1 and 2 (NRP-1, -2) (Grunewald et al. 2010), VEGFR2 is considered to be 
the major effector of VEGF-induced angiogenesis. Structurally, these receptors belong to the 
receptor tyrosine kinase family consisting of an extracellular domain that is arranged into 
seven immunoglobulin-like folds, a single transmembrane region, a juxtamembrane domain 
followed by split tyrosine kinase domain and cytoplasmic tail (Figure 1.11). The ligand-
binding site is situated in the second and third immunoglobulin domains (Fuh et al. 1998, 
Leppanen et al. 2010). VEGF receptors are activated through ligand-induced dimerisation, 
which is associated with activation of the receptor kinase domains resulting in auto-
phosphorylation. Auto-phosphorylation of the VEGFR2 leads to activation of several 
signalling pathways such as phosphoinositide-3 kinase (PI3K) and mitogen activated protein 
kinase (MAPK), and subsequently broad biological response in endothelial cells including 
proliferation, migration and cell survival. (Grunewald et al. 2010, Mac Gabhann and Popel 
2007, Penn et al. 2008, Rahimi 2006)  
Qi and colleagues (2003) showed that TIMP3 directly inhibited the binding of VEGF to its 
receptor (VEGFR2) and subsequently angiogenesis; the inhibition of TIMP3 was found to be 
independent of its MMP inhibitory action. Recent studies were carried out to localise TIMP3-
sequence involved in VEGFR2 inhibition. Qi et al. (2013) showed that two short synthetic 
peptides, corresponding to TIMP3-loop-6 and TIMP3-tail region inhibited the interaction 
between VEGF and VEGFR2. Similarly, Chen et al. (2014) demonstrated that a peptide 
comprising loop-4 and loop-5 also inhibited VEGFR2. N-domain TIMP3 failed to inhibit 
VEGFR2 indicating that it is the carboxyl-domain of TIMP3 alone that is responsible for 
inhibiting the interaction between VEGF and VEGFR2. 
As mentioned earlier TIMP3 is expressed in the RPE and it would seem this plays an 
important role in regulating neovascularisation of the retina. This is illustrated by the fact that 
eyes from knockout mice show abnormal vessel formation (Ebrahem et al. 2011, Janssen et 
al. 2008).  




















Figure 1.11: The VEGF receptors protein tyrosine kinases. 
A schematic diagram illustrating the interaction of VEGF receptor with VEGF and 
TIMP3; VEGF receptor is activated by binding to its dimeric ligand VEGF and 
inhibited through binding to TIMP3. Based on figures from Nagy et al. (2007), Penn 
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1.4.1.5 TIMP3 and EFEMP1  
The carboxyl-terminus of TIMP3 has been demonstrated to bind to epidermal growth factor 
fibulin-like extracellular matrix protein 1 (EFEMP1), which is also known as fibulin 3.  
EFEMP1 is a matrix glycoprotein and member of the fibulin protein family. A missense 
mutation (R345W) in the EGF domain of the EFEMP1 gene causes a dominant retinal 
macular degeneration termed Malattia Leventinese (ML) with a phenotype that resembles that 
of age-related macular degeneration (AMD) and Sorsby’s fundus dystrophy (SFD). This will 
be discussed in more details in section 1.5. (de Vega et al. 2009) 
 
1.5 Sorsby’s Fundus Dystrophy (SFD)  
TIMP3 is unique among the TIMP family in being specifically associated with the retinal 
disease known as Sorsby’s fundus dystrophy (SFD), which was firstly described in 1949 by 
(Sorsby and Mason 1949). SFD is defined as a rare autosomal dominantly inherited 
degenerative disease of the macula, which is the most sensitive part of the central retina, 
responsible for high-resolution colour vision. It is regarded as a single gene disorder caused 
by specific mutations in the TIMP3 gene. It is considered as a late onset disorder that results 
in rapid loss of central vision; however, the age of onset ranges from the third to seventh 
decade amongst affected individuals (Brew and Nagase 2010, Gregory-Evans 2000). 
Surprisingly, considering the wide tissue distribution of TIMP3 and its role in regulating 
MMPs, SFD patients are otherwise healthy with a normal lifespan and no evidence for any 
disease other than in the eye (Li et al. 2005). 
 
1.5.1 Retinal anatomy and SFD clinical manifestations 
The retina comprises several layers including photoreceptors, the retinal pigment epithelium 
(RPE), Bruch’s membrane and choroid. The RPE forms a single layer of cells and is 
responsible for transporting nutrients from the choroidal vascular bed to the photoreceptor 
cells via Bruch’s multilayered basement membrane as well as removal of waste products in 
the opposite direction. (Figure 1.12 A) (Brew and Nagase 2010, Kolb 1995)  
Histopathological analysis of retina from SFD patients shows increased deposition of 
extracellular waste products including proteins and lipids known as drusen, thickening in 
Bruch’s membrane and atrophy of the photoreceptors, RPE and choroid, presumably as a 
result of a reduction in the transport of nutrients and metabolites from choroid to retinal 
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layers. This is usually accompanied by the growth of new blood vessels through Bruch’s 
membrane resulting in haemorrhage and occasionally retinal detachment leading to total 
blindness. Most SFD individuals have a loss of central vision due to neovascularisation (wet-
type macular degeneration); nevertheless, SFD can also be essentially an atrophic (dry-type) 
of macular degeneration. (Figure 1.12 B) (Brew and Nagase 2010) 
 
 
Figure 1.12: Structure of the retina and the SFD phenotype.  
(A) Schematic diagram of normal human retina showing detailed layers. (B) Anatomy 
of SFD human retina demonstration drusen (navy arrow), choroidal 
neovascularisation, thickening in Bruch’s membrane and Illustration of growing new 
blood vessels those disturb retinal layers resulting in haemorrhage (black arrow) and 
retinal detachment in later stage of SFD. The retina layers were drawn using Servier 
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1.5.2 SFD mutations  
Currently, 15 different mutations have been shown to cause SFD.  In the literature, these have 
largely been numbered by excluding the signal peptide sequence, however more recently 
described mutations have been numbered to include this causing some confusion. These are 
shown in Table 1.5 using both numbering methods to aid comparison.  Figure 1.13 shows 
their position on the primary structure of TIMP3 excluding the signal sequence.  Eleven of 
these mutations are missense mutations that change a residue to cysteine, with all except 
S15C (Figure 1.14) occurring in exon 5 that codes for most of the carboxyl-domain of 
TIMP3.  Where examined, this additional cysteine has been shown to result in TIMP3 
dimerisation.  Moreover, there are two additional missense mutations in exon 5, E139K and 
H158R that do not change a residue to cysteine but do still result in TIMP3 dimerisation 
(Saihan et al. 2009, Mujamammi 2013), potentially by destabilising adjacent disulphide 
bonds. The nonsense mutation, E139X, results in deletion of most of the C-domain of TIMP3 
but again results in TIMP3 dimerisation as a result of an unpaired cysteine residue (Langton 
et al. 2000). The other novel mutation is a splice site mutation that was discovered in two 
Japanese families by Tabata et al. (1998). Sequence analysis of the TIMP3 gene revealed the 
presence of a single adenine insertion at the intron4/exon5 junction site that converts the 
acceptor site from CAG to CAAG.  The effect of this mutation on TIMP3 mRNA or protein 
expression was not examined.  While the consequence of such splice site mutations cannot be 
predicted, several possibilities were suggested by Li et al. (2005), encompassing exon 
skipping, intron retention and activation of a cryptic acceptor site (Figure 1.15). Although a 
splice site mutation can result in skipping of exons, in this case this is unlikely to yield a 
stable mRNA since exon 5 is the last exon of the TIMP3 gene. Another possibility is that 
intron 4 retention could lead to expression of a mutant protein, possibly with an unpaired 
cysteine residue. Alternatively the activation of a cryptic acceptor site in exon 5 could also 
result in an abnormal protein, again with the possibility of aberrant disulphide bond 
formation.  
Amongst different SFD families, the clinical presentation and age of onset vary depending on 
the type of mutation. For instance, individuals with the S156C mutation show symptoms in 
their third decade and have prominent neovascularisation in most affected individuals. In 
contrast the splice site mutation results in an exceptionally late onset form of SFD with a 
distinct phenotype including normal peripheral retina (Isashiki et al. 1999).  
  








Age of SFD 
onset (decades) 
Reference 
S15C (S38C) 5 Schoenberger and Agarwal (2012) 
Y128C (Y151C) 3 Gliem et al. (2015)  
E139X (E162X) 3-4 Langton et al. (2000)  
E139K (E162K) 5 Saihan et al. (2009) 
Y154C (Y177C) 6 Gliem et al. (2015)  
S156C (S179C) 2-3 Felbor et al. (1995) 
H158R (H181R) 5-7 Lin et al. (2006)  
Y159C (Y182C) 6 Fung et al. (2013) 
G166C (G189C) 2-4 Felbor et al. (1997b)  
G167C (G190C) 3-4 Jacobson et al. (1995)  
Y168C (Y191C) 3-4 Felbor et al. (1996)  
S170C (S193C) 4 Jacobson et al. (2002)  
Y172C (Y195C) 3-4 Jacobson et al. (2002)  

















Figure 1.13: TIMP3 mutations shown to be responsible for SFD.  
Yellow circles refer to those mutations changing to cysteine residues whereas the 
purple one refers to arginine. The red circle refers to the mutation changing to either 


























































Figure 1.14: TIMP3 structure showing the position of the S15C mutation 
relative to all other SFD mutations. 
The N-domain is coloured yellow and the C-domain grey with all known SFD 
mutations shown as orange spheres except for S15C, which is green. The TIMP3 
structure was modelled using the Phyr2 Server (Kelley and Sternberg 2009) and 
then rendered using PyMol software. 
 
  





Figure 1.15: Possible effects of splice site mutation on TIMP3. 
(A) Intron retention; (B) Exon Skipping; (C) Activation of cryptic acceptor site. SD: 
splice donor site and SA: splice acceptor site. The Red Cross refers to defective 
acceptor site.  
3 5 4 Poly A SD SA SD SA 
4 + intron 4+ 5 
3 5 4 Poly A SD SA SD SA 
3 5 4 Poly A SD SA SD SA SA 
A. Intron retention 
B. Exon skipping  
C. Activation of alternative acceptor site 
?
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1.5.3 Properties of SFD-TIMP3 protein 
The biochemical properties of mutant TIMP3 protein, produced by different SFD mutations, 
have been studied by expression in various types of cell including the African green monkey 
kidney cell line (COS-7), baby hamster kidney cells (BHK) and the human RPE cell line 
(ARPE19).  While the dimerisation of TIMP3 mentioned above was not reported in all cases, 
expression in RPE cells has always resulted in dimer formation, suggesting the different 
mutations all result in a common molecular phenotype and this would certainly explain the 
fact that the majority of mutations change a residue to cysteine.  
Like most dominantly inherited diseases, it is believed that SFD is due to a toxic effect of the 
mutant protein rather than haploinsufficiency and this is supported by a number of reports. 
For instance, Langton and colleagues (1998) showed that mutant S181C-TIMP3 protein was 
expressed as a dimer that retained its ability to inhibit MMPs and still localise to the ECM.   
Leco et al. (2001) showed that deletion of TIMP3 in mice did not give rise to an SFD 
phenotype; conversely, these mice exhibited enlargement in the lungs due to an imbalance 
between MMPs and their inhibitors. However, TIMP3 knock in mice carrying the S156C 
mutation developed abnormal changes in the Bruch’s membrane similar to those in aged 
normal mice (Weber et al. 2002). Moreover the activity levels of ADAMTS4 and 5, TACE 
and aggrecan cleaving MMPs was unchanged in tissues from both heterozygous and 
homozygous S156C mice (Fogarasi et al. 2008), indicating S156C retains its ability to inhibit 
these enzymes. Additionally the same authors showed that recombinant S156C-TIMP3 had a 
comparable ability to inhibit the interaction between VEGFR2 and its ligand to the wild type 
molecule. However, it should be noted that the S156C-TIMP3 used in their experiments was 
expressed from bacteria and was monomeric and not dimeric as described in other studies. 
Furthermore, immunohistochemical analysis of eyes from an SFD patient with the S181C 
mutation showed an accumulation of TIMP3 in the retina, rather than its absence (Fariss et al. 
1998) and this may be a result of SFD mutant TIMP3 dimers/multimers being resistant to 
turnover compared to the normal protein (Langton et al. 2005).  
High level expression of TIMP3 has been shown to trigger apoptosis in RPE cells (Majid et 
al. 2002) with some evidence that SFD mutant TIMP3, including S156C, G167C, Y168C and 
S181C have an additional proapoptotic effect (Majid et al. 2002), and so accumulation of 
TIMP3 in SFD may play a role in choroidal and retinal atrophy by inducing apoptosis in 
these tissues. 
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While all the evidence indicates SFD is not due to haploinsufficiency, dominant mutations 
can also have what is termed a dominant negative or antimorphic effect. In this case the 
mutant protein has a toxic effect by having a deleterious effect on the wild-type protein 
expressed from the normal allele. However studies in mice indicate this is not the case in SFD 
as only the S156C/S156C homozygous mice have any detectable phenotype whereas the 
S156C/wild-type heterozygotes are asymptomatic (Weber et al. 2002). 
 
1.6 Age-related macular degeneration (AMD) 
Although SFD is extremely rare, its phenotype is very similar to the more severe (wet or 
exudative) form of age-related macular degeneration (AMD). AMD is a degenerative disease 
of the retina that affects older people and is the major cause of blindness in industrialised 
countries.  In the UK alone over 500,000 people (2.4% of the population) were affected by 
this late stage form of the disease in 2012, and this is estimated to rise to approximately 
700,000 cases by 2020 (Owen et al. 2012), which will have a significant impact on personal 
independence and the economy.  As a result of the phenotypic similarities between SFD and 
AMD, it was suggested that TIMP3 might also play a role in the pathogenesis of AMD and 
this hypothesis was strengthened by the observation that the increased deposition of TIMP3 
found in the eyes of SFD patients is also observed in the eyes of AMD patients (Kamei and 
Hollyfield 1999). 
 
1.6.1 AMD clinical manifestations  
Age-related macular degeneration is a chronic progressive retinal disorder and affects various 
retinal layers including the choroid, Bruch’s membrane, RPE and photoreceptors; however, 
deregulation of metabolic processes in the RPE is considered to be the leading trigger of 
AMD due to the fact that these cells are responsible for synthesising all structural 
components of Bruch’s membrane, particularly type-I and IV collagen, laminin and 
metalloproteinases and their natural tissue inhibitors.  
AMD is associated with progressive visual impairment and occurs in two forms classified as 
dry or wet. Dry AMD is characterised by the formation of drusen, which are protein and lipid 
rich deposits under the retinal layers.  A number of small drusen are considered part of the 
normal ageing process, however in dry AMD these increase in number and size and begin to 
affect central vision.  Eventually these deposits result in atrophy of the RPE and 
photoreceptor layers (termed geographic atrophy) and can result in loss of central vision.  
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Approximately 15% of patients with dry AMD will go on to develop wet AMD, characterised 
by choroidal neovascularisation, haemorrhage, scarring and retinal detachment, which can 
result in sudden and severe loss of vision (Ferris et al. 2013, Nita et al. 2014, Saksens et al. 
2014). 
Despite these close similarities between SFD and AMD there are some pathological 
differences that distinguish SFD from AMD. In addition to dominant inheritance and age of 
onset, and these include differences in drusen composition, an early nyctalopia (poor night 
vision) and, in some cases, impaired peripheral vision (Gourier and Chong 2015). 
 
1.6.2 Genetic studies and TIMP3 in AMD  
Genetically, whilst SFD is a single gene disorder caused by mutations in TIMP3, AMD is 
considered to be a multi-factorial disease with both environmental and genetic risk factors 
and is not caused by changes to the coding sequence of TIMP3 (Felbor et al. 1997a). 
The strongest genetic risk factor found to be associated with AMD is a polymorphism 
(rs1061170) converting tyrosine-402 to histidine-402 in the gene that encodes complement 
factor H (CFH). The risk of developing AMD increases approximately 2.5 fold with one 
histidine at this position and up to 6 fold when histidine is present in both alleles in 
individuals of European decent (Edwards et al. 2005, Haines et al. 2005, Zareparsi et al. 
2005). Complement factor H is an important regulator of the alternative pathway of 
complement and these data implicate complement activation as a key factor in AMD 
pathogenesis. 
Despite the fact that high concentrations of TIMP3 are seen in the retina of both AMD and 
SFD patients (Fariss et al. 1998, Kamei and Hollyfield 1999), two genetic studies in 1997 
failed to find a connection between TIMP3 and AMD (De La Paz et al. 1997, Edwards et al. 
2005). However more recently Kaur et al. (2010) reported the presence of strong association 
between two TIMP3 intronic SNPs encompassing rs713685 and rs743751 and AMD, 
although the consequences, if any, on TIMP3 protein expression are unknown.  
However the increased TIMP3 protein expression described in AMD is not associated with 
increased mRNA expression (Bailey et al. 2001) and could therefore be associated with a 
decreased turnover of TIMP3 as observed in SFD. This hypothesis was supported by 
examination of drusen from normal and AMD retinas by Crabb et al. (2002) who observed 
the presence of apparently cross-linked TIMP3 as a consequence of oxidative reactions.  
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Cross-linked TIMP3, either as a result of mutation or oxidation could, for example, have an 
increased avidity for TACE resulting in decrease shedding of death receptors and increased 
apoptosis. 
An additional possibility is that TIMP3 cross-linking occurs as a result of advanced glycation 
end product (AGE) formation, a process that increases with age (Glenn and Stitt 2009). AGE 
products bind to pattern recognition receptors such as RAGE (receptor for AGE), which upon 
activation play a critical part in several inflammatory/degenerative diseases (Chuah et al. 
2013). It is possible that the toxicity of SFD-TIMP3 might result from the fact that it also 
behaves as a RAGE ligand. 
 
1.6.3 Advanced glycation end products (AGEs) and their receptor (RAGE)  
Increased modification of lipids, DNA and free amino groups on proteins, is considered to be 
related to the ageing process. AGEs can be formed from a non-enzymatic reaction between 
reducing sugars or dicarbonyls and primary amino groups on proteins. (Glenn and Stitt 2009) 
AGEs have been implicated as playing a role in several diseases, including Alzheimer’s 
disease, and in diabetic complications where the high glucose levels result in increased AGE 
formation. The best-characterised AGE receptor is RAGE.  
 
1.6.3.1 RAGE  
The receptor of advanced glycation end products (RAGE) was firstly described as a binding 
partner of AGEs found on the surface of endothelial cells (Neeper et al. 1992, Schmidt et al. 
1992). RAGE is a pattern recognition receptor that binds to a wide range of ligands including 
AGEs, S100 proteins, amyloid, β2-integrin-Mac-1, high mobility group box protein 1 and 
amophoterin (Chavakis et al. 2003, Hofmann et al. 1999, Taniguchi et al. 2003). The ligand-
receptor binding initiates downstream pro-inflammatory signalling pathways involved in 
several illnesses including viral infection, Alzheimer disease, diabetic complications and 
cancer (Liliensiek et al. 2004, Sasahira et al. 2005, Wendt et al. 2003, van Zoelen et al. 
2009). Activation of RAGE has also been shown to increase VEGF production by RPE cells 
(Ma et al. 2007). 
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1.6.3.1.1 RAGE structure  
The human gene for RAGE is situated on chromosome 6 in the major histocompatibility 
complex class III region. The gene encompasses 11 exons encoding a 404 amino acid protein 
with a molecular weight between 45 and 55kDa depending on glycosylation. The expression 
of RAGE is detected in a variety of cell types such as endothelium, neural tissue, smooth 
muscle cells and cardiac myocytes; and tissue including kidney, heart, brain and liver (Brett 
et al. 1993). Structurally, RAGE is a member of the immunoglobulin superfamily that 
comprises a signal peptide at the amino-terminus, a variable-type immunoglobulin-like 
domain, two tandem constant-type immunoglobulin-like domains, a trans-membrane domain 
and an intracellular cytoplasmic tail (Neeper et al. 1992) (Figure 1.16).  
Xie et al. (2008) showed that RAGE is present on the cell surface in oligomer form enabling 
recognition of multimeric AGE-modified proteins and more recently a study by Zong et al. 
(2010) demonstrated that RAGE-ligands such as AGEs and S100B initiated a process in 
which RAGE molecules form homodimers at the plasma membrane through their V-domain 
at the amino-terminus. 
 
1.6.3.1.2 RAGE Activation 
RAGE activation is achieved through ligand-receptor interaction in which most RAGE 
ligands, such as S100B and amyloid-β, are functional and have higher affinity in oligomer 
forms (Chaney et al. 2005, Ostendorp et al. 2007) (Figure 1.16A). This ligand-receptor 
binding results in phosphorylation of several transduction cascades such as 
phosphatidylinositol 3-kinase, mitogen-activated protein kinases (MAPK), Rac-1 and Cdc42, 
Jak/STAT (Janus kinase/signal transducer and activators of transcription) and the NF-κB 
pathway (Chuong et al. 2009, Hermani et al. 2006, Huttunen et al. 1999, Lander et al. 1997, 
Yeh et al. 2001, Wang et al. 2008). These pathways implicated RAGE in several cellular 
responses for instance migration, apoptosis, mobility, cancer and pro-inflammatory gene 
expression (Yan et al. 2009). 
At least five alternatively spliced soluble variants of RAGE exist (sRAGE) that lack the 
transmembrane domain and these are thought to act as antagonists of the receptor. Chuong et 
al. (2009) demonstrated that the extracellular domain of RAGE inhibited nuclear 
translocation of NF-κB (p65 and p52) by S100A4 in human salivary gland cell lines. 
Moreover, when HEK293T cells were incubated primarily with soluble RAGE or RAGE-V-
domain peptide prior to S100B treatment, RAGE dimerisation in response to S100B and the 
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Figure 1.16: Schematic representation of AGE receptor. 
(A) A model of RAGE activation by binding to its dimeric/oligomer ligands: RAGE-
ligand binding stabilises RAGE-dimer enabling interaction with a signalling adaptor 
protein through the cytoplasmic region of the receptor and activating signal 
transductions.  (B) A model of RAGE inhibition by sRAGE: RAGE binds to sRAGE 
that blocks the subsequent signal transduction. (Koch et al. 2010, Leclerc et al. 
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1.7 Malattia Leventinese  
Malattia Leventinese (ML) is another rare autosomal dominantly inherited degenerative 
disease of the macula with an early onset. In contrast to SFD, ML is phenotypically much 
more similar to dry AMD with CNV being less common.  The disease is characterised by a 
distinctive mosaic pattern of drusen, giving it the alternative name of Doyne’s honeycomb 
retinal dystrophy (Querques et al. 2013). ML is caused by a missense mutation in exon 10 of 
epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) gene 
(also known as fibulin-3) converting an arginine at position 345 to tryptophan (R345W) 
(Zhang and Marmorstein 2010, Takeuchi et al. 2010, Zhang et al. 2014). 
The gene of EFEMP1 is situated on chromosome 2 and contains 11 exons that encoded a 
protein sequence with a molecular weight of 55kDa. The 493 amino acid protein 
encompasses signal peptide, a calcium binding epidermal growth factor (cbEGF) domain 
with a peptide insertion, five tandem unmodified cbEGF domains and a C-terminal fibulin 
domain (Figure 1.17) (Zhang and Marmorstein 2010).  
Although EFEMP1 is widely expressed by endothelial and epithelial cells and in the brain, 
placenta, heart and eye (Timpl et al. 2003), its biological function is poorly understood. The 
EFEMP1 sequence is highly conserved in mammals and expressed in bone and cartilage 
structures throughout development, suggesting a conserved fibulin-3 role in the skeletal 
system in vertebrates (Ehlermann et al. 2003).  
Fibulin-3 is homologous to fibulin-5 that plays a significant role in regulating proliferation, 
invasion and migration of healthy and cancer cell lines. Like fibulin-5, fibulin-3 is also 
expressed in endothelial cells with its expression affecting their response to VEGF by 
inhibiting invasion, proliferation and angiogenic sprouting, inhibiting the expression and 
activity of metalloproteinases and stimulating the expression of tissue inhibitor of 
metalloproteinases. Fibulin-3 had the capacity to decrease tumour angiogenesis and growth 
(Albig et al. 2006). Recently, Lin et al. (2016) observed a reduction in MMP-2 and MMP-9 
and oxidative stress in hypertensive vascular remodelling as a consequence of fibulin-3 and 
suggested that up-regulation of fibulin-3 might improve vascular health and thus decrease 
certain cardiovascular risk factors.  
McLaughlin et al. (2007) found that mice lacking the EFEMP1 gene displayed decreased 
reproduction and early onset of ageing; however, these mice had no macular degeneration 
phenotype. This study indicates that the loss of EFEMP1 is not implicated in the pathological 
mechanism of mutant EFEMP1.  
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Marmorstein et al. (2002) demonstrated that the wild type EFEMP1 gene encodes a secreted 
protein (55 kDa) whereas mutant EFEMP1 encodes a poorly secreted misfolded protein that 
is also retained within the cells. ML mutant EFEMP1 protein accumulates in the RPE and 
between both the RPE and drusen. However, AMD eyes have also been found to contain 
accumulated EFEMP1 particularly overlying drusen formation. For this reason, it was 
concluded that the misfolding and accumulation of EFEMP1 might have a crucial part in the 
disease process of ML and AMD. Interestingly, EFEMP1 protein strongly binds to the C-
terminal domain of TIMP3. Significantly, this finding was supported by examinations of ML 
and AMD eyes, which identified accumulation and overlapping expression of TIMP3 and 
EFEMP1 (Klenotic et al. 2004). Fu et al. (2007) showed co-localised deposits of EFEMP1 
and TIMP3 between Bruch’s membrane and the RPE in Efempl-R345W mice and, there was 
also evidence of complement activation at this site. 
More recently, in addition to binding TIMP3, EFEMP1 has also been shown to be a binding 
partner for complement factor H (CFH) and colocalisation of CFH and fibulin-3 was 
observed in soft drusen from an AMD patient with the homozygous CFH polymorphism 
(Y402H) (Wyatt et al. 2013). This suggests that the interaction between TIMP3, EFEMP1 
and CFH could contribute to the aetiology of SFD, ML and AMD. 
Roybal et al. (2005) found that mutant EFEMP1 accumulated in the endoplasmic reticulum 
(ER) of ARPE19 cells. This accumulation resulted in activation of the unfolded protein 
response (UPR) signalling, elevation in VEGF expression and transcriptional stimulation of 
the VEGF promoter. Since the expression of ML mutant EFEMP1 cause ER stress and 
subsequently leads to RPE dysfunction and elevates the expressed VEGF, it may account for 
macular degeneration and choroidal neovascularisation (CNV).  
  





Figure 1.17: Domain structure of EFEMP1. 
Demonstration of domain organisation of EFEMP1 as reviewed by Hulleman and 
Kelly (2015) & Zhang and Marmorstein (2010). The carboxyl-terminus of EFEMP1 
(259-493) interacts with the carboxyl-terminus of TIMP3 particularly amino acid 
sequence between 105 and 188 (Klenotic et al. 2004). N249: N-glycosylation site at 
























1.8 Therapeutic treatments for retinopathies  
Treatment options for most retinopathies are limited and, at best, slow progression of the 
disease, rather than improve it.  Nevertheless newer treatments, particularly the relatively 
recent availability of anti-VEGF therapies to treat CNV, have significantly improved the 
prognosis for patients with neovascular complications.  Additionally the prospect for using 
gene therapy approaches to treat monogenetic disorders has greatly improved in recent years, 
and the retina, with its accessibility and immune-privileged status is one of the most 
promising targets for such treatments.  Current and prospective treatment options will be 
considered in more detail in the following sections. 
 
1.8.1 AMD treatments  
As age-related macular degeneration is the leading cause of irreversible loss of vision in 
western countries, many medical therapies have been established including photodynamic 
therapy for subfoveal choroidal neovascularisation (CNV), argon laser photocoagulation of 
extrafoveal CNV, anti-vascular endothelial growth factor (anti-VEGF) agents, transpupillary 
thermotherapy, radiotherapy, surgery and dietary supplementation (Bylsma and Guymer 
2005). 
Newer AMD therapeutic approaches have attempted to target drusen formation and delay the 
occurrence of choroidal neovascularisation. AMD patients with multiple large soft drusen are 
at higher risk of developing serious AMD complications that can be prevented by reducing 
drusen with prophylactic laser treatment or targeting proteins involved in drusen formation. 
Drusen formation has been linked to inflammatory responses leading to up-regulating 
proteins such as toll-like receptor 4, apolipoprotein (APOE) and complement factors B, C3 
and H (Crabb 2014). Amyloid β also localises within drusen and may play a role in their 
formation (Dentchev et al. 2003, Johnson et al. 2002). In a murine AMD model, amyloid β 
was detected in neovascular lesion and subretinal deposits and treatment with anti-amyloid β 
was shown to provide visual protection and prevent histopathological changes mimicking 
AMD (Ding et al. 2011). 
Extensive evidence has demonstrated that VEGF plays a crucial role in neovascularisation of 
AMD and other eye diseases.  Untreated neovascularisation can result in rapid vision loss, 
therefore VEGF has become a key target in the treatment of ocular neovascularisation.  
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Currently neovascular AMD is treated by intravitreal injection of either bevacizumab (trade 
name Avastin) or ranibizumab (trade name Lucentis), which are a humanised monoclonal 
antibody and a fragment of antibody, respectively, against VEGF. Bevacizumab was 
originally licenced for cancer treatment and ranibizumab for AMD.  However, as the cost of 
bevacizumab is much lower than that of ranibizumab per patient, a number of clinical trails 
have compared the two drugs for AMD treatment and these have found comparable efficacy 
and safety between bevacizumab and ranibizumab for treatment of neovascular AMD 
(Solomon et al. 2016). Other studies have also shown that a regular monthly treatment with 
these drugs gives better results on visual acuity than as needed treatment (Chakravarthy et al. 
2013). 
In addition to targeting VEGF, Fovista is a novel new treatment for neovascular AMD that 
targets platelet-derived growth factor (anti-PDGF).  PDGF receptors are highly expressed on 
pericytes. Pericytes are contractile cells that surround endothelial cells and play a critical role 
in angiogenesis and stabilisation of newly formed vessels. Fovista is being investigated in 
combination with anti-VEGF therapy such as ranibizumab. In phase two trails, Fovista and 
ranibizumab combination therapy showed superior efficacy in vision gain relative to 
ranibizumab alone (Cheung and Wong 2013, Jaffe et al. 2016). 
While anti-VEGF therapies have proved very successful in treating CNV in wet AMD, they 
do not prevent the retinal atrophy that underlies dry AMD, and which affects many more 
patients.  For this reason a number of alternative treatment modalities are being explored 
including anti-inflammatory agents, such as those targeting complement components 
(Yehoshua et al. 2014), and agents that target lipofuscin (Mata et al. 2013), or amyloid-β 
(Parsons et al. 2015). Oxidative stress, which is implicated in RPE damage, has also been 
targeted in a therapeutic/preventative approach by, for example, dietary supplementation 
(Chew et al. 2013). 
 
1.8.2 SFD treatment 
Although SFD is an inherited disorder, a few therapeutic approaches have been used help 
alleviate symptoms. The increased thickness in Bruch’s membrane functions as a barrier 
decreasing transportation of nutrients, waste products and blood between choroid, RPE and 
photoreceptors. As a consequence of this impaired nutrient transport, some individuals 
affected with SFD have nyctalopia in the early stage of the disease that may result from 
severe deficiency in vitamin A level in the photoreceptors. Night blindness disappeared 
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within one week of high-dosage vitamin A treatment (oral administration) leading to 
improvements in photoreceptor function (Jacobson et al. 1995). However, treatment with 
high-dosage of vitamin A can also have harmful effect in the retina and other tissue and 
hence it has not become widely used.  
Based on their success in AMD patients, most therapeutic interventions in SFD target the 
haemorrhage and neovascularisation that is a hallmark of the disease. Wong et al. (2003) 
reported that choroidal neovascularisation (CNV) in S181C-SFD patients is treatable by 
photodynamic therapy (PDT) and verteporfin.  In contrast, Sivaprasad et al. (2008) found that 
argon laser therapy and PDT did not effectively treat CNV from S181C-SFD patients.  Prager 
et al. (2007) demonstrated that systemic bevacizumab, anti-VEGF therapy, is an effective 
treatment for secondary CNV in SFD. Similarly intravitreal ranibizumab has proved very 
beneficial in treating CNV associated with SFD (Balaskas et al. 2013). However, treatments 
directed at CNV do not address the underlying atrophy and thus are only likely to delay loss 
of vision.   
 
1.8.3 Malattia Leventinese treatment 
Reported treatment for Malattia Leventinese is limited to those patients who develop CNV.  
Dantas et al. (2002) reported successful treatment of a 39-year-old Malattia Leventinese 
patient who developed choroidal neovascularisation with photodynamic therapy with 
verteporfin.  More recently, bevacizumab has also been reported to have some efficacy in 
treating CNV in ML (Sohn et al. 2011). 
 
1.8.4 Transplantation of retinal pigment epithelium  
Changes in the RPE are thought to initiate the disease process in AMD and other 
retinopathies, such as SFD.  Moreover these cells are essential for maintaining the 
photoreceptors, so that loss of the RPE inevitably results in atrophy of the photoreceptor 
layers.  For this reason replacement of RPE should prevent degeneration of photoreceptors 
and subsequently restore visual function in these retinopathies. These cells are also attractive 
due to the fact that they are well studied, form a simple monolayer and can readily be grown 
and expanded in culture.  
A number of approaches have been tested, including macular translocation (where the central 
photoreceptor layer is moved onto an area of healthy RPE), transplantation of RPE cells alone 
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or transplantation of a patch of RPE including Bruch’s membrane and partial thickness 
choroid from a peripheral site to the macula.  However, none of these techniques have proven 
as successful as initial animal experiments might have indicated, with various degrees of 
post-operative complications and RPE cell only transfers failing due to an inability of RPE 
cells to adhere to unhealthy Bruch’s membrane (Alexander et al. 2015). 
 
1.8.4.1 Stem cells transplantation 
A more recent approach to restoring RPE function and preventing photoreceptor death is to 
use stem cells.  Both human induced pluripotent stem cells (iPSCs) and human embryonic 
stem cells (hESCs) are capable of differentiating into RPE cells (Buchholz et al. 2009, Cho et 
al. 2012) and these are beginning to show promise in the clinic. 
Schwartz et al. (2016), for example, reported findings of two studies at phase I/II trial 
involving 18 patients affected with AMD and Stargardt disease who underwent subretinal 
transplantation of hESCs-RPE.  The results at 4 years follow up of the anatomical and 
functional level were encouraging as ≥ 50% of patient showed increased visual acuity, 
evidence suggesting potential cellular engraftment and no observation of adverse effect 
related to the cell therapy.  
 
1.8.5 Gene therapy in retinal diseases   
Clearly the ideal treatment for hereditary retinopathies would be to replace the defective gene 
itself, before irreversible damage occurs.  While gene therapy has not generally lived up to 
early promise, treatment of retinopathies is one area where it has shown some success.  This 
is largely because the eye possesses several unique characteristics that favour this approach.  
Primarily it comprises a small target that is readily accessible for gene delivery and 
subsequent in vivo assessment.  It is also an immune-privileged tissue, making rejection of 
delivery vectors less likely.  Additionally there are also a number of genetically well-defined 
animal models. Thus, retinal gene therapy has the potential to become a key therapeutic tool 
in treating inherited forms of blindness. (Alexander et al. 2007, Bennett et al. 2012, Borras 
2003, Chaum and Hatton 2002, Naik et al. 2009)  
After initial success in animal models, a number of clinical trials are now in progress for 
treating recessive retinal disorders.  Probably the most advanced of these is for Leber’s 
congenital amaurosis (LCA), caused by mutation in retinal pigment epithelium-specific 65-
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kDa (RPE65) gene affecting the visual retinoid cycle, with early results demonstrating safety 
and some efficacy (Jacobson et al. 2012). 
Treating recessive retinal disorders, such as LCA, simply requires transduction with a normal 
copy of the defective gene.  However, treatment of dominantly inherited disorders, such as 
SFD, would be much more complex as it would require effective suppression of the toxic 
gene (by for example short interfering RNA - siRNA) without targeting the normal allele 
which is, at best, likely to be very difficult.  Moreover even if it were possible, many 
dominant retinal diseases, such as SFD, can be caused by many different mutations, which 
would require a novel therapy for each one, making it a prohibitively expensive approach for 
treating rare disorders.  One way this can be circumvented is to use an siRNA molecule to 
target all copies of the target gene, but then supplement the missing gene with a cDNA that is 
not susceptible to the siRNA molecule.  This has now been successfully achieved in an 
animal model of autosomal dominant retinitis pigmentosa, which can be caused by over 150 
different mutations in the rhodopsin gene (Millington-Ward et al. 2011).  
While RNA interference is not a very efficient process and rarely results in complete 
suppression of the target mRNA in mammalian cells, gene editing using recent CRISPR/Cas9 
(clustered regularly interspaced short palindromic repeat (CRISPR)-associated Cas9 nuclease 
technology - reviewed in Savic and Schwank (2016) is an extremely efficient method for 
deleting target genes, making treatment of dominantly inherited retinal disorders a much 
more likely prospect.  
Gene therapy trials are not, however, limited to treating inherited retinopathies as gene 
therapy is also being explored as a way of delivering therapeutic molecules in AMD.  This is 
intended to enable long-term drug delivery without the need for frequent and unpleasant 
intravitreal injections.  For example an adeno-associated viral (AAV) vector is being used to 
deliver cDNA encoding soluble Fms- related tyrosine kinase-1 (sFLT-1), a naturally 
occurring inhibitor of VEGF (Rakoczy et al. 2015). 
  




1.9 Project hypotheses and aims 
 
The hypotheses of this project are: 
1. that all TIMP3 mutations found in Sorsby’s fundus dystrophy result in TIMP3 
dimerisation 
2. these TIMP3 dimers have a toxic effect on cells and trigger similar responses to 
those seen in age-related macular degeneration 
The initial aim of the project is to confirm that the intron 4/exon 5 splice site mutation, N-
domain mutation (Ser15Cys) and the newly identified C-domain mutations (Tyr128Cys, 
Tyr154Cys, Tyr159Cys), also result in TIMP3 multimerisation, which would provide 
overwhelming evidence that this is indeed the causative agent of the disease.  
If this is the case, we then aim to examine the effect of mutant forms of TIMP3 on apoptosis, 
inflammation and choroidal neovascularisation, which are hallmarks of both SFD and wet 
age-related macular degeneration.  We also aim to examine the effects of SFD mutations on 
the known interaction between TIMP3 and EFEMP1 as both molecules play a role in 
inherited retinopathies and have also been shown to accumulate in Bruch’s membrane in age-
related macular degeneration. 
How the aims will be addressed 
Dimerisation will be examined by expressing SFD TIMP3 cDNA constructs in retinal 
pigment epithelial cells followed by western blotting. However for the splice site mutation 
this will necessitate creating a synthetic TIMP3 gene construct that includes intron 4 and the 
whole of exon 5 and then examining the sequence of the mRNA products produced. 
While very high level expression of TIMP3 and SFD TIMP3 have been reported to trigger 
apoptosis in a variety of cell types, we will determine whether mutant TIMP3 expressed in 
situ in the ECM increases the sensitivity of RPE cells to proapoptotic ligands by measuring 
casepase3/7 activation.  We also aim to determine whether TIMP3 dimerisation alters its 
interaction with TACE, which is thought to play a role in TIMP3 mediated apoptosis by 
shedding death receptors.  The ability of SFD mutants to bind to TACE will be determined by 
co-expression in HEK293T cells and then using a pull down assay, followed by western 
blotting.  
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The effect of TIMP3 mutation on EFEMP1 binding will also be investigated by pull-down 
assay in the same way. 
TIMP3 potently inhibits angiogenesis through its ability to target VEGFR2.  However, 
despite the fact that high levels of TIMP3 are found in both SFD and AMD eyes, 
angiogenesis is a hallmark of both diseases.  We will examine the ability of vascular 
endothelial cells to invade through ECM containing either mutant or wild-type TIMP3 to 
determine if mutant TIMP3 is a less potent inhibitor of this process.   
Inflammation plays an important role in AMD and this is also almost certainly the case for 
SFD.  One way this is mediated in AMD is through activation of RAGE, which binds a 
number of products known to accumulate in Bruch’s with age.  As RAGE is a pattern 
recognition receptor, it is possible that TIMP3 dimerisation/multimerisation converts it into a 
RAGE ligand.  We will assess the effect of mutant TIMP3 on RAGE mediated inflammation 
using an NFκB reporter assay.  
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2.1 Materials   
2.1.1 General chemicals 
All general chemicals were purchased from Sigma-Aldrich apart from those listed in the table 
below:  
Chemicals Catalogue number Supplier 
Acetic acid (glacial, 100%) 1000632500  Merck KGaA 
Amersham Hyperfilm ECL 5x7’’ 28906835 GE Healthcare 
Ammonium persulfate (APS) 17-1311-01 PlusOne 
5-bromo-4-chloro-3-indolyl-β-D-
galactoside (X-gal) MB1001 Melford 
Bromophenol blue water soluble IC15250650 BDH 
CAPS (transfer buffer) BP321-500 Fisher BioReagents  
Coomassie brilliant blue (R-250) 6104-59-2 Fisher BioReagents 
Diethylpyrocarbonate (DEPC) 97062-650 BDH 
Ethanol (96% vol) BDH1158-4LP BDH 
Ethylenediaminetetraacetic acid 
(EDTA) BDH9232-500G BDH 
Glycerol  G33-1 Fisher Scientific 
Green cell tracker C2925 Invitrogen 
Hydrochloric acid (HCL) 15242380 Fisher Scientific 
Hyper ladder TM I BIO-33053 Bioline Laboratory 
IPTG MB1008 Melford 
Isopropanol (Propan-2-ol) A416-1 Fisher Scientific 
LB Agar High Salt Granulated  GL1706 Melford 
LB Broth High Salt Granulated  GL1704 Melford 
LIVE/DEAD® Fixable Blue Dead 
Cell Stain Kit, for UV excitation L23105 Thermo Scientific 
Methanol BDH1135-4LP BDH 
TransBlot Turbo TM Mini-size 
Nitrocellulose  1704158 Bio-Rad 
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Trypan Blue Dye 1450021 Bio-Rad 
Novex Sharp Pre-Stained Protein 
Standard LC5800 Fisher Scientific 
Paper Developer  1757855 Ilford Multigrade 
Phosphate buffered saline BR0014 Oxoid 
Precision Plus Protein TM Dual Color 
Standard 1610374 Bio-Rad  
Protease Inhibitor Cocktail Tablets 04693116001  Roche 
PVDF Transfer Membrane, 0.45µm 88518 Thermo Scientific  
Resolving Gel Buffer 1610798 Bio-Rad 
Semi-skimmed Milk - Tesco 
10% SDS Solution 1610416 Bio-Rad 
Sodium acetate (NaAc) anhydrous S2889 Sigma Aldrich 
Sodium chloride (NaCl) S0520 Melford 
Gibco® Sodium pyruvate 11360070 Thermo Scientific 
Stacking Gel Buffer 1610799 Bio-Rad 
TransIT-LT1 Transfection Reagent MIR 2300 Mirus 
Tris-base BP152-500 Fisher BioReagent 
10X TRIS/GLYCINE/SDS (running 
buffer) EC-870 Flowgen Bioscience 
Triton® X-100 BP151-500 Fisher Scientific 
Tween® 20 BP337-500 Fisher Scientific 
 
2.1.2 Disposable labware 
Labware Supplier 
0.2µm sterile filters PALL, Life Science 
0.2ml Single Thin Wall Tube STAR LAB 
7ml Bijou Container STAR LAB 
Carbon steel surgical blades Swann-Morton Limited  
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Cell scraper 25cm SARSTEDT  
Chromatography paper, grade 3mm WhatmanTM  
Cryovials (Micro tube 2ml)  SARSTEDT 
Detoxi-gel TM Endotoxin Removing 
Columns, 5 x 1 ml Thermo Scientific  
Fluoroblock inserts Falcon 
96 well plate (black wall & clear bottom) 
and their lid Greiner bio-one 
Microfuge tubes (500, 1500 and 2000 µl) Greiner bio-one 
Corning® 96 well plates, opaque bottom Sigma-Aldrich 
Petri dishes  (100mm) Sterilin  
Pipetting tips (20, 200 and 100µl) STAR LAB  
Sterile multi-well plates (6, 12, 24 and 96) Costar 
Sterile plastic pipettes (1, 5, 10 and 25 ml) Costar 
Sterile syringes (1, 5 and 10 ml) BD Plastipak 
Sterile tubes (15, 20 and 50 ml) SARSTEDT 
Tissue culture flasks (T25, T75 and T175) Thermo 
Tissue culture plates (60mm and 100mm) Thermo 
 
2.1.3 Antibiotics  
Bacterial culture Mammalian tissue culture 
Antibiotic Supplier Antibiotic Supplier 
Carbenicillin Melford Hygromycin B Sigma-Aldrich 
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2.1.4 Antibodies and recombinant protein  
Antibody Catalogue number Supplier 
Anti-Fas (human, activating) Monoclonal 
Antibody 
05-201 Millipore 
Anti-Tissue Inhibitor of Metalloproteinase-
3, First Loop antibody produced in Rabbit 
T7687 Sigma-Aldrich 
Anti-TIMP3 antibody produced in Rabbit SAB4502973 Sigma-Aldrich 
Anti-V5 Mouse Monoclonal Antibody R96025 Novex 
PE Mouse Anti-Human CD309 (VEGFR-
2) 
560872 BD Pharmingen 
PE Mouse IgG1, K Isotype Control 554680 BD Pharmingen 
Polyclonal Swine Anti-Rabbit 
Immunoglobulins/HRP 
P0399 DakoCytomation 
Polyclonal Goat Anti-Mouse 
Immunoglobulins/HRP 
P0447 DakoCytomation 
TACE (D22H4) Rabbit Monoclonal 
Antibody  
6978S Cell signalling 
TIMP3 (D74B10) Rabbit Monoclonal 
Antibody 
5673S Cell signalling 






Recombinant protein Catalogue number Supplier 
Recombinant human TIMP3 (rhTIMP3) 973-TM-010 R&D System 
Recombinant human vascular endothelial 
growth factor 165 (VEGF165) 
100-20 Peprotech 
S100B protein from bovine brain S6677 Sigma-Aldrich 
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2.1.5 Cells and culture growth media   
Cells Growth Media Supplier 
α-Selected competent cells  - Bioline  
ARPE19 cells DMEM:F12 ATCC 
COS-7 cells DMEM ATCC 
HEK293T cells DMEM ATCC 
HUVEC EBM2 Lonza 
All mammalian cell culture growth media were ordered from Lonza. 
 
2.1.6 Enzymes  
Enzyme Catalogue number Supplier 
BamHI R0136S NEB 
EcoRI R0101S NEB 
EcoRV R0195S NEB 
HindIII R0104S NEB 
NheI R0131S NEB 
NotI R0189S NEB 
SacI R0156S NEB 
Xbal R0145S NEB 
XhoI R0146S NEB 
 
2.1.7 Instrumentation  
Instrument Supplier 
Autoclave Rodwell 
Cell Counting Slides for TC20 TM Cell 
Counter Bio-Rad 
CO2 incubator SANYO 
Coulter Vi-Cell XR analyser Beckman 
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3730 DNA sequencer Applied Biosystem 
DNA electrophoresis devices Bio-Rad 
FACSCalibur BD Bioscience 
Flow hood Wolf labs 
FLUOstar Galaxy plate reader BMG labTech 
Gel Doc TM EZ system Bio-Rad 
HypercassetteTM Amersham Bio sciences 
Inverted widefield fluorescence microscope 
LeicaDMI4000B Leica 
LSRII  BD Bioscience 
Microscope Mini protean apparatus Bio-Rad 
Mini spin centrifuge Eppendorf  
NanoDrop spectrophotometer Thermo Scientific  
Orbital Shaker S01 STUART Science  
SpectraMax 5Me microplate reader Molecular devices 
Trans-Blot ® Turbo TM Transfer System Bio-Rad 
TC20 TM Automated cell counter Bio-Rad 
Thermo cycler for PCR G-STORM 
Thermomixer 5437 Eppendorf 
TL-100 ultracentrifuge Beckman 
UV transiluminator (model TX-312A) Spectroline 
Water bath Fisherbrand 
Water deioniser NANOpure Diamond TM Barnstead 
 
2.1.8 Kits   
Kit Supplier 
BCA Protein Assay Kit  Pierce  
Cell Meter Caspase 3/7 Activity Apoptosis 
Assay Kit (Green Fluorescence) 
Advancing Assay & Test Technologies 
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Dual luciferase reporter assay system Promega 
HaloTag ® Mammalian Pull-Down system Promega 
GenEluteTM Gel extraction Kit  Sigma-Aldrich 
GenEluteTM HP Plasmid Miniprep Kit  Sigma-Aldrich 
GenEluteTM Plasmid Midiprep Kit  Sigma-Aldrich 
Luciferase assay system Promega 
LumiGLO Reverse Chemiluminescent 
Substrate Kit  
KPL  
Kit  Supplier  
nanoScript reverse-transcriptase Kit  Primerdesign  
Precision DNase Kit  Primerdesign  
Protein standard (liquid, 2mg protein/ml) Sigma-Aldrich 
QIAfilter Plasmid Maxi Kit  Qiagen  
QIAfilter Plasmid Midi Kit  Qiagen  
QuikChange II Site-directed Mutagenesis 
Kit 
Agilent Technologies 
TOPO cloning kit  Invitrogen 
 
2.1.9 Primers  
All oligonucleotide primers were commercially synthesised by Eurogentec or Eurofins MWG 
Operon; and were dissolved in the required volume of water to give a final concentration of 










Reverse 5’ CTTGCAGTTACAACCCAG GTGATACCG 3’ 
Exon 5- 
SplT3.M.S1 
Forward 5’ CGGTATCACCTGGGTTGTAACTGCAAGTTCATTCCACTT TAGG AAACAGAGCTGCC 3’ 




CCAAT TGAAACAGAAG 3’ 
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Reverse 5’ GGCGGGCGGCCGCGCATCAGCTTCTGCTCACACTGCC3’ 
Exon 5- 
SplT3.M.S3 
Forward 5’ CGTCGTCCTCGAGAAGCTTACCATGACCCCTTGGCTCG G G 3’ 
Reverse 
5’ CTCCTCGCGGCCGCTCAGGACAGCAGACTGGCTAAAGG 






G G 3’ 
Reverse 
5’ CTCCTCGCGGCCGCTCACTTCTGGGTTTCAGGACAGCA 













Direction Sequence  
Ser15Cys 
Forward 5’ CAGGACGCCTTCTGCAACTGCGACATCGTG 3’ 
Reverse 5’ CACGATGCAGTTGCAGAAGGCGTCCTG 3’ 
Tyr128Cys 
Forward 5’ CAAGATCAAGTCCTGCTGCTACCTTGCTTTG 3’ 
Reverse 5’ CAAAGCAAGGCAGGTAGCAGCAGGACTTGATCTTG 3’ 
Tyr154Cys 
Forward 5’ ATTTCGGTTACTGGCAGCCAGGGTAACCGAAAT 3’ 
Reverse 5’ GTAGTGTTTGGACTGGCAGCCAGGGTAACCGAAAT 3’ 
 
Tyr159Cys 
Forward 5’ GGCTACCAGTCCAAACACTGCGCCTGCATC 3’ 




Direction Sequence  
PcDNA3 Forward 5’ CGACTCACTATAGGGAGA CCCAAGC 3’ 





Direction Sequence  
T3spl775-792  Forward 5’ AAGTGGTTTCAAGTGGGC 3’ 
T3spl1191- Reverse 5’ CTACTGAGAGGACTTTTTCGTC 3’  






Forward 5’ TGGCTTCTGGCTACCTAAGG 3’  
T3spl4576-
4553r  
Reverse 5’ AAGAGATGCCCAAAGGAGGAAGCG 3’  
T3spl3576-
3553r  
Reverse 5’ TACTCTCTTCCCACTCTGCGGTTC 3’  
T32167-2149r  Reverse 5’ TGCTTGCTGCCTTTGACTG 3’ 
T3spl3193-
3214  
Forward 5’ CAGTTGTAGGGTTTCTGTTGTG 3’  
T3spl2275-
2295  
Forward 5’ AAGGAACTACAAGAGAGTCGG 3’ 
T3spl1575-
1593  
Forward 5’ AGTCCAAACACTACGCCTG 3’ 
 
2.1.10 Software  
List of software Version 
CellquestPro 5.1 
FinchTV 1.5.0 
GraphPad Prism 6 6.0c 
Image J IJ1.46r 
Image Lab 4.0.1 build 6 
Macvector 14 
Quantity One 4.6.3 
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2.1.11  Vectors 
 
2.1.12 Web database/resources 
Website Purpose  
Blast Sequence alignment  
ENSEMBL  Genome database browser  
QuikChange Mutational primer design 
UCSC Genome database browser  
 
  
List of vectors Supplier 








pGL4-Luc2P/NF- KB /Hygro Promega 
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2.2 Methods  
2.2.1 Molecular Biology Methods  
2.2.1.1 DNA plasmid construction  
2.2.1.1.1 End point Polymerase Chain Reaction (PCR)   
The polymerase chain reaction is a common and cost-effective technique applied to amplify 
target segments of DNA. Briefly, the reaction is performed using a thermo cycler to process 
three essential steps including denaturation, annealing and extension. The first denaturation 
step consists of heating the reaction to a high temperature (typically 94°C) to separate the 
double stranded DNA template, while the annealing temperature (typically 55-65°C) allows 
hybridization of oligonucleotide primers to the single stranded DNA. Once annealed, strand 
extension is achieved at a slightly higher temperature (usually 72°C) to synthesise new 
double stranded DNA. Subsequently, the PCR results in exponential amplification of the 
target DNA fragments. 
 
2.2.1.1.2 Overlapping Polymerase Chain Reaction  
To synthesised cDNA splice variants identified from the Taq PCR products without any PCR 
errors, Phusion Hot Start FlexTM 2x master mix (New England Biolabs) was used as 
instructed by the manufacturer. Using SplT3.M (3.3.1.2) maxiprep as DNA template, two 
amplification reactions were run separately to generate the exon 1 to 4 (E1-4) sequence of 
TIMP3 that is the same in all identified cDNA splice variants; and the novel exon 5 (E5) 
sequences using specific primers for each splice product. The primers were commercially 
synthesised to overlap about the novel splice acceptor sites (Figure 2.1).   
  




Figure 2.1: Overlapping PCR method to create cDNA of novel splice products. 
 
2.2.1.1.3 Mutagenesis (QuikChange TM)  
The QuikChangeTM II Site-Directed Mutagenesis Kit facilitates the induction of genetic 
changes including substitution, insertion or deletion of single or multiple nucleotide bases in 
a specific DNA plasmid sequence. In brief, the mutagenesis process consists of three stages: 
synthesis of mutant strand, digestion of DNA template and transformation of competent cells.  
The mutant strand DNA synthesis stage requires two completely overlapping oligonucleotide 
primers that are complementary to each strand at the mutation site but contain the desired 
mutation.  Following denaturation of the plasmid template and annealing of the primers, 
strand extension using PfuUltra (High-Fidelity) DNA polymerase then copies the entire 
plasmid. The mutagenesis sample reaction was performed together with a control reaction. 
The control reaction contained the following: pWhitecript control plasmid (4.5kb), 
oligonucleotide control primers, dNTP mixture, 10x reaction buffer, water and PfuUltra HF 
DNA polymerase. The mutagenesis reaction was similar to the control reaction except that 
the DNA template was the normal TIMP3 construct and the primers were specific primers 
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amplified using a G-STORM 482 (GRI) thermal cycler. The thermo cycler was programmed 
according to mutagenesis protocol; this was 95°C for 30 seconds followed by 18 cycles that 
included: separation of dsDNA at 95°C for 30 seconds, annealing of the mutagenic primers at 
55°C for 1 minute, and elongation at 68°C for 1minute/kb. This PCR stage results in nicked 
double stranded DNA plasmid carrying the desired mutation and the remaining parental DNA 
template.   
In the second stage, the parental DNA plasmid template only is digested with DpnI, which is 
a specific endonuclease for methylated and hemimethylated DNA. Therefore, the PCR 
products were endonuclease digested with DpnI at 37°C for 60-90 minutes to digest the 
parental DNA template leaving the newly synthesised DNA intact. The final stage includes 
transforming the mutated plasmid into XL1-Blue supercompetent cells for nick repair and 
replication.  
The QuikChange TM II Site-Directed Mutagenesis kit was utilised in this project to create 
SFD-TIMP3 mutation constructs by substitution of specific single nucleotides in the wild-
type TIMP3 sequence. 
 
2.2.1.2 Vector preparation  
2.2.1.2.1 Restriction enzyme digestion  
Restriction endonuclease digestion was used for both DNA cloning or confirming successful 
ligation of cDNA (restriction enzymes are listed in section 2.1.6). To clone a cDNA of 
interest into the desired plasmid, both cDNA and plasmid sequences were digested with the 
same restriction enzymes based on the manufacturer’s protocol, in which the concentration of 
restriction enzymes was always less than 10% of the final reaction volume to avoid star 
activity (non-specific restriction). Where two enzymes had compatible reaction buffers, they 
were combined in a single digest. If the enzymes had incompatible reaction buffers, two 
separate digestions were performed, purifying the DNA between digests. 
To quickly confirm successful ligation of DNA inserts into vectors, prior to sequencing, a 
restriction digest was often performed, followed by agarose gel electrophoresis. 
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2.2.1.2.2   Ligation reaction  
Ligation reactions were performed to ligate inserts (cDNA of interest) into desired vectors. 
All ligation reactions were made using T4 DNA ligase in the supplied buffer (Promega, UK) 
in a total volume of 20µl. Generally 40ng of digested vector was used at a molar ratio of 3:1 
(insert: vector), in which the amount of inserts was calculated as shown in the equation 
below: 
ng of insert = (ng of vector * size of insert (Kb)) / size of vector (Kb) * molar ratio (3/1) 
For each ligation reaction, a control reaction was also performed, containing vector only 
without any insert. Ligation and control reactions were incubated 2 hours at room 
temperature and then overnight at 4°C; and subsequently 5µl from each reaction was used to 
transform 50µl of α-select chemically competent cells. 
 
2.2.1.3 Transforming α-Select Chemically competent cells  
Transformation was performed using α-Select Chemically competent cells. These bacterial 
cells are derived from the E.coli K12 strain, and are comparable to the DH5α strain. They 
contain different genetic markers that allow efficient transformation including lacZ for 
blue/white colour screening and endA1 and recA1 to improve the quality of plasmid DNA 
and minimise recombination, respectively.  α-Select Bronze efficiency cells were used for 
routine sub-cloning and α-Select Gold efficiency cells used for recovering products following 
ligations. 
Mutagenesis or ligation reaction products were transformed into α-Select cells according to 
the manufacturer’s instructions. Cells were taken out of -80 ̊C and allowed to thaw on wet ice 
(50µl aliquot per reaction). 5µl of DNA reaction was added to the cells, which were then 
mixed gently by swirling and incubated on ice for 30 minutes. After that, cells were heated at 
42 ̊C for 45 seconds and placed again on ice for 2 minutes.  450µl of sterile LB broth was 
then added to each tube and they were incubated at 37 ̊C for 60 minutes in an orbital shaker. 
Subsequently, transformed cells (50-100µl) were spread on LB agar plates containing 
appropriate selective antibiotics and incubated overnight at 37 ̊C. 
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2.2.1.4 Small and large scale bacterial cell culture  
In order to prepare small-scale (miniprep) bacterial cell cultures, single colonies were 
harvested from transformation LB agar plates and grown separately (one colony per culture) 
in 4ml of sterile LB broth that contained carbenicillin at a final concentration of 100µg/ml. 
The cultures were incubated overnight at 37 ̊C in a shaker at 250rpm.   
After miniprep culture, large-scale bacterial cultures including midi and maxi prep were 
prepared by mixing 50µl or 150µl of miniprep culture with 50ml or 150ml of sterile LB broth 
containing 100µg/ml carbenicillin, respectively.  
 
2.2.1.5 Plasmid DNA purification  
To purify plasmid DNA from small-scale bacterial culture (miniprep), a GenElute TM plasmid 
miniprep kit was used based on the manufacturer’s instructions. Briefly, the kit is based on 
SDS/alkaline lysis, acetate precipitation of genomic DNA and protein; and then binding of 
the plasmid to a silica binding column followed by washing and elution in TE or water.  
To extract the plasmid DNA from large-scale bacterial cultures, similarly, a GenElute TM 
plasmid Midiprep kit was utilised to isolate the plasmid DNA from midiprep bacterial 
culture. Qiagen Maxiprep kits work on similar principles to the GenElute miniprep kits 
except the plasmid DNA is bound to an anion exchange resin instead of silica and is eluted 
using high salt buffer. Eluted DNA is then precipitated with isopropanol and washed with 
70% ethanol to remove salts but also allow DNA sterilization, which is necessary for 
transfection of mammalian cells. 
 
2.2.1.6 Nucleic acid quantification  
Following the plasmid DNA isolation, the quality and quantity of plasmid DNA were 
measured using a NanoDrop spectrophotometer, in which a 260/280 ratio of 1.8 and 2.0 were 
regarded as highly pure for DNA and RNA, respectively. 
 
2.2.1.7 Agarose gel electrophoresis   
Agarose gels were prepared at 1-2% in 1XTAE buffer depending on the size of DNA to be 
separated. For 1% agarose gel, 0.6 of agarose was dissolved in 60ml 1XTAE buffer in a 
microwave oven and subsequently 3µl of ethidium bromide (from a 10mg/ml stock) was 
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added to give a final concentration of 0.5µg/ml. The agarose solution was poured into the 
casting plate with comb and allowed to set at room temperature. 
In the meantime, the DNA samples were mixed with orange G loading dye (20% v/v) prior to 
loading in the agarose gel. The gel was placed in the gel tank filled with 1XTAE. The DNA 
marker and samples were loaded into the gel and allowed to run at a constant voltage of 80V. 
After that, the gel was visualised under UV light using Gel Doc TM EZ System and bands with 
the desired sizes were excised, when required.  
 
2.2.1.8 DNA extraction from agarose gel  
A GenElute Gel Extraction kit was used to purify separated DNA from agarose gel slices, 
according to manufacturer’s protocol. In brief, excised gel slices were weighed and then 
melted in a ratio of 1:3 (w/v) of provided solubilisation buffer. Then DNA was extracted 
using a silica spin column and DNA elution in either the provided elution buffer or water.  
 
2.2.1.9 DNA sequencing   
In order to check the quality of all purified DNA plasmids and the absence of any induced 
PCR mutations, they were sequenced in the Medical School genomic core facility using an 
ABI capillary sequencer using specific sequencing primers that anneal before the desired 
region. 
 
2.2.1.10 DNA precipitation  
Plasmid DNA precipitation was performed to sterilise the purified DNA prior to transfection 
of mammalian cells. Briefly, 50µg of DNA eluted in 100µl elution buffer was mixed with 
10% of 3M of sodium acetate (NaAc, pH 6). Each DNA sample was then mixed with two 
sample volumes of absolute ethanol and incubated on ice for 10 minutes. Samples were 
centrifuged for 10 minutes at maximum speed and 4 ̊C. After that, the pellets were washed 
with 500µl of 70% Ethanol and centrifuged for 5 minutes. Finally pellets were air-dried 
inside a safety cabinet and re-suspended in sterile water at a concentration of 1µg/ml. 
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2.2.1.11 RNA isolation  
To isolate total RNA from mammalian cells, TRI-reagent was used according to the 
manufacturer’s protocol. The reagent is a monophase solution and contains phenol and 
guanidine thiocyanate. Briefly, the procedure is an improved single-step method that directly 
lyses cells in 1ml reagent per 10cm plate. The cell lysates were mixed by repeated pipetting 
to become homogenous and then incubated at room temperature for 5 minutes, following by 
vigorously mixing with 100µl of 1- bromo-3-chloropropane. The solution was incubated at 
room temperature for 2-15 min and then centrifuged at 12000g for 15 min at 4°C. The 
centrifugation separated the mixture into three layers encompassing: a red organic protein 
phase at the bottom of the tube, an interphase containing DNA in the middle and a colourless 
upper aqueous phase containing RNA (Figure 2.2). The RNA aqueous phase was transferred 
to a new tube and mixed with 500µl of 2-propanol to precipitate the RNA. The RNA mixtures 
were allowed to stand at room temperature for 5-10 min and subsequently centrifuged at 
12000g for 10 min at 4°C. The RNA pellets were washed and mixed by vortexing with 70% 
ethanol and then centrifuged at 12000g for 5min at 4°C. The resulting pellets were air-dried 
for 5-10min and subsequently re-suspended in 50µl DEPC-treated water (diethyl 
pyrocarbonate). The quality and quantity of RNA was measured using a NanoDrop 
spectrophotometer as described in section 2.2.1.5. The purified RNA was stored at -80°C 
until use for cDNA synthesis.   
  












Figure 2.2: Separation of TRI-reagent. 
The separation of TRI-reagent cell lysate into three layers encompassing red organic 
(protein), inter (DNA) and upper colourless phase (RNA). (Servier Medical Art used 
to prepare the figure, http://www.servier.co.uk/medical-art-gallery/) 
 
2.2.1.12 Genomic DNA removal   
The RNA extraction procedure should remove most of the genomic DNA; nevertheless, the 
Precision TM DNase Kit was used to guarantee the purity of RNA. The kit was used according 
to the manufacturer’s protocol prior to reverse transcription. In brief, 25µl of RNA samples 
were mixed with 2.5µl DNase enzyme in the supplied DNase reaction buffer and then 
incubated for 10 minutes at 30°C. After that, the DNase enzyme was inactivated by 5 minutes 
incubation at 55°C. RNA samples could be either used immediately or stored at -80°C. 
 
2.2.1.13 Reverse transcription (RT)  
In order to synthesise first strand cDNA from the isolated RNA, Precision Nanoscript TM 
reverse transcription kit was applied according to manufacturer’s protocol. The reaction was 
performed using specific oligonucleotide reverse primers in two stages including annealing 
and extension. The annealing stage was at 65°C for 5 minutes following by cooling on ice, 
and then an extension stage that included heating the reaction at 55°C for 20 minutes and 
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inactivation at 75°C for 15 minutes (detailed in Table 2.3). The synthesised cDNA was stored 
at -20°C until use.   
 
Table 2.1: Reverse transcription reaction steps. 
Annealing reaction components  Extension reaction components 
DNase-treated RNA (at 
1µg/µl)  2µl  nanoScript 10x buffer  2µl 
Oligonucleotide primers (at 
10µM)  1µl  dNTP mix (10µM)  1µl 
Nuclease free water Up to 10µl  DTT (100µM)  2µl 
- -  Nuclease free water 4µl 
- -  nanoScript enzyme 1µl 
- -  Annealing reaction 10µl 
 
 
2.2.1.14 PCR purification  
To purify PCR products from the reaction mixture, a GenElute TM PCR clean up kit was 
utilised based on the manufacturer’s protocol.  Like the other GenElute kits, DNA is purified 
on a silica membrane in a spin column, then washed and eluted in either the provided elution 
buffer or water. The purified DNA can be either stored at -20°C or used immediately in other 
reactions such as TOPO cloning. 
 
2.2.1.15 TOPO cloning 
In order to clone purified Taq PCR products, the TOPO TA cloning kit was applied as 
described in the manufacturer’s protocol. Briefly, the provided vector has a single 3’ 
deoxythymidine (T) overhanging residue that allows efficient ligation to the 
3’deoxyadenosine end of Taq PCR products. Additionally the ligating enzyme, 
topoisomerase I, is covalently bound at the 3’ phosphate of the deoxythymidine overhang. 
This provides a highly efficient way of cloning very small amounts of PCR product, as 
further restriction and purification are unnecessary. The products of the TOPO reactions were 
used to transform chemically competent E.coli as described in section 2.2.1.2.3.   




2.2.2 Mammalian cell culture methods 
 
2.2.2.1 COS-7 cell line  
African green monkey kidney cells (COS-7) are derived from the CV-1 cell line 
(Cercopithecus aethiops) by transformation with an origin defective mutant of SV40. They 
were used due to the fact that they express SV40 large T antigen, enabling vectors containing 
the SV40 origin of replication, such as pcDNA3, to replicate and transiently express high 
level of mRNA and protein.  
 
2.2.2.2 ARPE19 cell line  
ARPE19 is a human retinal pigment epithelial cell line derived from normal eyes (Dunn et al. 
1996). The ARPE19 cell line was used in this project, as RPE cells are the primary source of 
TIMP3 in the retina.  
 
2.2.2.3 HEK293T cell line   
HEK is human embryonic kidney cell line derived from a healthy-aborted fetus. The cell line 
was firstly transformed with adenovirus in the 1970s and named HEK293 based on Frank 
Graham’s 293rd experiment. Subsequently, HEK293 cell were transformed with the large T 
antigen of the SV40 virus that enable replication and amplification of vectors carrying SV40 
origin.  
 
2.2.2.4 HUVEC cell line  
These are primary human umbilical vein endothelial cells (HUVEC) and derived from 
endothelium of veins from umbilical cord. HUVEC cells express VEGFR1 and VEGFR2 and 
are commonly used for pharmacological and physiological investigation, for instance, blood 
coagulation, fibrinolysis and angiogenesis. They were grown until 90% confluent in complete 
growth medium comprising Endothelial Basel Medium 2 (EBM2) and the supplied 
supplement at 37°C in 5% CO2.  
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Serum starvation medium was used to examine endothelial cell signalling and function in 
vitro as complete growth medium contains VEGF and other growth factors that would 
interfere with signalling. Cells were grown to 90% confluence in complete growth medium 
and then washed twice with DPBS to guarantee complete removal of the complete growth 
medium. After that, cells were incubated in starving medium (0.5% FBS-EBM2) at 37°C in 
5% CO2 for 17-18 hours.  
 
2.2.2.5 Cell culturing procedures  
For routine culturing, when cells became 80-90% confluence they were passaged by 
trypsinisation. The medium was discarded from flasks and cells were washed in 5ml of DPBS 
(Dulbecco’s phosphate buffered saline), which was discarded. Then 3ml of trypsin/EDTA 
was added to the cells and incubated at 37°C in 5% CO2 for 8 minutes to remove cells from 
the surface of the flask. Cells detachment was checked under a microscope and, once 
complete, 7ml of complete growth medium was added to the cells to inactivate the trypsin-
EDTA. Suspended cells were centrifuged at 400g for 5 minutes. The resulting pellet was re-
suspended by addition of complete growth medium. Finally, the desired amount of cell re-
suspension was seeded into a fresh tissue vessel containing complete growth medium. 
Where functional assays required a specific number of cells, cells in suspension were counted 
using either Vi-CELL Cell Viability Analyser or TC20 Automated Cell Counter, and then the 
required numbers of cells were added to the desired tissue culture vessels.  
 
2.2.2.6 Cell detachment using 10mM EDTA 
Cells detachment using 10mM EDTA prepared in DPBS was performed instead of trypsin-
EDTA, when cell membrane proteins and receptors required being intact for the subsequent 
assays. Cells were passaged as explained in section 2.2.2.5, except that cells were incubated 
in 10mM EDTA for 5-20 minutes at 37°C instead of using trypsin-EDTA.  
 
2.2.2.7 Cell labelling  
To label cells with CellTrackerTM dye, cells at 90% confluence were rinsed twice with DPBS 
and then incubated at 37°C and 5% CO2 in serum-free medium containing CellTrackerTM 
Green dye at a concentration of 1:4000. 




2.2.2.8 Cryopreservation of mammalian cell lines 
Long-term preservation of cells is achieved using liquid nitrogen (-196°C). Cells were 
passaged as normal, however, cell pellets were re-suspended in a freezing medium composed 
of FBS (90%) and DMSO (10%). The re-suspension was put into cryopreservation vials 
(cryovials) and placed in a Mr Frosty box at -80°C for at least 24 hours to decrease the 
temperature gradually prior to transferring vials to a liquid nitrogen dewar.  
For thawing cell lines, complete growth medium was warmed to 37°C prior to use. Cryovials 
were retrieved from liquid nitrogen and allowed to defrost at room temperature inside the 
laminar flow cabinet. Cells were mixed with complete medium and then centrifuged at 500g 
for 5 minutes to remove DMSO. The pellet was re-suspended in complete medium and grown 
in tissue culture vessels at 37°C and 5% CO2. 
 
2.2.2.9 Chemical transfection of cell lines using TransIT-LT1 transfection 
reagent  
 In order to examine the mRNA/protein expression of the desired DNA plasmids, TransIT-
LT1 transfection reagent was used to transiently or stably transfect mammalian cells with the 
various DNA constructs. According to the manufacturer’s instructions, transfection was 
conducted in the desired tissue culture vessels when cells became ≥80% confluent (Table 
2.2). 24 hours prior to transfection, cells were seeded into the desired tissue culture vessels at 
a density of 0.8-3.0 x105 per well of a 6-well plate and incubated overnight in a 37°C, 5% 
CO2 incubator. The following day cells were ~80% confluent and TransIT-LT1 reagent and 
DNA complexes were prepared in sterile microcentrifuge tubes. Firstly, the serum free 
medium was mixed with plasmid DNA, and then TransIT-LT1 reagent was added and mixed 
by gentle repeated pipetting. The complexes were incubated at room temperature for 15-30 
minutes and then added drop-wise to different areas of the wells and rocked gently to ensure 
even distribution of TransIT-LT1: DNA complex and incubated at 37°C and 5% CO2 for 24-
48 hours prior to harvesting.  
Whilst transiently transfected cells were harvested at 48 hours post-transfection, stably 
transfected cells were passaged and grown in 25cm flasks containing 5ml complete growth 
medium and selection antibiotic such as Geneticin at 500µg/ml. Then, growth medium was 
regularly replaced with fresh growth medium and antibiotic until cells became confluent.  


















Culture vessels 6-well plate 6cm dish 10cm dish 
Complete growth media (ml) 2.5 6 15.5 
Serum-free medium (ml) 0.250 0.6 1.5 
DNA ( µl, stock 
concentration at 1µg/µl) 2.5 5.8 15 
TransIT-LT1 reagent:DNA 
ratio 3:1 4:1 6:1 8:1 3:1 3:1 
TransIT-LT1 (µl) 7.5 10 15 20 17.5 45 




2.2.3 Protein analysis 
2.2.3.1 Protein extraction  
2.2.3.1.1 Cell lysis  
In order to release cellular proteins and remove cell debris, mammalian cells were lysed in 
RIPA lysis buffer when needed. Briefly, cells were grown in 10cm diameter petri dishes in 
complete growth medium until they were 100% confluent. Then cells were washed twice in 
DPBS and scraped in 500µl of ice-cold RIPA lysis buffer. Cell lysates were transferred to a 
micro-centrifuge tube and a syringe with a 25-gauge needle was used to disrupt cell 
membranes and shear genomic DNA. Tubes were placed on ice for 30 minutes and mixed by 
vortexing every 15 minutes to complete solubilisation. To remove insoluble cell debris, a 10 
minutes centrifugation was performed at 4°C and 21000 g. Clear cell lysates were pipetted 
into new micro-centrifuge tubes and stored at -80°C until use for protein assay and western 
blotting.  
 
2.2.3.1.2 ECM preparation using hypotonic buffers  
ECM was prepared from transiently transfected COS-7 cells two days post-transfection while 
it was prepared from stably transfected ARPE19 cells 10 days post seeding. Untransfected 
and transfected cells were lysed using hypotonic buffers and their ECM was prepared based 
on the method described by Fischer and Werb (1995). Cells were treated with three buffers 
including Hypo-buffer, NP40-hypo and 0.1% Deoxycholate to remove all cells, leaving 
behind the ECM. Briefly, cells in tissue vessels were sequentially washed (2-3 times) and 
incubated 2-10 min in the above-mentioned buffers. Then, plates were washed with water 
using a squeeze bottle and allowed to air-dry. Dried plates were stored inverted at 4°C until 
use. The ECM was then extracted for western blotting by scraping directly into 1X SDS 
sample buffer. 
 
2.2.3.1.3 Cell removal using ammonium hydroxide  
ARPE19 cells were lysed using ammonium hydroxide (NH4OH) when ARPE19 basement 
membrane was required to be used for functional assays. ARPE19 cells were grown and 
maintained in tissue culture vessels for 10 days. The complete growth medium was discarded 
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and cells were incubated with 20mM NH4OH for 5 minutes at room temperature to lyse cells 
and then the ECM/basement membrane was gently washed several times with DPBS ready 
for the subsequent assays. 
 
2.2.3.2 Protein quantification  
The Pierce BCA protein assay kit was used according to the manufacturer’s protocol to 
determine the concentration of protein in ECM or cell lysates. The protocol briefly consists of 
two steps including formation of blue coloured complexes between copper sulphate solution 
and bicinchoninic acid (BCA) solution, and a second reaction between the preformed 
complex and test proteins. The second reaction products form a purple colour with a 
maximum absorbance at 562nm. Bovine serum albumin (BSA) was used to prepare six 
standard protein concentrations in the range (0-1mg/ml) with 1X sample buffer or lysis buffer 
depending on sample extraction method, and 25µl of sample was loaded into a well of a 96-
well plate (three wells for each tested sample). Similarly 10µl of protein sample was mixed 
with 90µl 1X sample buffer and then pipetted into wells. A mixture of copper II sulphate and 
BCA was prepared at 1:50 ratio and added to each standard and sample (200µl/well). After 
addition of the BCA- copper sulphate solution, the 96 well plates were incubated at 37°C for 
30min following by measuring the protein concentration in a Fusion plate reader at 570nm.  
 
2.2.3.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE)  
2.2.3.3.1 Gel preparation and electrophoresis   
10% polyacrylamide separating gels were prepared in a 1.5mm discontinuous mini gel system 
by mixing the reagents in Appendix 2. Firstly, the lower resolving gel layer was prepared and 
poured into the assembled plates. Water-saturated butanol (500ul per gel) was then added to 
the top of the gel to eliminate bubbles and to level the gel. After 1 hour at room temperature, 
the water-saturated butanol was discarded by washing with water and then excess water was 
removed using filter papers. Secondly, the upper stacking gel was prepared and poured onto 
the top of the resolving gel. A 1.5mm comb was immediately inserted in the assembled plate 
and then the gel allowed to set for 30 minutes.  
Meanwhile, all protein samples were quantified with BCA to ensure equal amounts of protein 
were loaded/well and diluted by mixing with 2X sample buffer as necessary. Samples were 
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run at 120 volts for 15 minutes and then at 150 volts for 60 minutes or until the bromophenol 
blue dye reached the bottom of the resolving gel.   
 
2.2.3.3.2 Protein transfer onto PVDF 
A Bio-Rad mini-Protean 3 blotting apparatus was used to transfer separated protein samples 
from resolving gel onto polyvinylidene diflouride (PVDF) or nitrocellulose membrane. 
PVDF membrane was firstly soaked in methanol for 2 minutes and then in CAPS transfer 
buffer for 5 minutes, whereas nitrocellulose membrane was immediately soaked in CAPS 
transfer buffer. Then the gel, two foam pads and four filter papers were placed in the CAPS 
transfer buffer for 10 minutes. After that, they were prepared in a mini gel holder cassette and 
inserted into the Mini Trans-Blot apparatus in CAPS buffer or a cassette of the Trans-Blot 
Turbo TM transfer system as shown in Figure 2.3. The proteins transfer process was performed 
overnight at 4 ̊C and 60mA constant current (Mini TransBlot) or 10-30 minutes at 2.5A 
(Trans-Blot Turbo TM). 
  














Figure 2.3: Illustration of prepared stack for protein transfer. 
The diagram shows the organisation of different layers in protein transfer apparatus. 
(A) Layers arrangement inside the Mini Gel Holder Cassette for Mini Trans-Blot 
apparatus. For Trans-Blot ® Turbo Transfer System, the same arrangement was 
made but without the foam pads.  
 
 
2.2.3.3.3 Blocking and probing of PVDF Membrane   
To prevent non-specific binding of antibodies to the PVDF or nitrocellulose membranes, they 
were incubated in blocking buffer for 1-6 hours on a shaker at room temperature or overnight 
at 4 ̊C.  
The blocked membrane was incubated in the desired primary and secondary antibodies 
(Table 1.6) used at the optimal concentration (see results chapters) and diluted in blocking 
buffer. The membrane was initially incubated in the primary antibody overnight at 4 ̊C on a 
shaker. The membrane was then washed 4 times (10 minutes each) with 1X TBST to 
eliminate unbound antibodies.  
Afterward, the membrane was incubated in polyclonal secondary antibody conjugated with 
horseradish peroxidase (HRP) for 1 hour at room temperature with gentle shaking. To remove 
unbound secondary antibodies, the membrane was washed 4 times (10 minutes each) with 1X 
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Table 2.3: List of primary and secondary antibodies used in western blotting. 
Primary Antibody  Purpose of use 
Anti-Tissue Inhibitor of 
Metalloproteinase-3, First 
Loop antibody produced in 
Rabbit 
A polyclonal antibody produced in rabbit and specifies to the 
first loop of human TIMP-3 (Amino-terminus of TIMP3), 
including wild type, all exon 5 SFD-mutant and splice site 
mutant TIMP3 proteins. 
Anti-TIMP3 antibody 
produced in Rabbit 
A polyclonal antibody, produced in rabbit, detects 
endogenous levels of full-length TIMP3 protein (Carboxyl-
terminus of TIMP-3) such as wild type and exon 1 SFD-
mutant TIMP3 proteins. 
TIMP3 (D74B10) Rabbit 
Monoclonal Antibody 
A monoclonal rabbit antibody corresponding to residues 
surrounding Lys 53, and used to detect the Amino-terminus 
of human TIMP3 including wild type and all exon 5 SFD-
mutant and splice site mutant TIMP3 proteins. 
Anti-V5 Mouse Monoclonal 
Antibody 
A monoclonal antibody, produced in mouse, recognises 
protein with V5 epitope tag. For example, pcDNA3- WT-




A monoclonal antibody, produced in mouse, recognises Halo-
Tagged proteins, including pHTC, pHTC-WT.TIMP3, pHTC-
S181C, pHTC-EFEMP1 (wild type and mutant), pcDNA3-
SS-HaloTag and pcDNA3-SS-HaloTag-EFEMP1 (wild type 
and mutant). 
TACE (D22H4) Rabbit 
monoclonal Antibody  
 
A monoclonal antibody, produced in rabbit, reacts with 
endogenous levels of total TACE protein. 
RAGE Rabbit Monoclonal 
Antibody 
A monoclonal antibody, produced in rabbit, recognises 
endogenous levels of total RAGE protein. 




A horseradish peroxidase-conjugated polyclonal swine anti-
rabbit antibody used to detect rabbit primary antibodies.  
Polyclonal Goat Anti-Mouse 
Immunoglobulins/HRP 
A horseradish peroxidase-conjugated polyclonal goat anti-
mouse antibody used to detect mouse primary antibodies. 
 
2.2.3.3.4 Detection of protein bands   
A LumiGLO Reverse Chemiluminescent substrate kit was used to detect secondary 
antibodies based on the manufacturer’s instructions. Briefly, the PVDF membrane was rinsed 
in 1X TBST and the excess wash buffer removed.  The membrane was placed into a tray in 
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which bands should be placed upwards and then the substrate solution was added directly for 
1 minute. Excess substrate was then removed and the membrane wrapped in a cling film. The 
wrapped membrane was then exposed to photographic film (Amersham Hyperfilm ECL) for 
a period of time between 1 second to 20 minutes. After exposure, the film was soaked in 
developing solution until the bands become clear then rinsed in tap water. Finally, the film 
was placed into fixing solution for 1-2 minutes, washed again in tap water and air-dried.  
 
2.2.3.4 Caspase 3/7 activity apoptosis assay  
To investigate the effect of WT.T3 and SFD-TIMP3 on ARPE19 cells apoptosis, Caspase 3/7 
activity was measured as an indicator for cell apoptosis using Cell Meter TM Caspase 3/7 
Activity Apoptosis Assay Kit according to manufacturer’s protocol. In brief, un-transfected 
ARPE19 cells and ARPE19 cells stably transfected with TIMP3-constructs were plated in 2% 
FBS supplemented DMEM growth media in 96-well plates at 2x104 cells per well and 
incubated at 37 ̊C and 5% CO2. 24 hours post seeding, cells were treated with Camptothecin 
(20µM) or anti-Fas activating antibody (15-20µg/ml) for 24 hours at 37 ̊C. Caspase 3/7 assay 
loading solution was added to treated cells at a 1:1 ratio (caspase solution: cell media) and 
incubated at room temperature covered from light for at least 1 hour. Fluorescence intensity 
was measured at an emission wavelength of 525nm and excitation wavelength of 490nm 
using the spectraMax plate reader.  
 
2.2.3.5 Endothelial cell signalling and functional assays 
2.2.3.5.1 Flow cytometry for VEGFR2 expression 
In order to examine the influence of ECM proteins from ARPE19 cells transfected with wild-
type and SFD-TIMP3 on VEGFR2 expression by vascular endothelial cells, the expression of 
the receptor was measured by flow cytometry.  
Un-transfected and transfected ARPE19 cells were grown in 6 or 10cm tissue culture dishes 
for 10 days in complete growth media and selection antibiotic for transfected cells. 
Meanwhile, HUVEC were grown until they became 90% confluent and then incubated 
overnight in serum-starved media (0.5% FBS-EBM2). The following day, ARPE19-ECM 
was prepared using NH4OH as described in section 2.2.4.1.3 and HUVEC were passaged as 
normal. Then, HUVEC were re-suspended in serum-starved medium and seeded at a density 
of 1-3x106 per plate onto three different treatment groups including a negative control 
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without treatment, a positive control group containing VEGF (at 10ng/ml) and tested group 
with ARPE19-ECM. All treated HUVEC groups were incubated at 37 ̊C for 4-5 hours.  
When treatment was completed, HUVEC were washed once with DPBS and detached by 
incubating in 10mM EDTA (prepared in DPBS) for 5-20 minutes at 37 ̊C (see 2.2.2.5-6). Cell 
pellets were re-suspended in 0.1% FBS-DPBS (110µl per sample) and then each sample was 
divided into micro-centrifuge tubes (50µl each), the first tube to be treated with PE 
(phycoerythrin) mouse anti-human CD309 (VEGFR2) and the second one for PE mouse 
IgG1, k isotype control. Tubes were mixed by gentle vortexing and then incubated for 15-30 
minutes in a covered ice bucket to protect from light. HUVEC were washed once in 0.1% 
FBS-DPBS and centrifuged for 5 minutes at 127g and the second wash was with DPBS only. 
To check cell viability, cell pellets were re-suspended in 500µl DPBS and mixed with 0.5µl 
of LIVE/DEAD® Fixable Blue Dead Cell Stain Kit. Tubes were incubated for 30 minutes in 
a covered ice bucket. Subsequently cells were washed once in 1ml of DPBS and then re-
suspended in 500µl of 1%PFA to fix stained cells, which could be either analysed 
immediately or stored at 4 ̊C protected from light for up to a week, prior to analysis by flow 
cytometry. 
 
2.2.3.5.2 Migration assay 
This assay was conducted to examine the effect of WT- and SFD-TIMP3 secreted in the 
ECM of transfected ARPE19 cells on the ability of HUVEC to invade/migrate through the 
matrix. HUVEC were grown in complete growth medium to reach 90% confluence and then 
serum starved overnight as described in section 2.2.2.4. CellTrackerTM dye was then used to 
label HUVEC (section 2.1.9) that were seeded at a density of 50x103 per insert onto 
ARPE19-ECM prepared using NH4OH in the Falcon® HTS FluoroBlokTM Inserts (8µm 
pores) in serum starved medium. The FluoroBlok inserts were placed into wells of 24-well 
plates containing serum starved medium and VEGF at 10ng/ml. The HUVEC were incubated 
at 37 ̊C for 4-5 hours to allow cells to invade ARPE19-ECM and migrate to the lower 
chamber containing VEGF. Since the membrane of the inserts is opaque to fluorescent light, 
only cells that have migrated through the membrane are visible under the inverted fluorescent 
microscope or to the plate reader. After incubation the inserts were washed twice in DPBS 
and placed in fresh 24-well plates. The migrated cells in the inserts were fixed in 1% PFA 
prepared in DPBS and visualised immediately or stored at 4 ̊C for up to one week. The 
migrated cells were visualised using a fluorescent microscope at a final magnification of 
200X (inverted widefield fluorescence microscope LeicaDMI4000B). The number of 
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migrated cells in the lower chamber was measured using a fluorescence plate reader at an 
excitation wavelength of 492nm and emission wavelength of 517nm.  
 
2.2.3.6 Protein Pull down assay     
To examine the interaction between EFEMP1 and TIMP3 proteins, a pull down assay was 
performed using HaloTag Mammalian Pull-Down and Labelling System kit and HEK293T 
cells. HEK293T cells were used for all pull down assays due to the fact that they are very 
highly transfectable cells and contain SV40 T-antigen allowing increased replication of 
vectors carrying SV40 region of replication. According to manufacturer’s instructions, the 
pull-down assay was achieved in four stages including creating HaloTag fusion constructs, 
transfecting mammalian cells with HaloTag constructs, protein pull-down and detecting 
proteins bound to the HaloTag fusion proteins by western blotting.  
 
2.2.3.6.1 Transfecting mammalian cells and cell lysate preparation  
HaloTag-EFEMP1-pcDNA3 and TIMP3-pcDNA3 constructs were already available in our 
laboratory. HEK293T cells were transiently transfected with HaloTag-EFEMP1 and TIMP3-
V5-KDEL constructs in 6-well plates (Section 2.2.3 & Table 2.2). 24 hours post transfection, 
transfected cells were washed with ice-cold DPBS and then harvested by gentle scraping in 
ice-cold DPBS followed by centrifugation at 4 ̊C for 5-10 minutes. Cell pellets were stored at 
-80 ̊C for at least 30 minutes before continuing with the cell lysis procedure. Thawed cells 
were re-suspended in 100µl mammalian lysis buffer provided in the kit and 2µl of 50x 
protease inhibitor cocktail and then incubated on ice for 5 minutes. Cell lysates were loaded 
onto QIAshredder columns to eliminate cell debris and shear genomic DNA and then the 
flow-through lysates were diluted with 100µl of 1X TBS buffer.   
 
2.2.3.6.2 Protein Pull-Down protocol  
HaloLink TM resin (25µl per cell lysate) was equilibrated by washing with 400µl of 1XTBS-
NP40 wash buffer followed by 2 minutes centrifugation at 800g at room temperature.  This 
was repeated three times. Diluted cell lysates were then added to HaloLink resin tubes and 
incubated at 4 ̊C overnight on a blood mixer. The following day, tubes were spun for 2 
minutes at 800g and then washed 4 times with 1X TBS-NP40 wash buffer, briefly 
centrifuging after each wash. Protein samples were eluted in 25µl of SDS-Elution buffer at 
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95 ̊C for 10 minutes and subsequently centrifuged at 800g for 2 minutes. The supernatant was 
transferred to fresh micro-centrifuge tubes. In the final step, 10µl of supernatant was analysed 
by SDS-PAGE and western blotting (section 2.2.1.3 & 2.2.1.4). 
 
2.2.3.7 RAGE signalling assays  
Since RAGE-ligand binding is known to result in activation of the NF-KB transcriptional 
pathway, NF-KB firefly luciferase reporter vectors were used in conjunction with Promega’s 
standard or dual luciferase reporter assay systems. The vectors comprised either the pGL4-
luc2P/NF- KB vector, which contains five copies of the NF-KB response element, or the 
pGL3-IL8-Luc vector, which contains a 212bp section of the human interleukin 8 promoter 
sequence inserted into the pGL3-basic reporter vector. The IL8 promoter sequence contains a 
number of NF-KB response elements, as well as additional transcription factor binding sites. 
 
2.2.3.7.1 Dual luciferase reporter assay system  
In order to investigate the effect of wild type- and SFD- TIMP3 on RAGE signalling, dual 
luciferase reporter assay was performed using ECM from both un-transfected and SFD-
transfected cells. The Dual Luciferase reporter assay system was carried out according to the 
manufacturer’s protocol. The assay enables distinct detection or both firefly and Renilla 
luciferase in the same sample.  Cells are transfected with both the firefly reporter vector and a 
constitutively active Renilla vector. By determining the ratio of firefly to Renilla luciferase 
activity, rather than just total luciferase activity, it is possible to control for differences in 
transfection efficiencies that may occur between samples.  The assay was divided into three 
stages involving transient co-transfection of mammalian cells, time course treatment of 
transfected cells and measurement of luminescence signals in cell lysates.  Firstly, HEK293T 
cells were seeded into 6-well plates at a density of 5x105 per well in 2% FBS-DMEM growth 
medium for 24 hours prior to transfection. The following day, cells were co-transfected with 
Renilla and firefly luciferase reporter vectors using TransIt-LT1 transfection reagent at ratio 
of 3:1 (TransIT-LT1: DNA). Transfection of HEK293T cells was performed at two different 
vector ratios including 4:1 and 40:1 for experimental vector: co-reporter vector in four 
separate groups depending on the firefly vectors used (Table 2.4). Transfected HEK293T 
cells were then incubated at 37οC and CO2 for 24 hours. After transfection, 24-well plates 
were coated with S100B (10µg/ml), control-BSA or AGEs-BSA (200µg/ml) prepared in 
0.05M bicarbonate buffer at 4οC for 24 hours (500µl/well). 




Table 2.4: Transfection group for dual luciferase reporter assay system. 
Groups   Group 1 Group 2 Group 3 Group 4 
Renilla 
luciferase  pTK-Ren pTK-Ren pTK-Ren pTK-Ren 
Firefly 
luciferase pGL3-Basic pGL3-Control 
pGL3-IL8-
Luc pNF- KB -Luc 
 
In the second stage, transfected HEK293T cells were washed once with DPBS and detached 
by incubating in 10mM EDTA prepared in DBPS at 37οC and CO2 for 5 minutes. Cells were 
collected in DPBS and centrifuged at 500 g at room temperature. The cell pellet was re-
suspended in 2% FBS-DMEM growth media and counted. The transfected cells were then 
plated at a density of 40x103 cells/well onto plates coated with the control proteins (S100B, 
normal BSA or AGE-BSA) or wells containing ECM from ARPE19 cells transfected with 
wild-type or SFD-mutant TIMP3.  The plates were then incubated for 12, 24, 48 or 72 hours 
at 37οC and 5% CO2. Finally, following incubation and when cells were no more than 95% 
confluent, the growth medium was removed and the cells washed once with DPBS 
(500µl/well). 100µl of passive lysis buffer was dispensed into each well and then the plates 
incubated at room temperature for 15 minutes with gentle shaking. The cell lysates were 
transferred to a microcentrifuge tube and frozen at -80οC or directly used in the reporter 
assay. For the luciferase reporter assay, 20µl of each of the cell lysates was transferred to an 
opaque 96-well plate and 30µl of luciferase assay reagent II (LAR II) added to each well. The 
mixture was mixed gently by repeated pipetting two to three times and the firefly luciferase 
activity was measured using a SpectraMax 5Me microplate reader. Then, 30µl of Stop & 
Glo® Reagent was mixed gently with each sample and the Renilla luciferase activity 
measured using the same microplate reader.  
 
2.2.3.7.2 Luciferase assay system   
To examine the influence of WT.T3 and SFD-TIMP3 on RAGE signalling and confirm the 
results of dual luciferase reporter assays, the Luciferase assay system was conducted based on 
manufacturer’s protocol. Like the Dual luciferase reporter assay, the luciferase assay was 
divided into three stages encompassing transient transfection of mammalian cells, treatment 
of transfected cells and luminescence signal measurement in cell lysates.  
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Firstly, HEK293T cells were seeded into 24-well plate at a density of 4x104 per well in 2% 
FBS-supplemented DMEM growth medium for 24 hours prior to transfection. The next day, 
cells were transfected with the desired DNA plasmids using TransIT-LT1 transfection 
reagent. The transfection was performed with three DNAs encompassing pGL4-luc2P/NF- 
KB, RAGE and pcDNA3-TIMP3 (WT/SFD mutant), and divided into four groups depending 
on the type of TIMP3 plasmids used per well (triplicate wells for each tested transfection 
TIMP3 DNA) (Table 2.5).   
Secondly, 24 hours post-transfection, transfected cells were incubated for another 24 hours. 
Following 24 hours of treatment, all transfected cell groups were washed once with DPBS 
and the provided 1X lysis buffer was added directly to cells (110µl per well). The plate was 
gently rocked to ensure complete distribution by the lysis buffer and then cells were scraped 
and collected in a microcentrifuge tube. The cell lysate tubes were placed on ice for 5 minutes 
following by a short vortex and then centrifugation at 4°C and 12,000g for 2 minutes. The 
supernatant was transferred to a new tube which could be either stored at -80°C or 
immediately used to measure luminescence signals. 
In the third stage, an opaque 96-well plate was utilised to prevent the luminescence from 
affecting adjacent wells. 20µl of cell lysate was added to each well of a 96-well plate and 
mixed carefully with 30µl of the luciferase assay reagent to prevent bubbles. The 
measurement of luminescence signals was performed using a SpectraMax 5Me microplate 
reader.  
  





Table 2.5: Transfection groups for luciferase assay system. 
 











RAGE RAGE RAGE RAGE 
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3.1 Introduction  
Many of the TIMP3 mutations have been examined and shown to result in TIMP3 
dimers/multimers, decreased TIMP3 turnover and accumulation of TIMP3 in the ECM 
(Langton et al. 2005). Despite these biochemical characteristics, mutant TIMP3 protein is still 
a functional MMP inhibitor (Langton et al. 1998, Langton et al. 2005, Saihan et al. 2009). 
This strongly implicates TIMP3 dimerisation in the SFD phenotype. However, four missense 
mutations and a splice site mutation in the TIMP3 gene have also been reported to cause 
SFD, including a Ser15Cys in exon 1, Tyr128Cys, Tyr154Cys and Ty159Cys in exon 5, and 
a splice site mutation caused by a single adenosine insertion at the intron4/exon5 junction site 
(Fung et al. 2013, Gliem et al. 2015, Schoenberger and Agarwal 2012, Tabata et al. 1998). 
The effect of these four missense mutations on the TIMP3 protein has yet to be determined, 
however the splice site mutation was previously shown in our lab to give rise to several splice 
variant mRNA species and a protein with high molecular weight (Alsaffar 2011) when 
expressed in COS-7 cells. Nevertheless, this is quite an artificial non-human expression 
system mediated by episomally replicated vector and it was deemed important to examine the 
consequence of these mutations on TIMP3 protein produced by human retinal pigment 
epithelial cells, as these are the source of the protein in the retina.  If any of these mutations 
failed to dimerise/multimerise it would cast great doubt on the hypothesis that this is a 
prerequisite for the disease process.  
The hypothesis of this chapter is that TIMP3 dimerisation/multimerisation is a prerequisite 
for the SFD phenotype. Hence the initial aim is to confirm the common molecular 
characteristics of the Ser15Cys, Tyr128Cys, Tyr154Cys, Tyr159Cys and splice site mutations 
and, for the splice site mutation, to relate this to mRNA produced. SFD patients’ samples 
were not available; therefore, this aim would be achieved by creating and expressing mutant 
gene constructs in retinal cells (ARPE19).  
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3.2 Methods  
3.2.1 Creation of SFD-TIMP3 gene constructs  
3.2.1.1 Creation of S15C, Tyr128Cys, Tyr154Cys and Tyr159Cys 
SFD-TIMP3 gene constructs encompassing S15C, Y128C, Y154C and Y159C were created 
using the QuikChange II site-Directed mutagenesis kit. The PCR mutagenesis reaction was 
applied as described in section 2.2.1.1.3 but using pcDNA3-WT-TIMP3-V5-KDEL as a DNA 
template instead of pcDNA3-WT-TIMP3 and primers listed in section 2.1.9. pcDNA3 is a 
mammalian expression vector that contains the cytomegalovirus (CMV) promoter upstream 
of a multiple cloning site for insertion of the cDNA of interest, together with antibiotic 
resistance markers. These resistances markers include ampicillin and neomycin allowing 
selection in bacterial and mammalian cells, respectively. 
 
3.2.1.2 Creation of the splice site mutation construct  
Synthetic TIMP3 gene constructs with and without the splice site mutation had previously 
been prepared in our laboratory. Briefly, an artificial TIMP3 gene was synthesised 
commercially by Eurofins MWG Operon, which contained a splice site mutation at the 
intron4/exon5 junction. Since the complete TIMP3 gene is very large (approximately 61kb), 
the construct omitted the first 3 introns that would not be expected to affect splicing at the 
intron4/exon5 site, reducing the overall size to 5.4kb. In order to reduce synthesis costs, the 
gene was synthesised in two parts. The first part of the gene, named T3spl1 (2.8kb in size), 
consisted of exons 1, 2, 3, 4, all of intron 4 and the coding region of exon 5 up to the natural 
EcoRI site in the untranslated region. The second part, named T3spl2 (2.6kb), contained the 
rest of untranslated region of exon 5 (Figure 3.1 & 3.2, Appendix 1). T3spl1 included XhoI, 
HindIII and EcoRV restriction sites at the 5’ end and EcoRI and NotI sites at the 3’ end, 
whilst the T3spl2 had SalI and EcoRI sites at the 5’ end and NotI and EcoRV sites at the 3’ 
end. Both synthesised parts (T3spl1 and T3spl2) were delivered in pBlueScript II SK (+), a 
cloning vector. 
T3spl1 was subcloned into the pcDNA3 mammalian expression vector by restricting the 
cDNA and pcDNA3 vector with HindIII and NotI, followed by ligation, mini-preps and 
sequence verification (sections 2.2.1.2, 2.2.1.4 & 2.2.1.9). This construct was named T3spl1-
M and contained the complete coding sequence but without the full exon 5 sequence. An 
equivalent wild-type gene construct was then made from this construct using the 
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Quikchange® Site-Directed mutagenesis kit with primers that removed the aberrant 
adenosine residue and named T3spl1-WT. Full length gene constructs were then made from 
these two clones by restricting them with EcoRI and NotI and ligating in similarly restricted 
T3spl2, excised from pBlueScript. Again mini-prep DNA was prepared and the sequence 
verified. These full-length gene constructs were named SplT3.WT and SplT3.M 











Figure 3.1: Synthetic TIMP3 gene containing the splice site mutation. 
The wide pale blue boxes represent coding exons and narrow pale blue boxes 


































































Figure 3.2: Synthetic TIMP3 gene construct map. 
The vector map illustrates the structure of the pcDNA3-splice site-construct. The key 
features included TIMP3 exons (Exon 1-4 and Exon 5) shown in pink enclosing 









3.2.1.3 Transfection of mammalian cells   
In order to examine expression of the S15C, Y128C, Y154C and Y159C -TIMP3 and the 
splice-site-TIMP3 mutations, TransIT-LT1 transfection reagent was used to transiently or 
stably transfect either COS-7 or ARPE19 cells respectively with the various DNA constructs. 
According to manufacturer’s instruction, transfection was conducted as explained in section 
2.2.2.9 in 10cm tissue culture dishes (COS-7 cells) or 6 well plates (ARPE19 cells) when the 
cells became 50-70% confluent. Following transfection, whole cell lysates and ECM proteins 
were prepared as described in sections 2.2.3.1.1 & 2.2.3.1.2 to analyse in western blotting 
using equal protein concentrations (sections 2.2.3.2 & 2.2.3.3). 
 
3.2.2 cDNA synthesis for the splice site mutation  
3.2.2.1 Amplification PCR  
Polymerase chain reaction (PCR) was performed to amplify SplT3.WT and SplT3.M cDNAs 
using Taq DNA polymerase 2x Master Mix according to the manufacturer’s protocol (section 
2.2.1.1.1), and specific oligonucleotides primers (section 2.1.9, Table 3.1). The components 
of the PCR reaction were gently mixed and then briefly centrifuged to collect liquid to the 
bottom of the eppendorf. This reaction produced PCR products with 3’deoxyadenosine 
overhangs that allow direct cloning into TOPO TA cloning vectors according to the 
manufacturer’s protocol explained in section 2.2.1.15.    
  




Table 3.1: Taq polymerase amplification reaction. 
Thermocycling condition 
Initial denaturation: 
95°C for 30sec 
55°C for 1min 
65°C for 2min 
35 cycles: 
94°C for 20sec 
60°C for 1min 
65°C for 2min 
Final extension: 
65°C for 10min 
Store 10°C 
I 125 
3.2.3 Splice site-cDNA gene constructs 
3.2.3.1 Creation of splice-site cDNA constructs  
Phusion Hot Start Flex™ 2x master mix was used as described in section 2.2.1.1.2 and figure 
2.1, to generate cDNA splice variants identified from the Taq PCR products, but without the 
errors that were apparent from the use of that enzyme. 
Using the SplT3.M maxiprep as template DNA, two separate reactions amplified the 
sequence of exon 1 to 4 (E1-4) and novel exon 5 (E5) sequence of each splice product, using 
primers that overlapped about the novel splice acceptor sites (section 2.1.10 & 2.2.1.1.2). The 
PCR products of these first reactions were run on agarose gels and bands with the correct 
sizes purified and utilised in a second PCR reaction. Then, the second PCR products were 
ligated into pcDNA3 vector following by transformation of α-Selected Gold Competent cells 
and plasmid DNA isolation as described earlier in sections 2.2.1.3 & 2.2.1.5. Extracted DNA 
was sequenced using T7 forward primer to check its quality, and then used to transfect 
mammalian cells to test protein expression. 
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3.3 Results  
3.3.1 Characterisation of TIMP3 missense mutations  
3.3.1.1 S15C, Y128C, Y154C and Y159C TIMP3 cDNA construct creation and 
expression 
SFD-TIMP3 gene constructs comprising S15C, Tyr128Cys, Tyr154Cys and Tyr159Cys were 
sequenced using T7 forward primer to confirm successful mutagenesis (Figure 3.3).   
Western blotting of the whole cell lysates was performed to investigate whether the above-
mentioned missense mutations would form dimeric TIMP3. Blots revealed that all cells, 
SFD-TIMP3 transfected, expressed a monomeric TIMP3 at 22kDa. In addition, a dimeric 
TIMP3 variant at ~48kDa was observed only in the non-reduced blot of SFD-TIMP3 
transfected cells; upon reduction the 48kDa proteins disappeared and gave intense 
monomeric proteins at 22kDa (Figure 3.4).   




Figure 3.3: Automated sequencing SFD-TIMP3 mutant gene constructs. 
The chromatograms illustrate part of sequencing data of exon 5 in Wild-type TIMP3 
against SFD-TIMP3 including (A) Ser15Cys, (B) Tyr128Cys, (C) Tyr154Cys and (D) 
Tyr159Cys that have a single cytosine or adenine base substituted with a guanine 
base; and their corresponding protein sequences in which the substituted amino 
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Figure 3.4: Western blotting of whole cell lysate from ARPE19 transfected with 
SFD-TIMP3 gene constructs. 
The figures illustrate western blotting analysis of whole cell lysates from AREP19 
cells transfected with the designated SFD-TIMP3 mutant proteins and probed with 
anti-V5 epitope tag monoclonal antibody. All transfected cells expressed a protein at 
approximately 22kDa, corresponding to monomeric TIMP3, and a higher molecular 
mass protein at approximately 50kDa, corresponding to TIMP3 dimer, on non-
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3.3.2 Characterisation of TIMP3 splice acceptor site mutation  
3.3.2.1 Splice site gene construct creation and expression  
Splice site WT and splice site mutant gene constructs were sequenced using nine sequencing 
primers that cover the whole splice construct sequence (primers listed in section 2.1.10) to 
confirm either the absence or presence of splice mutation and to check the quality of the rest 
of sequences (Figure 3.5). 
Western blotting of ECM from ARPE19 cells revealed the presence of a level of endogenous 
TIMP3 at 22 and 28kDa that correspond to the previously reported unglycosylated and N-
glycosylated TIMP3, respectively. ARPE19 cells transfected with WT-TIMP3 and splice-WT 
resulted in intense bands at 22kDa and 28kDa in both non-reduced and reduced gels 
compared to un-transfected cells. S181C-TIMP3 was used as a mutant positive control and 
was shown to express an additional band at 48kDa that reduced to 22kDa. In contrast the 
splice-mutant transfected cells gave rise to novel bands at approximately 15, 30 and 60kDa in 
non-reduced gels. Upon reduction the 30 and 60kDa bands disappeared and there was a 
concomitant increase in intensity in the 15kDa band, indicating that the 30 and 60kDa may be 
dimeric or multimeric forms, respectively (Figure 3.6). 
  






Figure 3.5: Atuomated sequencing of SplT3 -WT and -Mutant gene constructs.  
(A) The chromatograms illustrate part of sequencing data of intron 4/exon 5 in both 
SplT3.WT and SplT3.M; the mutant has a single adenosine base inserted at the 
intron 4/exon5 junction site. (B) Sequencing alignment of SplT3.WT and 
SplT3.Mutant shows the presence of the desired splice-site mutation, in red square, 




































Figure 3.6: Western blotting of the ECM from ARPE19 transfected with 
SplT3.WT and SplT3.M gene constructs.  
The figures demonstrate western blotting analysis of ECM from AREP19 cells either 
un-transfected or transfected with wild type TIMP3 (WT.T3), Ser181Cys (S181C) 
and SplT3.WT and SplT3.Mutant (SplT3.M), probed with polyclonal anti-TIMP3 
antibody. All cells showed endogenous TIMP3 at 22kDa, whereas S181C and 
SplT3.M showed additional higher molecular weight proteins at 50kDa and 30 and 
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3.3.2.2 Identification of the splice site cDNA products  
In order to investigate mRNA transcripts from cells transfected with SplT3.WT and 
SplT3.Mutant constructs, total RNA was isolated and polymerase chain reaction (PCR) was 
performed to amplify SplT3.WT and SplT3.Mutant cDNA as described in sections 3.3.1.6.1-
2 & 3. 
A non-denaturing agarose gel was run to examine the quality of the extracted RNA (DNAse 
treated RNA samples); and showed two bands corresponding to large (28S) and small (18S) 
ribosomal RNA (rRNA) subunits that confirmed RNA integrity and lack of any significant 
genomic DNA contamination (Figure 3.7 A). N.B. the markers are a DNA ladder used in 
order to confirm proper running of the gel and cannot be used to determine the size of non-
denatured RNA.  
cDNAs were prepared from both ARPE19 and COS-7 transfected cells by reverse 
transcription and then amplified by PCR using Taq polymerase at an annealing temperature 
of 64.4°C using 5’ primer that binds to the N-terminus of TIMP3 and a 3’ primer that binds to 
the end of exon 5 just upstream of the polyadenylation site. The reactions were analysed on 
agarose gels which showed that SplT3.WT gave rise to one predominant product between 
600-800bp and the SplT3.Mutant at least four bands at 1kb, 1.5kb, 2.5kb and 4kb (Figure 3.7 
B & C). The PCR products from both wild type an mutant constructs were excised, and 
mutant PCR products were re-amplified using the same thermocycler conditions to increase 
the yield, shown in figure 3.10 D. All PCR products were then cloned into the TOPO vector 
to enable DNA sequencing. 
Subsequently a 96 well plate of isolated miniprep plasmids was prepared for sequencing 
using a universal primer (T7 forward) that binds to the TOPO vector. Automated sequencing 
revealed the presence of a single WT product and five mis-splicing products with proper 
donor and splice acceptor sites. All the mutant products were shown to splice into exon 5 
downstream of the normal acceptor site in non-coding regions (Figure 3.8 A & B). There 
were also some PCR products with non-consensus splice sites or only a short sequence of 
exon 5, which were presumed to be artefacts. The identified mutant splice products were 
translated and seen to give rise to five predicted novel C-terminal sequences S1, S2, S3, S4 
and S5 (Figure 3.8 C & 3.9), several with potentially unpaired Cys residues. NB One of the 
Cys residues that forms part of the C-domain of TIMP3 is coded from exon 4 so that exon 5 
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sequences that lack a Cys residue would potentially also result in an unpaired Cys in the 
expressed protein. 
  





















Figure 3.7: Agarose gel electrophoresis of splice site RNA and Taq PCR 
products.  
(A) Non-denaturing agarose gel electrophoresis of RNA samples, the two bands 
correspond to the large and small rRNA subunits (28S and 18S, respectively) and 
confirm RNA integrity with no obvious genomic DNA contamination (both ARPE19 
and COS-7 cells show identical bands). (B) & (C) Taq PCR products of wild type and 
mutant splice constructs, respectively. (D) Electrophoresis of repeat Taq PCR of 


















































































































































































































































































Figure 3.8: Identification of splice site cDNA products.  
(A) Splicing sites of TOPO cloned PCR products identified using BLAT (UCSC 
genome browser), as shown above each PCR product has a splice acceptor site that 
differs from the normal site. All these new splice acceptor sites lie within the non-










Figure 3.9: Illustration of the potential primary structures of the splice cDNA 
products.  
Representation of amino acid composition of the splice site mutant products, 
including S1, S2, S3, S4 and S5, that spliced into the non-coding region of exon 5 
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3.3.2.3 Creation of the splice site cDNA constructs and expression  
All the splice mutant products identified from COS-7 and ARPE19, including S1, S2, S3, S4 
and S5 (shown in Figure 3.9), were produced without any PCR errors using SplT3.M as 
template DNA and Phusion Hot Start Flex 2x master mix. 
The created splice mutant products were purified, digested with HindIII and NotI; and then 
utilised in a ligation reaction with similarly cut pcDNA3 to give splice mutant product-
constructs which were named SplT3.M.S1, SplT3.M.S2, SplT3.M.S3, SplT3.M.S4 and 
SplT3.M.S5. These five constructs were digested with HindIII and NotI to confirm the 








Figure 3.10: Splice cDNA gene constructs.  
The figure demonstrates restriction digest of the splice constructs with HindIII and 
NotI to confirm the presence of splice created products. All splice constructs showed 
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Following creation of splice constructs, COS-7 and ARPE19 cells were transfected using 
TransIT-LT1 reagent with maxiprep plasmids of SplT3.WT, SplT3.M, SplT3.M.S1, 
SplT3.M.S2, SplT3.M.S3, SplT3.M.S4 and SplT3.M.S5 constructs (section 2.14). Whereas 
ECM proteins were prepared from COS-7 plates 72 hours post transfection, transfected 
ARPE19 cells were selected with Geneticin in 25cm2 flasks until confluent, prior to seeding 
onto 10cm tissue culture plates for 10 days and then harvesting the ECM. 
ECM proteins from both COS-7 and ARPE19 were isolated and quantified by BCA protein 
assay. Western blotting with anti-TIMP3 was performed using equal amounts of ECM 
proteins of SplT3.M.S1, S2, S3, S4 and S5 from either COS-7 or ARPE19, in which both cell 
lines exhibited similar results. All splice transfected cells showed a level of endogenous 
TIMP3 species at 22kDa corresponding to un-glycosylated TIMP3 on both non-reduced and 
reduced blots. However, only two splice cDNA products showed a high molecular mass 
species on non-reduced blots, SplT3.M.S1 and SplT3.M.S5. SplT3.M.S1 expressed 
additional species at approximately 30 and 60kDa in the non-reduced blot and upon reduction 
they disappeared and gave rise to a 15kDa protein which was considered to be the monomer 
form of a mutant protein. The other splice product, SplT3.M.S5 expressed two novel protein 
species at approximately 30 and 50kDa in the non-reduced blot; however only the 30kDa 
band completely disappeared on the reduced blot with the appearance of an ~15 kDa band 
(Figure 3.11 A & B).  
  

















Figure 3.11: Western blotting of the ECM from ARPE19 transfected with splice 
cDNA gene constructs.  
The figures demonstrate western blotting of ECM from AREP19 cells transfected 
with splice wild type TIMP3 (SplT3.WT), splice mutant TIMP3 (SplT3.M) and splice 
cDNA gene constructs including S1, S2, S3, S4 and S5, probed with polyclonal anti-
TIMP3 antibody. All cells transfected with splice wild type and mutant TIMP3 
constructs expressed endogenous level of TIMP3 at 22kDa. (A) S1 showed 
additional protein species at 30 and 60kDa that reduced to 15 and 22 kDa proteins 
and resemble the protein species from the original splice construct (SplT3.M). (B) S5 
also showed additional proteins species at 30 and 50kDa in non-reduced condition, 





















































































3.4 Discussion  
As outlined earlier, all of the SFD mutations examined to date had been demonstrated to 
result in TIMP3 dimerisation/multimerisation and retain their ability to inhibit MMPs but 
with impaired turnover in the ECM relative to the normal protein (Langton et al. 2000). This 
led to the hypothesis that accumulation of TIMP3 dimers/multimers is a causative factor in 
the disease. However, five TIMP3 SFD mutations have been identified but not examined for 
protein expression and dimer formation. Two of these are unusual mutations and include a 
mutation in the N-terminal domain (Ser15Cys) and a splice site mutation, caused by a single 
adenosine insertion at the intron4/exon5 acceptor site (CAG to CAAG) and could potentially 
challenge this hypothesis.  
Here we confirm that all of the missense mutations that result in a change to a Cys residue do 
indeed appear to form dimers as non-reduced western blotting of the whole cell lysates from 
ARPE19 cells transfected with Tyr128Cys, Tyr154Cys, Tyr159Cys and Ser15Cys revealed 
anti-TIMP3 antibody-reactive bands at approximately 22kDa and 48kDa.  In all cases the 
48kDa band disappeared upon reduction, with a concomitant increase in intensity of the 
22kDa band, strongly indicative of disulphide bonded TIMP3 dimer formation in all cases. In 
most cases the bands appeared as doublets indicative of glycosylated and non-glycosylated 
forms of the protein. 
As outlines in Chapter 1, the effect of the splice site mutation is unpredictable, with 
possibilities including exon skipping, intron retention and activation of cryptic acceptor sites. 
Western blotting of the SplT3.M construct form ARPE19 cells gave rise to novel TIMP3 
species at ~15, 30 and 60kDa in the non-reduced blot that were not present in the SplT3.WT 
control. The 30 and 60kDa species are likely disulphide bonded dimer/multimeric mutant 
protein because they appeared to be absent in the reduced blot, and the intensity of the 15kDa 
band increases, relative to the 22kDa TIMP3 band upon reduction. The presence of the 
15kDa band in the non-reduced gel might be indicative of incomplete dimerisation of the 
mutant or it could be an additional cDNA product that was not identified, without any 
unpaired cysteine residues.  
Sequencing of the various novel splice site products produced in either COS-7 cells or 
ARPE19 cells only showed evidence for mis-splicing into the non-coding region of exon 5 
with the potential to translate into TIMP3 molecules with completely different C-domain 
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sequences compared to wild-type TIMP3 (Table 3.5, Figure 3.9). These novel C-domain 
sequences contain various numbers of Cys residues. Although all theoretical proteins could 
potentially result in TIMP3 dimerisation, S1, S3, S4 and S5 have an odd number of cysteine 
residues in the C-terminus. It is also possible that other splice mutant products might be 
present but were not successfully cloned. 
 
Table 3.2: Analysis of splice cDNA mutant products.  
 
 
In order to determine whether any of the novel mRNA species cloned could actually produce 
TIMP3 protein dimers, constructs of splice mutant products S1, S2, S3, S4 and S5 were 
created and used to transfect COS-7 and ARPE19 cells. ECM from these cells was analysed 
by western blotting. Only two of the splice constructs, S1 and S5, gave rise to novel bands of 
the expected sizes for dimeric and monomeric forms of the protein on non-reduced and 
reduced gels respectively.  S1 gave rise to novel bands at ~30 and 60kDa on the non-reduced 
blot and ~15kDa protein upon reduction, although the mobility of these bands did not seem to 
match the predominant novel dimers/monomers produced by the actual SplT3.M construct.  
In contrast S5 demonstrated novel bands at both 30 and 50kDa with some evidence for even 
higher MW products. This particular splice product potentially gives rise to a protein with 
three Cys residues in the C-domain, which could possibly concatermerize, resulting in 









Cell lines COS-7 COS-7 ARPE19 COS-7 ARPE19 COS-7 
Amino acid (w/o 
signal peptide) 127 197 134 132 143 
Total number of 
Cys residues 7 10 7 9 9 
Protein Size kDa 14.6 22.8 15.3 15.1 16.6 
Dimer 
formation Dimer NO NO NO Dimer 
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multimers of various sizes.  Upon reduction at least some of the 50kDa band remained and 
the 30kDa band disappeared with a concomitant appearance of a novel 15kDa band but also a 
relative enhancement of the 22kDa band corresponding to wild-type TIMP3.  The ~50kDa 
band could be a multimer form of the mutant protein that did not completely reduce to the 
15kDa species or a heterodimer of mutant and wild-type TIMP3. The latter possibility is 
supported by the fact that the 22kDa band increases in intensity following reduction. None of 
the other identified splice products (S2, S3 and S4), showed any evidence of expression at 
their expected sizes. It is possible that these cDNA sequences failed to express stable mRNA 
or their protein products were rapidly degraded and this is highly likely for the long nonsense 
protein sequence on the end of S2, which would almost certainly elicit degradation by the 
proteasome so that no functional protein would be produced. While it is inconclusive whether 
any of the mis-spliced mRNA species cloned explain the predominant dimers seen with the 
SplT3.M gene construct, undoubtedly the splice mutation can give rise to mutant dimers in 
ARPE19 cells. Expression of dimers from the splice construct was much less pronounced 
than for the other mutant TIMP3 species examined here and this is not surprising as splicing 
at secondary splice acceptor sites is likely to be less efficient and not all of the mis-spliced 
sequences are likely to be expressed. This reduced expression of TIMP3 dimers from the 
splice site mutation may well explain the significantly later age of onset of the disease in the 
Japanese families (Tabata et al. 1998). 
Interestingly, all the predicted proteins have exon 5 sequences that are completely different 
from normal TIMP3. This would almost certainly affect their ability to inhibit VEGFR2 since 
the inhibitory activity of TIMP3 toward VEGFR2 has been localised to the C-terminal 
domain. This may well explain the choroidal neovascularisation observed in SFD.  It is also 
possible that dimerisation at the C-domain prevents or impairs VEGFR2 binding for all the 
other SFD mutant proteins, even though they retain an essentially normal C-domain. 
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4.1 Introduction  
As discussed in Chapter 1, TIMP3 has been reported to be pro-apoptotic due to inhibition of 
TACE, resulting in decrease shedding of death receptors including FAS, TNF-RI (tumour 
necrosis factor receptor-1) and TRAIL-RI (TNF-related apoptosis inducing ligand receptor-1) 
(Ahonen et al. 2003, Bond et al. 2002). 
It has previously been shown that over-expression of wild-type or SFD-mutant TIMP3 in 
primary RPE cells by transient transfection with naked vector or using adenovirus resulted in 
increased apoptosis and that there was an apparent increase in cell death/apoptosis with SFD-
TIMP3 relative to the wild-type protein (Majid et al. 2002). However, this study did not 
examine whether these cells were more prone to apoptosis induced by specific 
receptors/ligands, nor propose a mechanism by which mutant SFD proteins may increase the 
apoptotic response. 
More recently it has been shown that under basal conditions, TACE (ADAM17) is 
predominantly present on the cell surface as a homodimer that binds TIMP3, maintaining 
TACE in the inactive form.  Phosphorylation of the cytoplasmic domain of TACE, via the 
ERK or p38 MPAK pathways, results in dissociation of the dimers into monomers and the 
dissociation of TIMP3, thus enabling activation of TACE (Xu et al., 2012). This raises the 
question as to what effect SFD mutation-induced dimer formation may have on this process. 
This report did not ascertain whether one or two molecules of TIMP3 bind to the TACE 
dimers.  However, if the latter is the case, it is possible that TIMP3 dimers stabilise the TACE 
dimers through the increased avidity of bivalent binding, resulting in an apparent increase in 
TACE inhibition and thus, apoptosis.  
It is hypothesised, therefore, that TIMP3 dimers may stabilise this TACE dimerisation 
leading to decreased activation and thus increased apoptosis of retinal cells in SFD. To test 
this hypothesis, the expression of TACE in ARPE19 and TIMP3-transfected ARPE19 cells 
was initially examined by SDS-PAGE and western blotting. Then, the sensitivity of 
untransfected ARPE19 and ARPE19 stably transfected with SFD-TIMP3 constructs cells to 
anti-Fas activating antibody induced apoptosis was tested by measuring caspase 3/7 activity 
using caspase 3/7 activity apoptosis assay kit. Finally, the ability of SFD-TIMP3 to stabilise 
TACE dimers was investigated by pull down assay and western blotting.   
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4.2 Methods   
4.2.1 Transfection of ARPE19 cells  
To investigate the influence of wild type and SFD TIMP3 on TACE, ARPE19 cells were 
stably transfected with pcDNA3-WT.T3, -E139X, -S156C, -H158R and -S181C using 
TransIT-LT transfection reagent (described in section 2.2.2.9).  
Untransfected or stably transfected cells were then seeded onto 10cm tissue culture dishes at 
a density of 10x106/plate to check for TIMP3 protein expression and, once confirmed, cells 
were prepared for the apoptosis assay.  
 
4.2.2 TACE expression by SDS-PAGE and western blotting   
To examine TACE expression in retinal cells, untransfected and SFD-TIMP3 transfected 
ARPE19 cells were seeded at a density of 10x106 /plate in 10cm tissue culture petri dishes 
and grown until they reached 80-90% confluence. Then, all cells were collected and stored at 
-80°C until lysed in RIPA lysis buffer for analysing in SDS-PAGE (10% or 7.5%) and 
western blotting (sections 2.2.3.1.1 & 2.2.3.3).  
TACE was detected by incubating PVDF membrane in primary antibody polyclonal rabbit 
anti-TACE antibody at 1:2000 dilution overnight at 4°C in a shaker; and subsequently in 
secondary antibody which was swine horseradish peroxidase-conjugated anti-rabbit antibody 
at 1:10000. Separated proteins were observed using chemiluminescent substrate. 
 
4.2.3 Caspase 3/7 activity apoptosis assay 
The effect of wild type and SFD-TIMP3 on ARPE19 cell apoptosis was examined by 
measuring caspase 3/7 activity using Cell Meter TM Caspase 3/7 Activity Apoptosis Assay 
Kit. The apoptosis assay was performed as instructed by the manufacturer and described 
earlier in section 2.2.3.4. 
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4.2.4 TACE pull down assay    
To investigate whether endogenous TACE dimers can be stabilised by binding to SFD-
TIMP3, HaloTag mammalian pull-down and labelling systems kit was used in a similar way 
to section 2.2.3.6. 
HEK293T cells were transfected with pHTC-HaloTag vectors including empty pHTC vector 
(negative control), pHTC-WT-T3 and pHTC-S181C. The pHTC-HaloTag vector contains a 
multiple cloning site upstream of the HaloTag cDNA sequence. These are expressed under 
the CMV promoter and the vector also contains the neomycin resistance cassette, allowing 
constitutive stable expression of proteins bearing a C-terminal HaloTag in mammalian cells. 
A C-terminal HaloTag was used, as this was least likely to affect the MMP-inhibitory 
function (and presumably TACE binding) of TIMP3 that is mediated through the N-terminal 
domain.  
The expression of TACE and HaloTag constructs in HEK293T cells was confirmed prior to 
proceeding with the TACE pull down assay. As described in section 2.2.3.6, TACE pull 
down was accomplished in four stages comprising constructing HaloTag fusion vectors, 
transfecting HEK293T cells with HaloTag vectors, pull down and detecting Halotag fusion 
proteins by immunoblotting against polyclonal anti-TACE.  
pHTC-WT.T3-Halotag and pHTC-S181C-HaloTag constructs (previously prepared in my 
supervisor’s laboratory) were used to transiently transfect HEK293T cells in 6-well plates 
(see section 2.2.2.9 & Table 2.2). At 24 hours post transfection, cells were treated with PMA 
(0-25nM) for 30 minutes at 37 ̊C and then cells were harvested and handled as described in 
sections 2.2.3.6.1 & 2.2.3.6.2.   
Another approach was also performed to pull down TACE in similar way as explained above 
except that a water-soluble and reducible crosslinker, DTSSP (3,3-Dithiobis 
sulfosuccinimidyl propionate), was used after PMA treatment. In brief, transfected cells were 
treated with PMA for 30 minutes at 37 ̊C and then washed in PBS. The next step was to 
incubate cells in 1mM DTSSP at 4 ̊C for 60 minutes, in which the reaction was then stopped 
by adding 1M Tris (pH 7.5) at a final concentration between 10-20mM for 15 minutes at 
room temperature. Finally, cells were handled as described sections 2.2.3.6.1 & 2.2.3.6.2.   
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4.3 Results   
4.3.1 TACE expression in ARPE19 cells  
The anti-TACE antibody detected two distinct species between 100-150kDa in all cells, 
either untransfected or transfected with WT.T3, E139X or S181C, which may correspond to 
inactive and activated forms of the molecule (Xu et al. 2012).  A very minor band was also 
observed at approximately 90kDa, which may correspond to degradation products of the 








Figure 4.1: Western blot of TACE expression in ARPE19 cells. 
Non-reduced western blot of cell lysates from untransfected ARPE19 cells or 
ARPE19 cells transfected with the pcDNA3-TIMP3 constructs indicated and probed 






















































































































4.3.2 Measuring Caspase 3/7 activity   
To determine whether wild-type or SFD-TIMP3 increases the sensitivity of ARPE19 cells to 
induction of apoptosis, cells were stably transfected with WT.T3, E139X, S156C, H158R or 
S181C constructs, and analysed by western blotting to confirm TIMP3 expression and dimer 
formation in the SFD-TIMP3 transfectants. Cells were then treated with camptothecin 
(20µM) or anti-Fas activating antibody (at 10, 15 or 20 µg/ml) and caspase 3/7 activities from 
the cells measured using the Cell Meter Caspase 3/7 activity apoptosis assay kit (see section 
2.2.3.5). 
Initially caspase 3/7 activity was measured in complete growth medium. The first three 
experiments performed in complete growth medium showed insignificant differences 
between those cells expressing WT.T3 and those expressing SFD-TIMP3 for all treatments 
(Figure 4.2 A, B & C).  
Subsequently the experiments were repeated but using serum depleted (2% FBS) “starvation” 
medium to grow and treat the cells. All untreated ARPE19 cell lines exhibited similar caspase 
3/7 activities at 48 hours post seeding (Figure 4.3 A). At 24 hours, camptothecin treated cells 
exhibited increased caspase 3/7 activity compared to untreated cells; however SFD-TIMP3 
transfected cells showed increased apoptosis relative to wild-type transfected cells and this 
was shown to be statistically significant for the E139X, S156C, H158R and S181C mutants 
(P-values: 0.0085, 0.0007, 0.0484 and 0.0016 respectively; Figure 4.3 B).  
Similarly ARPE19 cells treated with anti-Fas for 24 hours also showed an apparent increase 
in caspase 3/7 activity in the SFD-mutant transfected cells relative to WT.T3 transfectants, 
although in this case this was only significant for the E139X and H158R mutants (Figure 4.3 
C).  
Taken together these data suggest that all of the SFD-mutants increase the sensitivity of 









Figure 4.2:Caspase 3/7 activity in ARPE19 cells treated in complete growth 
medium.  
Caspase 3/7 activity in: (A) untreated ARPE19 cells; (B) ARPE19 cells treated with 
camptothecin (20µM); (C) ARPE19 treated with anti-Fas activating antibody (at 10, 




























































































































































































































































Figure 4.3: Caspase 3/7 activity in ARPE19 cells treated in serum depleted (2% 
FBS) growth media. 
Caspase 3/7 activity in: (A) untreated ARPE19 cells; (B) ARPE19 cells treated with 
camptothecin (20µM); (C) ARPE19 treated with anti-Fas activating antibody (at 
15µg/ml). +/* Represents significant P-value, in graphs and tables, compared to 
untransfected and WT.T3 transfected ARPE19 cells, respectively. Data are 
presented as mean ± S.E. of three independent experiments and analysed using 
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4.3.3 TACE pull down assay  
Immunoblotting confirmed the expression of endogenous TACE in HEK293T cells, revealing 
bands between 100-150 kDa (Figure 4.1 A).  
In addition, HEK293T cells transfected with pHTC-HaloTag vectors including pHTC-vector, 
pHTC-WT.T3 and pHTC-S181C were also examined for TACE and TIMP3 expression. 
pHTC-HaloTag transfected cells expressed TACE identical to untransfected cells (Figure 4.4 
A). Western blotting analysis of HEK293T cells transfected with WT.T3 and S181C showed 
TIMP3 species at ~60kDa in the reduced gel (corresponding to the TIMP3-HaloTag fusion 
protein); however, S181C also had an additional faint species at ~120 kDa, which might be 








Figure 4.4: Western blotting of TACE and TIMP3 in HEK293T cells.  
Cells were transfected with pHTC-WT.T3-HaloTag and pHTC-S181C-HaloTag in 6-
well plates. (A) TACE: Cell lysates from untransfected HEK293T and transfected 
with HaloTag vectors were analysed in SDS-PAGE and western blotting (anti-
TACE). (B) Western blotting of TIMP3 in HEK293T cells transfected with pHTC-
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Since TACE-mediated ectodomain shedding is regulated by TIMP3, association between 
TIMP3 and TACE was examined using the HaloTag pull down system. HEK293T cells were 
transfected with pHTC-HaloTag vector, pHTC-WT.T3-HaloTag and pHTC-S181C-HaloTag 
and then treated with PMA (0-25nM) following by pull down as described in section 5.3.5.  
It was anticipated that SFD-TIMP3 dimers may increase the stability of the interaction with 
TACE, relative to wild-type TIMP3 monomers, and this increase may be detected in an 
increased resistance to PMA-induced dissociation of the TACE/TIMP3 complex which may 
then be detected by pulling-down any TIMP3 associated TACE using the HaloTag on the 
TIMP3. 
Western blotting analysis revealed the presence of TACE species between 100-150kDa 
corresponding to the previously reported inactive and activated forms in the cell lysates of all 
transfected cells whether untreated or PMA-treated (Figure 4.5). However pull down samples 
showed no TACE precipitation, indicating the absence of TACE-TIMP3 interaction.   
The pull down assay was repeated using the reducible crosslinking agent, DTSSP, in an 
attempt to stabilise any potential TIMP3-TACE interactions. Immunoblotting analysis of 
reduced gels showed TACE at 100-150kDa in cell lysates and pull down supernatant in all 
samples either HaloTag vector or TIMP3-Halotag constructs but very faint bands were 
observed in some pull down eluate samples, however this was not restricted to any one 
HaloTag fusion protein species and may be contamination from other wells (Figure 4.6).  
  

















Figure 4.5: Western blotting analysis of TACE pull down in HEK293T cells. 
HEK293T cells were transfected with empty pHTC-HaloTag vector, pHTC-WT.T3-
HaloTag and pHTC-S181C-HaloTag and then treated with PMA (0-25nM). Cell 
lysates were analysed by non-reduced western blotting using anti-TACE polyclonal 
antibody. (A) Empty pHTC-HaloTag vector; (B) pHTC-WT.T3-HaloTag; (C) pHTC-
























































































Figure 4.6: Western blotting analysis of TACE pull down in HEK293T cells 
following DTSSP cross-linking. 
HEK293T cells transfected with HaloTag vectors were firstly treated with PMA (0-
25nM) and then with DTSSP crosslinker (1mM). Cell Lysates were subjected to 
reduced western blotting using anti-TACE polyclonal antibody. (A) pcDNA3-SS-
HaloTag vector (empty); (B) pHTC-WT.T3-HaloTag; (C) pHTC-S181C-HaloTag. (1) 

































































While it has previously been shown that high level transient expression of TIMP3 directly 
induces apoptosis of RPE cells, and that SFD-mutant forms of TIMP3 seem to have an 
increased apoptotic effect (Majid et al. 2002), it was not known whether lower level stable 
expression of these molecules would have an effect on apoptosis. Clearly the production of 
ARPE19 cells stably expressing wild-type and SFD-TIMP3 proteins should select against 
directly pro-apoptotic levels of TIMP3. Nevertheless it is possible that lower level expression 
still increases the sensitivity of these cells to pro-apoptotic agents, which may be more 
relevant to the physiological situation. 
Preliminary experiments, in which cells were grown in complete serum, failed to show any 
consistent differences in caspase activity between untransfected and TIMP3 transfected cells, 
with or without camptothecin or anti-Fas. However using serum deprived culture medium, 
clear differences became apparent and this may reflect an increased sensitivity to apoptosis in 
media containing lower concentrations of growth factors. Using this media, there did appear 
to be a slight increase in caspase activity in untreated cells transfected with either wild-type 
of SFD-TIMP3, although this was not significant. However treatment with either 
camptothecin or Fas activating antibody, revealed a significant difference in apoptosis 
between both untransfected and wild-type TIMP3 transfected cells and those transfected with 
all four different SFD mutant forms of TIMP3.  While this did not reach significance for all 
mutants with both drugs, nevertheless it was significant for all mutants with at least one of 
the drugs. Camptothecin causes DNA damage by irreversibly binding to the topoisomerase 
I/DNA complex, resulting in apoptosis.  The anti-Fas antibody is a surrogate for membrane 
bound Fas ligand and activates Fas receptor (CD95), also triggering apoptosis. 
Effects of TIMP3 on Fas-induced apoptosis can readily be explained by TACE inhibition and 
decreased shedding of death receptors (Ahonen et al. 2003). The effects of TIMP3 on 
camptothecin-induced apoptosis probably reflects the fact that this drug increases the cells’ 
sensitivity to naturally occurring apoptotic ligands present in the media or on other cells, 
which transduce their effects through death receptors on the cell surface. 
We then went on to explore one possible mechanism by which SFD mutant forms of TIMP3 
may result in increased sensitivity to Fas activating antibody, that being by stabilising the 
dimeric, inactive form of TACE (Xu et al. 2012), which would potentially result in increased 
expression of Fas receptor on the cell surface. This was done by attempting to pull-down 
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TIMP3/TACE complexes using HaloTagged wild-type or SFD mutant TIMP3.  In this case 
transient transfection of HEK293T cells was used as these cells had previously been reported 
to express TACE (Endres et al. 2003), transfect readily, and also should yield high-level 
protein expression from vectors containing the SV40 origin of replication (as pHTC-HaloTag 
does), due to the presence of the SV40 large T antigen.  Western blotting confirmed that these 
cells express high levels of endogenous TACE protein, with the anti-TACE antibody 
detecting two particularly strong bands between 100-150kDa; and that the TIMP3 and SFD-
TIMP3 HaloTagged fusion proteins are expressed as monomer and dimer respectively.  
Despite this, the HaloTagged wild-type or SFD mutant TIMP3 proteins failed to pull down 
any TACE protein, even in the absence of PMA or when DTSSP reducible crosslinker was 
used. There are a number of reasons why this may be the case, for example the HaloTag may 
interfere with TIMP3 binding to TACE. While the tag was placed on the C-terminus to avoid 
interfering with the proteinase binding site, the fact that TIMP3 only appears to bind to 
TACE dimers (Xu et al. 2012) may indicate that a second site on the TIMP3 molecule is also 
involved, which could be masked by the HaloTag. While it is possible that solubilisation of 
the TACE in the lysis buffer results in dissociation of TIMP3, the DTSSP cross-linker should 
have prevented this. Had time permitted, the former may have been addressed using a smaller 
tag, such as the haemagglutinin- (HA-) or Myc-tags.  
An alternative or additional explanation for the increased pro-apoptotic effect of SFD-
TIMP3, relative to wild-type, might be that the mutant protein has been shown to have an 
increased resistance to degradation (Langton et al. 2005) and so accumulates in the ECM, 
resulting in increased TACE inhibition. This may not be particularly apparent in these 
experiments as HEK293T cells do not produce a great deal of ECM and the caspase 3/7 
activity was measured 2 days post-seeding so there would probably be relatively low levels of 
TIMP3 relative to TACE, which was highly expressed on these cells. To tackle this issue, the 
extracellular matrices from cells transfected with wild type or SFD-mutant TIMP3 could be 
used as treatment for un-transfected ARPE19 cells to see if the higher levels of TIMP3 
present in this matrix have a pro-apoptotic effect. Nevertheless, the finding of this chapter 
suggested that retinal cells expressing mutant TIMP3 are more susceptible to pro-apoptotic 
ligands than those expressing the normal molecule and this could play a role in the 
geographic atrophy of SFD.   
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Chapter 5: The effect of SFD-TIMP3 on VEGFR2 
 
  




As discussed in Chapter 1, TIMP3 is a potent inhibitor of VEGFR2 (Qi et al. 2003) and this 
activity is likely to be a key reason for its expression by RPE cells in the retina where it 
probably plays a vital role in preventing vascularisation of the photoreceptor layer. As 
choroidal neovascularization is a common feature of SFD, it seemed likely that TIMP3 
dimerisation may be affecting the interaction of the molecule with VEGFR2.  It is possible 
that CNV is entirely a result of Bruch’s membrane thickening, triggering increased VEGF 
expression. However this raises the question as to why the increased expression of TIMP3 
observed in SFD (Fariss et al. 1998) fails to prevent this.   
Previous work in our laboratory and elsewhere (Chen et al. 2014) (Qi et al. 2013) 
(Mujamammi 2013) has demonstrated that the majority of VEGFR2 binding residues of 
TIMP3 are localised in the C-terminal domain, where the vast majority of the mutations also 
lie. Based on these observations TIMP3 dimerisation may impair or prevent TIMP3 binding 
to VEGFR2. Alternatively it is possible that TIMP3 dimers mimic the dimeric VEGF ligand, 
which activates the receptor by dimerisation.  While it has been reported that wild-type and 
S156C TIMP3 are equally potent at inhibiting VEGF binding to VEGFR2 (Fogarasi et al. 
2008), these experiments utilised S156C TIMP3 expressed from bacteria and the molecule 
was almost completely monomeric, with wild-type and mutant forms appearing identical on 
non-reduced SDS-PAGE gels. 
Preliminary data from our laboratory (Mujamammi 2013) indicated that at least two of the 
SFD mutants, H158R and S181C, did indeed show a reduced ability to inhibit VEGF-
mediated invasion of endothelial cells in vitro; however whether this is more widely 
applicable to other SFD mutants and the precise mechanism of the inhibition were unknown.  
Moreover, it has been reported that the S156C mutant form of TIMP3 induces angiogenesis 
by increasing the surface expression of VEGFR2 (Qi et al. 2009). This latter possibility could 
potentially explain the increased invasiveness of endothelial cells, rather than a decreased 
ability to inhibit VEGFR2. 
The hypothesis of this chapter is that all SFD-TIMP3 mutants have a decreased ability to 
inhibit VEGF-mediated angiogenesis, either through upregulation of and/or decreased 
inhibition of VEGFR2. This would be examined using two techniques: flow cytometry to test 
cell surface expression of VEGFR2, and endothelial cell migration to investigate TIMP3 
inhibition.   




5.2 Methods  
Ideally the binding characteristics of mutant forms of TIMP3 would be determined using 
purified proteins.  However, previous experience from our laboratory and elsewhere has 
shown this to be extremely difficult, precluding this as a realistic method for comparing 
several different mutants.  While TIMP3 has been successfully purified from bacteria, as 
mentioned above, the protein then fails to dimerise.  
Human umbilical vein endothelial cells (HUVEC) were used in this chapter due to fact that 
they are one of the few cell types, readily available, known to express VEGFR2. However, 
these primary cells transfect poorly making it very difficult to introduce TIMP3 mutant 
constructs into the same cells.  Moreover, the primary source of TIMP3 in the retina appears 
to be the RPE rather than the choroid (Della et al. 1996).  For these reasons, as mentioned 
above, we have previously assayed the inhibitory effect of two SFD mutants using an 
endothelial invasion assay in which HUVEC cells are allowed to invade through ECM from 
TIMP3-transfected ARPE19 cells in response to VEGF.  The aim here was to repeat this for 
several different SFD mutants but also to determine the effect of this ECM on VEGFR2 
expression.  
 
5.2.1 The effect of SFD-TIMP3 proteins expressed in situ on HUVEC VEGFR2 
expression 
ARPE19 cells were stably transfected with WT.T3 or S15C, E139X, E139K, S156C, H158R 
or S181C SFD mutants as described (section 2.2.2.9) and maintained in their complete 
growth medium (section 2.2.2.2). ARPE19-ECM was prepared using ammonium hydroxide 
lysis (section 2.2.3.1.3) for flow cytometry for VEGFR2 expression (sections 2.2.2.4, 2.2.2.6 
& 2.2.3.5.1) and for western blotting for TIMP3 protein expression (section 2.2.3.3). 
 
5.2.2 The effect of SFD-TIMP3 proteins expressed in situ on VEGF-induced 
HUVEC invasion/migration 
The invasion assay was carried out as described in section 2.2.3.5.2 using ECM (section 
2.2.3.1.3) from ARPE19 cells, either untransfected or transfected with WT.T3, S15C, E139X, 
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E139K, S156C, H158R or S181C TIMP3 in FluoroBlock TM inserts in complete growth 
medium. To perform migration assay (section 2.2.3.5.2), ARPE19 basement membrane was 
then prepared using ammonium hydroxide lysis buffer (section 2.2.3.1.3). To confirm SFD-
TIMP3 expression, the same cell lines were simultaneously grown in plates and their ECM 
prepared by ammonium hydroxide lysis to analyse in western blotting (section 2.2.3.1.3).   
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5.3 Results  
5.3.1 Western blotting of ARPE19 cell lines used in flow cytometry and 
migration assays 
Western blotting was performed alongside the flow cytometry and migration assays, which 
confirmed the expression of TIMP3 protein as well as SFD-TIMP3 dimers (Figure 5.1). 
When comparing the untransfected cells to those transfected with the SFD mutants on the 
non-reduced blot it is apparent that the majority of the mutant protein is expressed in 
dimeric/multimeric form. Upon reduction there was a concomitant increase in the monomeric 







Figure 5.1:Western blotting of TIMP3 expression by ARPE19 cell lines used in 
flow cytometry and migration assay.  
Western blots of cell matrix from ARPE19 cells transfected with SFD-TIMP3 
confirmed the expression of TIMP3 protein and the presence of dimeric/oligomeric 
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5.3.2 The effect of SFD-TIMP3 mutants on VEGFR2 expression in HUVEC  
HUVEC cells were allowed to grow for 5 hours (the length of time cells were incubated with 
the ECM in the invasion assays) on ECM from untransfected or WT.T3, S15C, E139X, 
E139K, S156C, H158R or S181C transfected ARPE19 cells as described in (section 
2.2.3.6.1).  None of the mutant transfected cells showed a significant difference in VEGFR2 
expression, relative to wild-type TIMP3 transfected cells, nor was there any significant 
difference between untransfected and transfected cells, indicating that incubation of HUVEC 
cells with ECM containing SFD-TIMP3 mutants does not significantly affect the expression 
of VEGFR2 in these cells. HUVEC treated with VEGF did show a small but significant 
decrease in VEGFR2 expression (Figure 5.2 & 5.3), relative to untreated cells.  
  














Figure 5.2: Expression of VEGFR2 on HUVEC treated with VEGF or ECM from 
transfected ARPE19 cells. 
Flow cytometric determination of VEGFR2 expression on HUVEC treated with VEGF 
or ARPE19 cell ECM from untransfected, wild type TIMP3 (WT.T3) or the specified 
SFD-TIMP3 mutant transfected cells. The Y axis shows percentage VEGFR2 
expression, relative to cells treated with ECM from wild-type TIMP3 ARPE19 cells. 
None of these differences were significant; although VEGF-treatment did 
significantly, decrease VEGFR2 expression, relative to untreated HUVEC (p-value = 
0.0031). Data are representative of triplicate experiments (as means ± S.E) and 
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Figure 5.3: Flow cytometric analysis of VEGFR2 expression on HUVEC cells.  
Representative graphs showing binding of Phycoerthrin mouse anti-human VEGFR2 










5.3.3 The effect of SFD-TIMP3 mutants on HUVEC migration 
The cell matrix from cells transfected with wild type TIMP3 inhibited HUVEC migration by 
approximately 60% compared to the cell matrix from untransfected cells (Figure 5.4). On the 
other hand, ECM from SFD-TIMP3 transfected cells showed less inhibition than that from 
wild type TIMP3 that was approximately 30% compared to untransfected cells.  
  



























Figure 5.4: Migration of HUVEC through cell matrix of ARPE19 cell lines.  
(A) Represents the percentage of HUVEC cells migrating to the underside of 
FluoroBlok inserts compared to those cells migrated through untransfected ARPE19-
ECM (B) Representative micrographs of the migrated HUVEC cells. P-value is 
shown as a variable number of asterisks and relative to un-transfected; ++++ relative 
to WT.T3 in the graph and in the table below the graph. Data are as means ± S.E of 
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" !" 0.0015" 0.0062" 0.0027" 0.0014" 0.0014" 0.0006"




As outlined earlier, CNV is a common feature of SFD and the fact that TIMP3 mutations in 
SFD almost exclusively affect the C-terminal domain, which has also been implicated in 
VEGFR2 binding, indicates that these mutations may affect the TIMP3/VEGFR2 interaction.  
Moreover, earlier work in our laboratory indicated that His158Arg and Ser181Cys TIMP3 
show reduced inhibition of endothelial cell invasion relative to the wild-type molecule 
(Mujamammi 2013).  However it has also been reported that the S156C mutation up regulates 
VEGFR2 expression on endothelial cells (Qi et al. 2009) and this could offer an alternative 
explanation for the increased invasion of the endothelial cells in these experiments.   
In this chapter we have demonstrated that several other SFD mutants, namely S15C, E139X, 
E139K and S156C, also appear to have a reduced ability to inhibit endothelial cell invasion 
through ECM containing these proteins.  Expression of the mutant proteins by the ARPE19 
cells, determined by western blotting, was somewhat variable, but not sufficient to explain 
the differences in invasion seen between wild-type and mutant proteins. This was particularly 
apparent for the S156C mutant where expression was, if anything, higher than for the wild-
type (Figure 5.1). 
Flow cytometric analysis of VEGFR2 expression showed no significant difference in 
VEGFR2 expression between cells incubated on ECM containing wild-type or mutant forms 
of the protein (Figure 5.2). This suggests that upregulation of VEGFR2 on the HUVEC by 
the mutant proteins, including S156C, is not the explanation for the increased invasion seen 
on the ECM containing mutant TIMP3, even for S156C. This supports the notion that TIMP3 
dimerisation inhibits the ability of the molecule to bind to VEGFR2 and could help to explain 
the CNV seen in this disease, despite high levels of TIMP3 in Bruch’s. 
The data presented by Qi et al. (2009), indicate that over-expression of S156C TIMP3 in 
porcine aortic endothelial (PAE) cells increases expression of VEGFR2 on the cell surface, 
and also VEGFR2 expression is upregulated in the eyes of Timp3S156C/S156C mice.  While it 
might be argued that over-expression of the protein in this system is very artificial, and that 
RPE cells, rather than vascular endothelial cells, appear to be the main source of TIMP3 in 
Bruch’s (Della et al. 1996), the increased expression in transgenic mice is more difficult to 
dismiss (although the A3 anti-VEGFR2 antibody used in these experiments has been shown 
to cross-react with other molecules (Smith et al. 2010). 
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While, in our assay, increased VEGFR2 expression does not appear to be the explanation for 
the enhanced invasion seen with mutant TIMP3, it may play a role in some cells.  Another 
possibility is that VEGF itself maintains the expression of VEGFR2 on the cell surface. Wild-
type TIMP3 would inhibit this effect, potentially decreasing VEGFR2 on the cell surface, 
whereas mutant TIMP3, which does not inhibit the receptor, would not do so and could give 
rise to the perceived increase in VEGFR2. However in our case VEGF did not increase 
VEGFR2 expression on the HUVEC cells (Figure 5.2) but appeared to slightly decrease it. 
This may be a cell type specific effect and account for the differences between the HUVEC 
used here and the PAE cells used by Qi et al. (2009). 
Taken together the data shown in this chapter indicate that SFD mutation-induced 
dimerisation of TIMP3 appears to impair its ability to inhibit VEGFR2. However this may 
only be shown conclusively if it becomes possible to purify sufficient quantities of the 
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Chapter 6: Investigating the interaction of TIMP3 with 
EFEMP1 
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6.1 Introduction  
As outlined in Chapter 1, Malattia Leventinese (ML), like SFD, is a rare autosomal dominant 
retinal dystrophy that leads to irreversible visual loss, usually in middle age. The disease is 
caused by a single mutation in the gene EFEMP1 (converting arginine at 345 to tryptophan) 
(Stone et al. 1999). Like SFD and AMD, ML is characterised by the presence of extracellular 
deposits (drusen) between the retinal pigment epithelium (RPE) and Bruch’s membrane, 
although in this case these form a characteristic honeycomb pattern and neovascularisation is 
rare.   
EFEMP1 and TIMP3 have been shown to accumulate in the eyes of patients with both ML 
and AMD (Klenotic et al. 2004). Efemp1R345W/R345W mice also show deposits of EFEMP1 and 
TIMP3 as well as evidence of complement activation in the RPE and Bruch’s membrane (Fu 
et al. 2007). TIMP3 mutations in SFD also result in accumulation of TIMP3 protein, however 
EFEMP1 expression in eyes from SFD patients has not been examined. As TIMP3 and 
EFEMP1 are binding partners (Klenotic et al. 2004), it might be expected that accumulations 
of TIMP3 in SFD would also lead to EFEMP1 accumulation, providing a common link 
between all three diseases. This assumes that SFD mutant forms of TIMP3 still bind 
EFEMP1. 
The hypothesis of this chapter is that SFD-TIMP3 mutants retain their ability to bind to 
EFEMP1 resulting in TIMP3/EFEMP1 protein complexes that may contribute to SFD as well 
as ML.  The initial aim of this chapter, therefore, was to investigate the interaction between 
EFEMP1 and TIMP3 using the HaloTag pull-down assay.   
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6.2 Methods  
6.2.1 Plasmid construct preparation 
Plasmid constructs used for the EFEMP1-TIMP3 protein pull down assays were already 
created in my supervisor’s laboratory from previous projects. Plasmid constructs (listed in 
Table 6.1, Appendix 2) were used to transform α-gold competent cells to prepare highly pure 
maxi prep DNA (sections 2.2.1.3 and 2.2.1.4).  
 
Table 6.1: Plasmid construct used for EFEMP1-TIMP3 pull-down. 
No First pull-down plasmid constructs  Purpose 
1 pHTC-EFEMP1-HaloTag (wild type). These vectors have EFEMP1 fused 
to HaloTag at the C-terminus, 
facilitating their binding to HaloTag 
resin. 
2 pHTC-EFEMP1-HaloTag (mutant). 
3 pcDNA3-TIMP3 (wild type). Vectors contain TIMP3 (WT or 
S181C) producing proteins without a 
tag as targets for the EFEMP1 fusion 
proteins. 
4 pcDNA3-S181C (TIMP3 mutant). 
No Second pull-down plasmid constructs  Purpose 
1 pcDNA3-SS-HaloTag. 
A vector containing HaloTag alone 
but with a chymotrypsinogen signal 
sequence to enable secretion - for use 
as a negative control in pull-down 
assay to guarantee that the HaloTag 
or resin do not interact to any other 
untagged proteins.  
2 pcDNA3-SS-HaloTag-EFEMP1 (wild type).  Vectors contain HaloTag with 
chymotrypsinogen signal peptide 
followed by the EFEMP1 (WT or 




4 pcDNA3-TIMP3-V5-KDEL (wild type). TIMP3 proteins with C-terminal V5 
Tag to make them easily detectable 
and KDEL endoplasmic reticulum 
(ER) retrieval sequence, used to 
prevent TIMP3 being secreted and 
binding to the ECM.  
5 pcDNA3-S181C-V5-KDEL (TIMP3 mutant). 
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6.2.2 EFEMP1 and TIMP3 HaloTag pull-down assay  
6.2.2.1 Transfection of HEK293T cells and cell lysate preparation  
HEK293T cells were transfected in 6-well plates as explained in section 2.2.3.6 with the 
plasmid combinations shown in table 6.2. The transfection of mammalian cells was divided 
into three groups including control vector, wild type EFEMP1 and mutant EFEMP1 
(R345W). However, the first pull-down transfection was performed using COS-7 cells and 
incubated for 48 hours, whereas the second pull down transfection used HEK293T cells for 
24 hours.  This shorter period following transfection was previously found to be optimal for 
constructs bearing the KDEL sequence (see below) that was exploited in the second 
experiment.   
Following transfection of the COS-7 cells or HEK293T cells, they were harvested and stored 
at -80°C followed by cell lysate preparation as described in section 2.2.3.6. 
Both EFEMP1 and TIMP3 localise to the ECM where TIMP3, in particular, binds very 
tightly.  This means that most of the expressed TIMP3 will be found in that location. 
However denaturing conditions, necessary to remove TIMP3 from the ECM, would almost 
certainly disrupt any interaction between TIMP3 and EFEMP1.  KDEL is a four amino acid 
signal sequence found on the C-terminus of soluble ER resident proteins, such as chaperones, 
that prevents them being lost by secretion.  KDEL receptors are found in vesicular tubular 
clusters and the Golgi apparatus (secretory structures downstream of the ER) and these bind 
KDEL bearing proteins, sending them back to the ER via COPI-coated vesicles (Ellgaard and 
Helenius 2003). Previous work in my supervisor’s laboratory (unpublished observations) had 
shown that appending the KDEL sequence to the C-terminus of TIMP3 caused it to be 
processed correctly (e.g. glycosylation and disulphide bond formation, including formation of 
SFD dimers) but caused most of the protein to be retained inside the cell.  In this location the 
TIMP3 would be in a soluble form, still able to bind normally associated proteins, but in a 
form that could be extracted without using denaturing conditions.  
 
  




Table 6.2: HEK293T cells transfection for EFEMP1-TIMP3 pull-down. 









pcDNA3-TIMP3 (wild type) 
pcDNA3-S181C (mutant) 








EFEMP1 (wild type) 




EFEMP1- (R345W mutant) 
pcDNA3-TIMP3-V5-KDEL (wild type)  
pcDNA3-S181C-V5-KDEL (mutant) 
 
6.2.2.2 Protein pull-down protocol and Western blotting  
EFEMP1-TIMP3 protein pull-down was performed as described in section 2.2.3.6.2. Cell 
lysates, pull-down supernatant and pull-down eluate (10µl of each) were analysed by SDS-
PAGE and western blotting (section 2.2.3.3). To detect TIMP3-KDEL-V5 proteins, the 
membranes were blocked in 5% blocking buffer and immunoblotting against V5 Epitope Tag 
monoclonal antibody at 4 ̊C overnight. This was followed by 4 washes in TBST wash buffer 
and then 1-hour incubation in goat anti-mouse HRP conjugated secondary antibody. To check 
the expression of EFEMP1-HaloTag protein, the membranes were re-probed with anti-
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6.3 Results  
6.3.1 Western blotting of EFEMP1-TIMP3 pull-down  
Initial pull-down experiments were performed using COS-7 cells transfected with pHTC-
EFEMP1-HaloTag (wild type or mutant) and pcDNA3-TIMP3 (wild type or S181C mutant) 
(Table 6.2). Western blot analysis of both cell lysates and pull-down eluates failed to detect 
any TIMP3 proteins at the expected sizes (24 and 48kDa for wild-type and mutant TIMP3 
respectively - Figure 6.1).  The band at approximately 58kDa, present in all samples, is due to 
non-specific binding of the anti-TIMP3 antibody to a cellular protein.  As alluded to earlier, 
this probably reflects the fact that most of the TIMP3 expressed was localised to the ECM 
and the non-denaturing lysis buffer used to solubilise the cells for the pull down experiments 
would be unlikely to remove this.  However an additional confounding factor may be the fact 
that the C-terminal domain of EFEMP1 was shown to be responsible for TIMP3 binding 
(Klenotic et al. 2004) and the relatively large HaloTag protein (approximately 35kDa), 
present on the C-terminus, may interfere with this interaction. 
In order to attempt to circumvent the former issue the ER retention signal, KDEL, was 
appended to the C-terminus of the TIMP3 proteins, as discussed earlier. While the HaloTag 
protein can be fused to the N-terminus of proteins in the pHTN vector (equivalent to pHTC 
but with a multiple cloning site on the C-terminal end of HaloTag), the HaloTag sequence 
lacks a signal sequence and so fusion proteins are directed into the cytosol. To remedy this, a 
new vector had been created in our laboratory in which the human chymotrypsinogen signal 
peptide (MAFLWLLSCWALLGTTFG) was appended to the N-terminus of the HaloTag 
protein, with a multiple cloning site at the C-terminal end (pcDNA3-SS-HaloTag). The 
revised pull-down experiments, therefore, utilised pcDNA3-SS-HaloTag-EFEMP1 (wild type 
or R345W mutant) and pcDNA3-TIMP3-V5-KDEL (wild type or S181C mutant).  
Following these changes TIMP3 protein, in both wild type and SFD mutant forms, was 
clearly detectable in the cell lysate and also in the eluate from the HaloTag binding resin 
(Figure 6.2A).  The non-reduced blot of S181C TIMP3 (Figure 6.2C) confirmed that the 
mutant was expressed and pulled down in the dimeric form (bands at approximately 44 and 
48kDa, corresponding to unglycosylated and glycosylated dimer).  Figure 6.2A also confirms 
that R345W EFEMP1 retains its ability to bind TIMP3. 
Re-probing the membrane with anti-HaloTag antibody (Figure 6.2B) clearly showed high-
level expression of the HaloTag-EFEMP1 fusion protein at the expected size (approximately 
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90kDa) in the cell lysate.  Following pull-down, analysis of the supernatant showed that the 
vast majority bound to the HaloTag resin.  No HaloTag-EFEMP1 was detectable in the resin 
eluate, confirming the fact that the binding of HaloTag to the haloalkane on the resin is 
irreversible.  While pull down of TIMP3 was not as great as might be expected with this high 
level of expression of EFEMP1 (much of the TIMP3 remained in the supernatant), it did 
appear to be specific in that the HaloTag only control, did not result in pull-down of any 
TIMP3 (Figure 6.2D). Again, re-probing with anti-HaloTag antibody (Figure 6.2E) 
confirmed expression of the HaloTag protein at the expected size (approximately 35kDa), 











Figure 6.1: Western blotting analysis of first EFEMP1-TIMP3 pull-down. 
COS-7 cells were transfected with pHTC-EFEMP1-HaloTag (wild type or mutant) 
and pcDNA3-TIMP3 (wild type or S181C mutant) and used for pull-down followed by 
western blotting. The membrane was probed with anti-TIMP3 first loop primary 
antibody to detect TIMP3 protein expression in cell lysates and pull-down eluate. 







































































































































































































Figure 6.2: Western blotting of the second EFEMP1-TIMP3 pull-down 
experiment.  
Western blotting of EFEMP1-TIMP3 pull-down in HEK293T cells transfected with 
pcDNA3-SS-HaloTag-EFEMP1 (wild type or mutant) (A, B & C) or pcDNA3-SS-
HaloTag (D & E) together with pcDNA3-TIMP3-KDEL-V5 (wild type or S181C 
mutant). (A), (C) & (D) the membranes were initially probed with anti-V5 Epitope Tag 
antibody to detect the TIMP3 protein expression (reduced and non-reduced, 
respectively), and then (B) & (E) stripped and probed with monoclonal anti-HaloTag 
antibody to show EFEMP1 expression. WT: wild type and Mut: mutant.  
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The data shown here, using N-terminally HaloTagged EFEMP1, indicate that both wild type 
and S181C mutated forms of TIMP3 are able to bind EFEMP1 in the pull-down assay 
although, as this is not a quantitative assay, differences in binding affinity cannot be ruled 
out. This being the case, it is likely that the high level expression of TIMP3 in SFD eyes will 
also be accompanied by deposition of EFEMP1, raising the possibility that TIMP3/EFEMP1 
complexes play a role in ML, SFD and AMD. These complexes alone may be sufficient to 
interfere with traffic of nutrients across Bruch’s membrane but accumulation of TIMP3 
would also likely interfere with clearance of other proteins from the RPE by MMPs and 
deposition of additional proteins. As EFEMP1 has been shown to bind complement factor H 
(CFH), these complexes may also contain CFH protein. If this sequesters this protein, 
impairing its ability to regulate complement activation, it might explain the inflammatory 
aspect of these diseases. 
If this were the case, however, it would not entirely explain the phenotypic differences 
between these diseases, with ML resembling dry AMD and SFD resembling wet AMD. 
However in ML the proposed protein complexes would contain normal TIMP3, which 
inhibits VEGFR2.  In contrast we have shown the SFD mutant forms of TIMP3 have an 
impaired ability to inhibit VEGFR2. This could explain why SFD, but not ML, is 
characterized by choroidal neovascularisation. If in AMD these protein complexes are the 
result of oxidation/AGE formation, then TIMP3 may be partially functional with respect to 
VEGFR2 inhibition, with increasing cross-linking with time leading to an ever-diminishing 
ability to inhibit VEGFR2 and a gradual progression from dry to wet AMD.  The unique 
honeycomb patterning of drusen found in ML may reflect the fact that the R345W mutation 
impairs protein secretion and result in accumulation of mutant protein in the endoplasmic 
reticulum, possibly together with TIMP3, triggering the unfolded protein response (Roybal et 
al. 2005). Overloading the unfolded protein response can induce apoptosis (Fribley et al. 
2009). It is possible that this initial accumulation within the cell affects the pattern of 
deposition of the protein complexes in ML.  In contrast SFD mutations do not impair TIMP3 
secretion (unpublished observations from our laboratory) and so accumulation of TIMP3 in 
Bruch’s is likely to be diffuse. This is also likely to be the case in AMD where any cross-
linking occurs extracellulary.  
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Taken together, these data further support a potential common mechanism in the etiology 
of ML, SFD and AMD.  
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As mentioned in the introduction, there are numerous phenotypic similarities between SFD 
and AMD, including thickening in Bruch’s membrane, drusen, photoreceptor dysfunction, 
RPE disruption and sub-retinal neovascularisation (Saksens et al. 2014). However AMD is a 
multifactorial disorder, not directly associated with mutations in the TIMP-3 sequence. 
Nevertheless these similarities, together with the observation that abnormally high 
concentrations of TIMP-3 are present in the retina in both diseases, suggests a potential role 
for TIMP3 in AMD and a link between these two degenerative eye diseases. 
We have now demonstrated that all known SFD mutations result in TIMP3 oligomerisation.  
Moreover our laboratory has previously shown that this impairs turnover of the mutant 
proteins, which retain their ability to inhibit MMPs (Langton et al. 2005), potentially 
resulting in decreased ECM turnover.  The questions remain as to what mechanism(s) could 
give rise to TIMP3 accumulation in AMD and whether such accumulation in both SFD and 
AMD has effects other than disruption of normal proteolysis.  
In fact protein cross-linking is a well-established consequence of ageing and can result from 
oxidation, usually as a result of the generation of reactive oxygen intermediates (ROI) from a 
number of processes such as chronic inflammation and ultraviolet (UV) light exposure or 
through the formation of age-related glycation end products (AGEs), and advanced 
lipoxidation end products (ALEs) which result from glucose or lipid based modification of 
proteins (and other macromolecules), respectively (Glenn and Stitt 2009). Accumulation of 
AGEs has a detrimental effect on the retina, at least in part, due to activation of AGEs 
receptor (RAGE) that is a cell surface pattern recognition receptor and found to play an 
important role in a number of degenerative diseases such as AMD.  
RAGE appears to be activated by ligand-induced dimerisation leading to activation of 
multiple protein kinases; for instance, Janus kinase (JAK), MAPKs, signal transducer and 
activator transcriptions (STATs) and activation of NF-KB pathway (Zong et al. 2010, 
Hermani et al. 2006, Yeh et al. 2001, Lander et al. 1997, Yan et al. 1994). This activation 
associates RAGE with a variety of inflammation-related cell responses including migration, 
apoptosis and pro-inflammatory gene expression (Yan et al. 2009, Zong et al. 2010). 
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For AMD one possibility is that the age-related formation of advanced glycation end products 
(AGEs) results in TIMP3 cross-linking which could produce a toxic form of the protein 
analogous to that produced in SFD, and affect its interaction with for example TACE or 
VEGFR2. Conversely, it is also possible that the toxicity of SFD-TIMP-3 is due to the fact 
that it mimics AGE products and binds to AGE receptors. 
The hypothesis of this chapter was that SFD-TIMP3 transcripts activate RAGE through direct 
binding and therefore the initial aim was to investigate the effect of SFD-TIMP3 on RAGE 
signalling. To test this hypothesis, the effect of SFD-TIMP3 on RAGE activation was 
examined by using human embryonic kidney 293T (HEK293T) cells transfected transiently 
with NF-κB-luciferase reporter constructs, as these cells were previously transfected with a 
similar reporter gene and demonstrated by Zong et al. (2010) to have activated NF-κB 
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7.2 Methods  
7.2.1 Vectors  
A number of firefly luciferase reporter vectors including pGL3-Basic, pGL3-Control, pGL3-
IL8-Luc, pGL4-Luc2P/NF-KB and pNF-KB, were prepared using maxiprep kits (sections 
2.2.1.3, 2.2.1.4 & 2.2.1.5) and transfected either alone, in conjunction with the standard 
Luciferase Reporter assay or together with the Renilla luciferase control vector, pTK-green 
Renilla Luc vector (pTK-Ren) in conjunction with the Dual Luciferase reporter assay (Table 
7.1, Appendix 3). The firefly pGL3-Basic, pGL3-Control and pGL4-luc/NF-KB were 
purchased from Promega, whereas pGL3-IL8-Luc, and pTK-Renilla were a kind gift from Dr 
François Guesdon, University of Sheffield. Also, SFD-TIMP3 constructs encompassing 
WT.T3, E139X and S181C were also available in our lab in the pcDNA3 vector and prepared 
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Table 7.1: Luciferase reporter DNA plasmids.  




Renilla Luc  
Renilla 
luciferase 
Constitutively active thymidine 







Contains 4 tandem copies of the NF-
KB transcription factor binding site 
fused to a TATA-like promoter 
(PTAL) region from the Herpes 












pGL3-Control Luc+ Contains constitutively active SV40 promoter and enhancer sequences. 
Positive control 
vector 











Contains SV40 promoter and 
enhancer sequences and five copies 
of the NF-KB response element. Also 
has hygromycin resistance cassette 




7.2.2 Transfection of mammalian cells  
7.2.2.1 Transfection of ARPE19 cells with TIMP3 constructs  
To examine the effect of TIMP3 on RAGE activation, ARPE19 cells were stably transfected 
with WT.T3, E139X and S181C in pcDNA3 using TransIT-LT transfection reagent (section 
2.2.2.9). WT.T3, E139X and S181C in pcDNA3 vector were already available in our lab 
(section 7.3.1). Cells were seeded into 6-well plates at a density of 15x104 cells per well in 
complete growth medium and grown overnight until cells became 50-70% confluent. 
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Transfection was performed at 6:1 transfection ratio (TransIT-LT1: DNA) and 48 hours post-
transfection cells were trypsinised and seeded into T25 flask containing complete growth 
media and 50µl of Geneticin (500µg/ml). Cells were allowed to reach the desired confluence 
level before preparing 10cm plates for examining protein expression. 
 
7.2.2.2 Transfection of HEK293T cells with luciferase reporter vectors  
HEK293T cells were transfected transiently with the desired luciferase reporter vectors in 6-
well plates or 24-well plates for the dual luciferase reporter assay system (section 2.2.3.4.1) 
or luciferase assay system (section 2.2.3.4.2), respectively.  
 
7.2.3 ARPE19-ECM preparation for the dual luciferase assay  
In order to prepare ARPE19-ECM for the dual luciferase reporter assay, un-transfected 
ARPE19 cells or ARPE19 cells stably transfected with WT.T3, E139X or S181C were grown 
to 80-90% confluence in T75 flasks, removed and counted (section 2.2.2.5) then seeded into 
10cm tissue culture dishes (1x106 per plate) to check TIMP3 protein expression by western 
blotting or 24-well plates (32x103 per well) to be used in dual luciferase reporter assay. Cells 
were maintained for 10 days in complete growth medium without or with selection antibiotic 
for un-transfected and transfected cells, respectively.  
The cells were then removed from the tissue culture dishes to analyse ECM protein 
expression using hypotonic buffers described in 2.2.3.1.2. Similarly ARPE19 cells were 
removed from the 24-well plate surface to prepare ECM for the dual luciferase reporter assay 
by incubating in 20mM NH4OH for 5 minutes as described in section 2.2.3.1.3. 
 
7.2.4 RAGE induction in mammalian cells  
10cm tissue culture dishes were coated with RAGE ligands including S100B (10µg/ml) and 
AGE-BSA (200µg/ml) prepared in 0.05M bicarbonate buffer and incubated at 4°C for 24 
hours. Then, un-transfected HEK293T were seeded into either un-coated or coated plates at 
1x106/plate and maintain for 2 days in 2% FBS-starving growth media. After the treatment 
period, cells were lysed in RIPA lysis buffer (see section 2.2.3.1.1) and cell lysates were 
stored at -80°C until analysed by SDS-PAGE and western blotting.  




7.2.5 RAGE and TIMP3 expressions by western blotting   
To examine RAGE expression in HEK293T cells and TIMP3 in ARPE19-ECM, SDS-PAGE 
and western blotting were performed (section 2.2.3.3). Polyclonal rabbit RAGE antibody was 
used to detect RAGE at dilution of 1:2000, and primary polyclonal rabbit anti-TIMP3-N-
terminal antibody (first loop) was used to identify TIMP3 at 1:3000. Subsequently, the 
secondary antibody was swine horseradish peroxidase-conjugated anti-rabbit antibody at 
1:10000 used for both primary antibodies. The PVDF membrane was developed using 
chemiluminescent substrate (section 2.2.3.3.5). 
 
7.2.6 Luciferase assays 
7.2.6.1 Dual Luciferase reporter assay system with RAGE ligands and 
ARPE19-ECM treatments  
To examine the effect of wild type or SFD-mutant TIMP3 on RAGE signalling pathways, 
dual luciferase reporter assay was performed using ECM prepared from un-transfected and 
TIMP3-constructs transfected as explained in section 2.2.3.7.1.  
 
7.2.6.1.1 Co-transfection of HEK293T cells 
HEK293T cells were transfected with four luciferase reporter vectors accompanied by 
Renilla luciferase control vector (2.2.3.7.1).  
 
7.2.6.2 Luciferase assay system  
Luciferase assay system kit was applied according to manufacturer’s instruction to study the 
effect of wild type and mutants TIMP3 on AGE receptor and to confirm data from the dual 
luciferase reporter assay (see section 2.2.3.4.2).    
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7.3 Results   
7.3.1 Dual luciferase assay  
Initially experiments were carried out using the dual luciferase reporter assay (section 
2.2.3.7.1) as this is supposed to give more reliable results in transient transfection 
experiments than the firefly luciferase assay alone as any differences in transfection 
efficiency between cells are controlled by measuring the ratio of firefly luciferase from the 
reporter to constitutively expressed Renilla luciferase. Extracellular matrix from ARPE19 cell 
expressing wild type- or SFD- TIMP3 was used as the source of TIMP3 proteins and 
HEK293T cells, known to express RAGE, were transfected with the reporter constructs.  
 
7.3.1.1 Expression of RAGE in HEK293T    
Prior to measuring RAGE activation, the expression of RAGE by HEK293T cells was 
examined on both untreated cells and cells treated with different RAGE ligands or ARPE19 
ECM containing TIMP3 proteins, to ensure any changes in activation that might be observed 
were not in fact due to changes in receptor expression. 
In order to examine RAGE expression in HEK293T cells, they were seeded onto tissue 
culture petri dishes coated with RAGE-ligands S100B (10µg/ml) or AGE-BSA (200µg/ml) or 
ECM from ARPE19 transfected with WT.T3, E139X and S181C. At 2 days, cells were lysed 
in RIPA lysis buffer and then subjected to western blotting. 
Western blotting analysis of whole cell lysates extracted from HEK293T cells revealed the 
presence of immune reactive protein species at approximately 55kDa, the expected size of 
glycosylated RAGE, in all un-treated and ligand treated cells in non-reduced gels (Figure 
7.1A). In comparison with RAGE-ligand treatment, HEK293T cells treated with ARPE19-
ECM showed similar bands at 55kDa. The expression of wild type and mutant TIMP3 in the 
ECM of ARPE19 cells was also confirmed using TIMP3 antibody in Figure 7.1B, although 
expression of S181C, appeared to be much stronger than E139X. 
 
  











Figure 7.1: RAGE expression in mammalian cells.  
(A) Western blotting analysis of RAGE expression in HEK293T cells showed a 
species at approximately 55kDa using polyclonal RAGE antibody. (B) Western 
blotting of ECM from ARPE19 cells transfected with WT.T3, E139X and S181C 
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7.3.1.2 Dual luciferase reporter assay system  
To investigate the activation of NF-KB in HEK293T cells treated with RAGE ligands or WT- 
and SFD-TIMP3, the dual luciferase reporter assay was initially optimised to determine 
which particular reporter vector gave the best response, to ascertain the optimal transfection 
ratio (experimental vector: co-reporter vector) and to determine the optimal incubation time 
with the RAGE ligands. Two different reporter vectors were initially tested pGL3-IL8-Luc 
and pNF-KB-Luc together with two control vectors pGL3-Basic and pGL3-Control (Table 
7.1). RAGE-ligands S100B and AGE-BSA were used at 10µg/ml as reported by Howes et al. 
(2004) and Zong et al. (2010). 
The dual luciferase reporter assay was performed by transfecting HEK293T cells with each 
of the four reporter vectors together with the control Renilla-luc vector (at 4:1 transfection 
ratio of experimental vector: co-reporter vector) and then 24hrs post transfection cells were 
treated with S100B for 12-48 hours.  Little, if any induction in response to S100B was seen 
with the pNF-KB-Luc reporter but the pGL3-IL8-Luc gave a clear response at 24hrs post-
induction. Surprisingly the pGL3-Control vector also showed an apparent increase in 
induction in response to S100B and it is possible that this is due to NF-KB binding sequences 
in the SV40 enhancer present in this vector (Figure 7.2). For this reason the pGL3-IL8-Luc 
vector was chosen for further optimisation experiments. 
  
  





Figure 7.2: Optimisation of dual luciferase reporter assay parameters. 
Optimisation of dual luciferase reporter assay parameters.  
Transfected HEK293T cells treated with S100B for (A) 12hrs, (B) 24hrs & (C) 48hrs. 
Fold activity was calculated as the ratio of firefly to renilla and then normalised to the 
untreated vector transfected cells. *: P= 0.0211; **: P= 0.0082; NS: not significant. 
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In the following experiments, transfection of HEK293T cells was performed, using pGL3-
IL8-luc, with Renilla-luc vector, at two transfection ratios (experimental vector: co-reporter 
vector) encompassing 4:1 and 40:1. At 24 hours post-transfection, transfected cells were 
treated with S100B (10µg/ml) or AGE-BSA (200µg/ml) for 12-48 hours (Figures 7.3 and 
7.4).  
This showed that a ratio of 40:1 firefly:Renilla gave a much higher induction than for 4:1 in 
response to S100B at 12 hours treatment, giving a 3.5 fold induction (Figure 7.4). 
  





Figure 7.3: Dual luciferase reporter assay (4:1 transfection ratio). 
HEK293T cells were transfected with reporter vectors at 4:1 transfection ratio 
(experimental vector: co-reporter vector) and then 24 hours post-transfection cells 
were seeded onto wells coated with S100B (10µg/ml) or AGES-BSA (200µg/ml). 
Representation of RAGE-ligands treated HEK293T cells for (A) 12 hrs, (B) 24hrs  & 
(C) 48 hrs. Fold activity was initially calculated as the ratio of firefly to renilla and 
then the ratio of ligand treated to untreated vector transfected cells. Data of two 
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Figure 7.4: Dual luciferase reporter assay (40:1 transfection ratio).  
HEK293T cells were transiently transfected with reporter vectors and then seeded 
onto wells coated with S100B (10µg/ml) and AGES-BSA (200µg/ml) 24 hours post-
transfection. Demonstration of RAGE-ligands treated HEK293T cells for (A) 12 hrs, 
(B) 24hrs  & (C) 48 hrs. Fold activity was initially calculated as the ratio of firefly to 
renilla and then the ratio of ligand treated to untreated transfected cells. **** 
Comparison between pGL3-IL8-luc untreated and RAGE-ligands treated cells. Data 
are as means ± S.E of two replicate experiments and analysed using one-way 
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Following this optimisation, experiments were performed using the ECM from TIMP3 and 
SFD-TIMP3 transfected ARPE19 cells using the pGL3-IL8-Luc vector: pTK-Luc at a ratio of 
40:1 and measuring luciferase activity after 12 hours (Figure 7.5). This showed that ARPE19 
cell matrix alone induced a strong luciferase response in the HEK293T cells, which was not 
significantly changed in response to matrix containing WT-TIMP3. However there did appear 
to be a significant increase ~1.5 fold in the luciferase response for matrix containing the 
S181C SFD mutant protein.  However this result was put into some doubt by the fact that the 
E139X mutant gave a much lower response than either untransfected or WT-TIMP3 
transfected cell ECM. 
These data are difficult to explain but may be a combination of the facts that ARPE19 ECM 
will contain many factors that could induce an NF-KB response through RAGE or other 
receptors that couple to NF-KB.  Moreover the IL8 promoter sequence contains additional 
transcription factor binding sites that may respond to other stimuli.  Lastly Figure 7.1 shows 
that E139X was poorly expressed, relative to the endogenous TIMP3 or the S181C mutant.  
As a result of this it was decided to carry out a simplified luciferase reporter assay in which 
pcDNA3-TIMP3/SFD-TIMP3 vectors were co-transfected into HEK293T cells together with 
a new reporter vector, pGL4-Luc2P/NF-KB that contains five tandem copies of the NF-KB 
response sequence upstream of Luc2P, a luciferase enzyme codon optimised to give high 
expression in mammalian cells.  As the pcDNA3 vector contains the SV40 origin or 
replication this should give high level, transient expression of the TIMP sequences in these 
cells. 
Additionally it was decided to also co-transfect the cells with a vector containing RAGE 
(pcDNA3-RAGE) to ensure that responses were not limited by the endogenous expression 
level of RAGE in HEK293T cells. 
  


























Figure 7.5: Dual luciferase reporter assay (40:1 transfection ratio, ARPE19 
ECM treatment). 
HEK293T cells transiently transfected with reporter vectors were seeded onto 
ARPE19-ECM, prepared using NH4OH, 12 hours post-transfection. (A) & (B) 
Demonstration of 12hrs ARPE19-ECM treated HEK293T cells. (C) The Table shows 
the p value of cells treated with WT/SFD-TIMP3 ECM relative to un-transfected 
ARPE19-ECM. **** Comparison between pGL3-Basic ARPE19-ECM, and 
WT.T3/SFD-TIMP3-ECM. ++++ Comparison between pGL3-IL8-luc ARPE19-ECM and 
other pGL3-IL8-luc WT/SFD-TIMP3 ECM treated including E139X and S181C. Data 














































































































































































































7.3.2 Co-transfection of TIMP3/SFD-TIMP3, RAGE and pGL4-luc2p/NF-KB 
using the Luciferase assay system  
In order to investigate the effect of RAGE ligands or WT- and SFD- TIMP3 in NF-KB 
transcriptional activity, luciferase assay system was performed using HEK293T cell 
transfected with triple DNAs including pGL4-luc2P/NF-KB, RAGE and SFD-TIMP3. 
 
7.3.2.1 RAGE expression in HEK293T cells  
The expression of RAGE and SFD-TIMP3 in transfected HEK293T was initially examined 
prior to proceeding with the luciferase assay. To examine the expression of RAGE and 
dimeric TIMP3 in SFD-TIMP3 transfected HEK293T, cells were transfected with pGL4-
luc2P/NF-KB, RAGE and SFD-TIMP3 constructs including E139X, S181C and 
SplT3.Mutant (section 2.2.3.7.2). 48 hours post transfection, cell lysates were prepared to 
check the expression of RAGE, whereas, for TIMP3, cells were removed using hypotonic 
buffers and then ECM was extracted using 2X SDS sample buffer. Both samples, cell lysates 
and ECM, were subjected to western blotting (section 7.3.5). 
Un-transfected HEK293T cell produced a basal level of RAGE under normal condition at 
55kDa; conversely, transfected HEK293T cells showed a strong expression at 55kDa.  The 
positive control is the extracellular domain of RAGE fused to Human IgG1 Fc domain and 
ran at the expected size of 80-90kDa (Figure 7.6A). 
Western blotting analysis of ECM extracted from HEK293T cells demonstrated that TIMP3 
species were expressed at 20- and 30- kDa in all un-transfected and TIMP3-transfected cells 
in non-reduced gel, corresponding to the previously reported un-glycosylated and 
glycosylated protein, respectively (Figure 7.6B). Also, ECM from SFD-TIMP3 transfected 
cells showed additional higher molecular weight protein species in non-reduced gels; for 
instance, S181C-TIMP3 expressed a protein at ~48kDa, E139X-TIMP3 expressed a protein at 
30kDa and SplT3.Mut expressed two species at ~15 and 30 kDa. Upon reduction, the 
dimeric-TIMP3 bands reduced to 24kDa, 15kDa and 15kDa for S181C, E139X and 
SplT3.Mut, respectively. This confirmed that SFD-TIMP3 mutants expressed in HEK293T 
cells at 48 hours post transfection; enabling the possibility of performing luciferase assays 
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using HEK293T cells transiently transfected with triple DNA encompassing pGL4-luc2P/NF-









Figure 7.6: Western blotting HEK293T cell transfected with luciferase reporter 
vector, RAGE and SFD-TIMP3.  
HEK293T cells were transfected with pGL4.Luc/NF-KB, RAGE and TIMP3 constructs 
including WT.T3, E139X, S181C and SplT3.Mutant. (A) RAGE expression in cell 
lysates using polyclonal RAGE antibody. (B) Expression of TIMP3 protein in the 
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7.3.2.2 Luciferase assay 
Following the western blotting analysis of HEK293T cells transfected with triple DNAs that 
confirmed the expression of both RAGE and TIMP3, the luciferase assay was performed 
using those HEK293T cells transfected with three DNA vectors: pGL4-Luc2P/NF-KB, RAGE 
and TIMP3 constructs including (WT.T3, E139X, S181C and SplT3.M) (see section 
2.2.3.4.2).  
While cells transfected with WT-TIMP3 showed some induction of luciferase activity this 
was significantly increased in cells transfected with all of the SFD-TIMP3 mutants 
(approximately 2-3 fold increase, relative to WT-TIMP3, p>0.0001) (Figure 7.7 C & D), 
indicating that SFD-mutant forms of TIMP3 may indeed activate RAGE. 
 
  












Figure 7.7: Luciferase assay of HEK293T cells transfected with reporter 
vectors and SFD-TIMP3.  
HEK293T cells were transiently transfected with luciferase reporter vector, RAGE 
and SFD-TIMP3 in 24 well plate and, 24 hours post-transfection, incubated for 
another 24 hours. (A) & (B) Relative luminescence unit (RLU) and fold activity, 
respectively. (++++ Comparison between SFD-TIMP3 and WT.T3 transfected cells). 
Fold activity was calculated as the ratio of SFD-transfected to WT.T3-transfected 
cells. Data of a three replicate experiments are shown as means ± S.E and analysed 






























































































































7.4 Discussion  
Advanced glycation end products receptor (RAGE) is a cell surface pattern recognition 
receptor that is widely expressed in a diversity of cell types; for instance, smooth muscle 
cells, cardiac myocytes, endothelium and neural tissue (Brett et al., 1993). RAGE binds to 
multiple ligands that include amphoterin high mobility group box-1 (Hofmann et al., 1999), 
Mac-1 (Chavakis et al. 2003), amyloid-β (Yan and Sage 1999) and S100 protein (Ghavami et 
al. 2008). Structurally, RAGE belongs to the immunoglobulin superfamily and consists of 
five domains including N-terminal signal peptide, V-type immunoglobulin- like, C-type 
immunoglobulin- like, a single trans-membrane and C-terminal intracellular cytoplasmic tail 
per (Neeper et al. 1992, Koch et al. 2010). The cytoplasmic domain is considered as a 
fundamental domain for RAGE-mediated cell signalling.  
Previous binding studies showed that RAGE ligands including S100B and Amyloid-β 
function as oligomers that trigger RAGE activation through receptor dimerisation on the 
plasma membrane. RAGE dimerisation is believed to be responsible for recognising AGE-
modified protein. (Chaney et al. 2005, Ostendorp et al. 2007, Xie et al. 2008, Zong et al. 
2010)  
It is well established that S100B occurs in dimer and tetramer forms and that S100B tetramer 
has higher binding affinity toward RAGE than the dimer form. S100B tetramer was observed 
to promoted cell survival and cause a strong cell growth, suggesting that such oligomer 
induces RAGE activation via receptor dimerisation at the V domain (Ostendorp et al. 2007). 
All examined SFD-TIMP3 mutants have been shown to form dimers therefore the hypothesis 
here was that SFD-TIM3 dimers could mimic RAGE-ligands through direct binding to the 
receptor resulting in activation of RAGE signalling pathways. Western blotting confirmed 
RAGE expression on HEK293T cells and also that this expression was not affected by the 
various test ligands. 
A considerable amount of time was spent in attempting to optimise the dual luciferase 
reporter assay as a means of assessing RAGE induction.  While this appeared relatively 
successful for exogenously added RAGE ligands, S100B and AGE-BSA, treating the reporter 
cells with ECM from untransfected and TIMP3/SFD-TIMP3 transfected ARPE19 cells was 
somewhat inconclusive with untransfected and WT-TIMP3 transfected ARPE19 ECM 
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showing similarly high levels of induction and S181C TIMP3 an apparently significantly 
increased induction, relative to WT-TIMP3 but E139X TIMP3 showing very poor induction 
relative to even untransfected ARPE19 cells.  Western blotting had indicated that the level of 
expression of E139X TIMP3 was somewhat lower than S181C TIMP3 but this would not 
seem to be sufficient to explain the differences seen.  As alluded to earlier, it is possible that 
the level of TIMP3/SFD-TIMP3 expressed in the ARPE19 ECM is relatively low compared 
to the many other proteins that might be present there that could potentially induce an NFκB 
response, and this may have been exacerbated by using the IL8 promoter sequence that will 
respond to transcription factors in addition to NFκB. 
In order to try and circumvent these issues the pcDNA3-TIMP/SFD-TIMP3 vectors were 
directly transfected into the ARPE19 cells, together with RAGE and a new reporter vector, 
pGL4-Luc2P/NF-KB, that was expected to give higher expression of the modified luciferase 
gene and only in response to NF-KB.  While only preliminary, this seemed to produce much 
more consistent results, with all three SFD-mutant forms of TIMP3 tested giving a consistent 
3-4 fold stronger induction of the NFκB reporter than the normal molecule.   
However these experiments do not prove that the NFκB response is due to RAGE activation, 
it is possible that this is due to a different mechanism altogether.  One way to confirm this 
would be to knock-down the expression of RAGE using small interfering RNA (siRNA) 
molecules and see if the SFD-induced NFκB response is supressed.  Nevertheless the data 
presented here indicate that, unlike the wild-type molecule, SFD-TIMP3 has a 
proinflammatory effect on cells, which could contribute to the SFD phenotype. 
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As has already been mentioned, TIMP3 is unique among the TIMP family in being extremely 
highly conserved across species and this probably reflects the fact that it has such wide-
ranging binding partners and functional activities. Not only it does inhibit all MMPs it also 
inhibits several members of the adamalysin family, and such plays wide ranging roles in 
regulating inflammation and cell matrix turnover. Moreover TIMP3 has unique 
characteristics that are independent of its ability to inhibit proteinases, including VEGFR2 
inhibition, EFEMP1 binding and tight association with glycosaminoglycans in the ECM. 
These latter properties may be particularly important in the eye where TIMP3 is 
constitutively expressed by the retinal pigment epithelial and choroidal endothelial cells and 
is a constituent of Bruch’s membrane.  
These facts go some way towards explaining why mutations in the TIMP3 gene are 
associated with an inherited ocular disease, Sorsby’s fundus dystrophy. Although the 
literature has enriched our understanding of the biochemical properties of wild type TIMP3, a 
definitive answer as to how SFD-TIMP3 mutations give rise to a disease with an exclusively 
ocular pathology remains uncertain, and this has been the focus of this thesis.  Moreover, 
there are a number of clues that suggest TIMP3 plays a role in other retinopathies, such as 
Malattia Leventinese and age-related macular degeneration.  AMD, in particular, is likely to 
have an ever increasing impact on quality of life and economic cost to health services as the 
elderly population increases and so establishing a common mechanism underpinning these 
diseases, if indeed one exists, has great potential for the development of new therapeutic 
strategies to alleviate these currently incurable conditions.  
 
8.2 SFD-TIMP3 dimerisation  
This project initially aimed to strengthen our hypothesis that TIMP3 dimerisation is a 
common characteristic of all SFD mutants and essential for SFD pathogenesis. Although 
most of the SFD mutations have been assessed in our laboratory, this project has examined 
five previously identified mutations where the effects on dimerisation were unknown.  These 
included the recently described C-terminal mutations Y128C, Y154C and Y159C, and the 
novel mutations in the N-domain, S15C, and at the intron4/exon5 splice site.  
This project has now demonstrated that all of these diverse mutations result in dimeric 
TIMP3 protein, providing overwhelming evidence that dimerisation is a prerequisite for SFD.     
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This would suggest that dimerisation of TIMP3 results in a protein with novel properties that 
could play a toxic role in the disease. Previous work in our laboratory by Langton et al. 
(2005) demonstrated that TIMP3 dimers and multimers show impaired turnover, relative to 
the wild-type molecule, likely explaining the increased TIMP3 protein deposition in the eye 
of SFD individuals observed by Fariss et al. (1998). 
As the majority of data indicate that mutant TIMP3 retains its ability to inhibit MMPs, it is 
possible that this increased deposition of a potent proteinase inhibitor in Bruch’s is sufficient 
to explain the SFD phenotype as decreased proteolysis might account for thickening of 
Bruch’s membrane which could in turn lead to hypoxia, the release of VEGF and 
subsequently choroidal neovascularisation. However, if mutant TIMP3 retains its ability to 
inhibit VEGFR2, as reported by Fogarasi et al. (2008), it is difficult to explain why the high 
level of TIMP3 in the eyes of these patients does not inhibit this process. 
Moreover, it is easily conceivable that other types of mutation in TIMP3 could impair its 
clearance from Bruch’s yet all result in dimerisation. This lends support to the hypothesis that 
dimerisation of TIMP3 has a very specific effect on its function. This may be through 
increased avidity for cell surface proteins, such as TACE, or enabling TIMP3 to cross-link 
and potentially activate receptors. 
   
8.3 The physiological functions of SFD-TIMP3 mutants  
A number of possibilities have been explored in this thesis with varying degrees of success. It 
has previously been observed that very high concentrations of TIMP3 induce apoptosis in 
various cell types, and that SFD mutant forms appear more toxic (Baker et al., 1999; Majid et 
al., 2002). However here we explored whether lower concentrations of SFD-TIMP3, 
expressed in situ in the ECM of RPE cells, may make them more susceptible to other pro-
apoptotic ligands. 
This did indeed appear to be the case as the apoptosis assay data presented in Chapter 4 
provides evidence for SFD-TIMP3 increasing the sensitivity of ARPE19 cells to Fas-induced 
apoptosis with all examined mutations including E139X, S156C, H158R and S181C 
demonstrating increased apoptosis relative to wild-type TIMP3.  This may be particularly 
relevant in the retina as the concentrations of TIMP3 found to be directly pro-apoptotic in 
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vitro may not be reached in vivo, but may still be important in combination with other pro-
apoptotic ligands that may be found there.   
The pro-apoptotic effects of TIMP3 have been ascribed to its ability to inhibit sheddases, 
particularly TACE, and it is possible that dimerisation increases the avidity of TIMP3 for this 
protein on the cell surface.  This possibility was made all the more intriguing by the report 
that TIMP3 stabilises TACE in an inactive dimeric form, with activation resulting in 
dissociation of TIMP3 and an active TACE monomer (Xu et al. 2012).  While the pull-down 
assay, using C-terminally HaloTagged TIMP3, failed to confirm any increased association of 
the mutants with TACE following PMA-induced activation, this was probably more a result 
of limitations of the assay and it is possible that the relatively large HaloTag (approximately 
30kDa) impaired the binding of the fusion protein to TACE. 
An additional or alternative possibility, however, is that TIMP3 dimers/multimers are 
recognised by the pattern recognition receptor RAGE, activation of which is known to induce 
apoptosis in these cells (Howes et al. 2004).  The data presented in Chapter 7 demonstrated 
that SFD-TIMP3 mutants appeared to have a pro-inflammatory effect in the HEK293 NF-KB 
reporter assay.  While this effect was also seen with known RAGE ligands, unfortunately 
time did not allow for direct confirmation that the effect of SFD-TIMP3 was mediated by 
RAGE rather than other pro-inflammatory mechanisms.  
Another intriguing possibility was that dimerisation of TIMP3 may actually convert the 
molecule into a VEGFR2 agonist, activating the receptor in the same way as the dimeric 
ligand and potentially explaining the choroidal neovascularisation that is characteristic of the 
disease in most patients.  However, binding to VEGFR2 is mediated via the C-terminal 
domain of TIMP3 (Qi et al. 2003) and so this possibility can almost certainly be excluded for 
the E139X mutant that lacks all but fifteen amino acids of the C-terminal domain and also for 
the splice site mutation, which we show in Chapter 3, appears to result in TIMP3 proteins 
totally lacking this domain.  Despite this, both of these mutations still give rise to dimers and 
these patients still exhibit CNV. 
It had previously been reported that SFD mutant forms of TIMP3 induce increased 
expression of VEGFR2 on the surface of porcine aortic endothelial cells, potentially 
explaining why the increased level of TIMP3 expressed in Bruch’s membrane of SFD patient 
retinas does not prevent the characteristic neovascularisation (Qi et al. 2009). However here 
we did not find any increase in VEGFR2 on the surface of HUVEC incubated on ECM 
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containing SFD-mutant forms of TIMP3.  Nevertheless, this matrix showed reduced ability to 
inhibit invasion of HUVEC relative to the same matrix containing wild-type TIMP3. As 
virtually all mutations affect the C-domain of TIMP3, the most likely explanation for this is 
that dimerisation about this domain masks the VEGFR2 binding site of TIMP3. The S15C 
mutation in the N-domain is clearly an exception, yet these patients still exhibit CNV 
(Schoenberger and Agarwal 2012).  However, S15C does lie in close proximity to the C-
domain of TIMP3 (Figure 1.14) so it is possible that dimerisation about this residue still 
masks VEGFR2 binding.  This also explains the contradiction between this data and that 
described by Fogarasi et al. (2008), who found that S156C-TIMP3 expressed in bacteria 
retained its ability to inhibit VEGFR2, as that protein was not dimeric. 
Previous studies have shown EFEMP1 to be a binding partner of TIMP3 (Klenotic et al. 
2004).  The pull-down assay data in Chapter 6 demonstrated that mutation of either molecule 
did not inhibit this interaction so that accumulation of one protein, caused by mutation, may 
cause a similar accumulation of its binding partner. Such protein complexes may prevent 
trafficking of nutrients across Bruch’s membrane and hence lead to deposition of other 
protein molecules seen in SFD and ML. As EFEMP1 binds to complement factor H (CFH), 
deposition of TIMP3-EFEMP1 complexes are likely to be accompanied by CFH, potentially 
sequestering this molecule, preventing its ability to regulate complement activation.  
 
8.4 A common pathogenesis mechanism linking SFD, AMD and ML 
Whereas SFD and ML are very rare, AMD is the leading cause of central vision loss in the 
elderly population in industrialised nations, and prevalence increases exponentially with age 
(Owen et al. 2012, Saksens et al. 2014); therefore there is a pressing need for a better 
understanding of the molecular aetiology of this disease.  
Multiple factors seem to link AMD, SFD and ML including phenotypic similarities, the 
accumulation of TIMP3 and EFEMP1 and the fact that EFEMP1 is a binding partner for 
complement factor H, polymorphisms in which are the biggest known risk factor for AMD.  
While accumulation of TIMP3 or EFEMP1 in SFD and ML, respectively, are caused by 
specific mutations, age-related protein modifications, such as oxidation and AGE formation 
may play a role in this accumulation in AMD.  Accumulation of TIMP3, by whatever 
mechanism, is likely to inhibit clearance of damaged proteins from Bruch’s membrane, 
impairing nutrient transport.  If this process also results in sequestration of CFH (Wyatt et al. 
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2013), it is likely to create a low-grade pro-inflammatory environment, which again is 
symptomatic of all three diseases.  
There are of course phenotypic differences between these diseases, with SFD bearing much 
more similarity to wet AMD and ML to dry AMD.  ML also shows a unique mosaic pattern 
of drusen formation. While these differences may be indicative of a different mechanism, 
they could also be explained by the differences in initiating agent.  Mutations in EFEMP1 
initially cause intracellular accumulation of the molecule, potentially also affecting the 
distribution of associated proteins which may then be released as the tissue atrophies.  The 
differences in CNV between ML and SFD could well relate to the fact that, in contrast to 
SFD, any TIMP3 accumulating in ML will still be a functional VEGFR2 inhibitor. 
Additionally, accumulation of these protein complexes may trigger activation of RAGE and 
other pattern recognition receptors, which can increase release of VEGF (Roybal et al. 2005) 
and trigger apoptosis (Howes et al. 2004). Accumulation of mutant EFEMP1 in the 
endoplasmic reticulum also leads to increase VEGF expression by RPE (Roybal et al. 2005). 
 
8.5 Therapeutic implications 
As described earlier in section 1.8, a number of approaches have been used to treat AMD, 
SFD and ML; however the vast majority target the damage caused by choroidal 
neovascularization.  While recent drugs targeting VEGF, such as ranibizumab, have been a 
great success in this respect, they only limit this damage and do not address the geographic 
atrophy that also characterizes these diseases and results in slower but inevitable vision loss. 
As outlined in section 1.8, recent breakthroughs in gene editing have made gene therapy a 
more realistic possibility for treating both genetic and age-related retinopathies, and the eye is 
probably the most treatable tissue in the body in this respect.  However, gene therapy has 
largely failed to live up to expectations over several decades and other treatment options are 
urgently needed to help alleviate the predicted increased burden AMD is set to inflict on 
society. 
The data presented in this thesis strengthen the potential connection between ML, SFD and 
AMD.  If, as postulated, accumulation of TIMP3, EFEMP1 and CFH complexes are an 
important factor in disease pathology, then this suggests that targeting these complexes with 
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drugs that prevent their association and/or trigger their dissociation, may be an important new 
therapeutic target that would have the potential to address both geographic atrophy and CNV.  
 
8.6 Limitation of the project 
The many different functional/molecular targets examined in this project meant that that 
much of the data is still quite provisional and needs further work to draw definitive 
conclusions. Work was hampered by the time taken to successfully establish the many 
different assays required. However, because TIMP3 is such a multi-functional molecule and 
it was unknown which, if any, of these functions might be affected by dimerisation, it was 
thought necessary to take a wide approach.  Nevertheless, it has highlighted a number of 
areas that are ripe for further investigation, particularly where this may lead to the 
development of new therapeutic strategies. 
Work on TIMP3 is greatly hampered by the difficulty in producing significant quantities of 
purified protein, and this is even more problematic for the mutant forms. This is at least partly 
due to relatively low levels of expression, the protein being highly basic and also strongly 
localising to the ECM.  SFD-TIMP3 expressed in bacteria fails to dimerise (Fogarasi et al. 
2008), and as this is almost certainly a prerequisite for disease, bacterial expression is not an 
option.  For this reason, all the work described here was on proteins expressed in situ.  While 
this is a much better reflection of the in vivo situation, it makes it much more difficult to 
clearly establish the molecular mechanisms involved.  Moreover, all cell types examined 
express TIMP3 endogenously to some extent, which can further complicate results.   
There have also been reports that SFD-mutant forms fail to dimerise in some mammalian 
cells, which would further complicate purification of the relevant molecule.  For example, (Qi 
et al. 2009) reported that S156C TIMP3 overexpressed in ARPE19 cells was monomeric and 
(Lin et al. 2006) showed that H158R expressed in HEK293 did not dimerise.  However we 
have shown that both of these proteins form dimers in ARPE19 cells (Langton et al. 2005, 
Mujamammi 2013).  In the case of H158R, it seems the discrepancy is due to the relative low 
levels of expression achieved by those authors, although in our hands dimerisation was less 
pronounced and this may well explain the relatively late age of onset of the disease in these 
patients.  In the case of the S156C mutant in ARPE19 cells this could be explained by the fact 
that the TIMP3 was being detected by using a C-terminal FLAG tag (Qi et al., 2009).  It is 
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quite possible that dimerisation about the C-domain sterically inhibits recognition of the 
FLAG epitope by the antibody.  
 
8.7 Future work 
Although this project has made some progress in understanding the molecular mechanism of 
SFD and indicated possible links to AMD, more precise data are required that will require 
production of significant quantities of purified recombinant proteins. As outlined above, this 
is technically challenging.   
It is also obviously important to be able to determine whether multimeric TIMP3 produced as 
a result of ageing shares similar properties to SFD-TIMP3.  As we have shown here (section 
2.1.9), it is possible to create AGE-modified proteins in vitro but this does require very high 
concentrations of pure protein and this could only likely be achieved by expression in 
bacteria. 
To date production of recombinant TIMP3 in bacteria has required refolding of the protein 
which is produced in an insoluble form.  This may be suitable for AGE-modification but it 
does seem to preclude dimer formation of SFD-TIMP3 (Fogarasi et al. 2008). Functional 
dimeric VEGF has, however, been successfully purified from E.coli inclusion bodies 
(Scrofani et al. 2000) and so it may still be possible under appropriate conditions.  
Production of TIMP3, fused to a protein know to be soluble in bacteria, such as glutathione-
S-transferase or maltose binding protein, may help in this respect, although the redox 
potential inside bacteria is not favourable for disulphide bond formation.  Fusion proteins do, 
however, also have other potential disadvantages with respect to TIMP3 as addition of even a 
single amino acid residue at the N-terminus of the molecule abrogates its MMP-inhibitory 
activity (Langton et al. 2005) and cleavage of most N-terminal fusion proteins leaves behind 
additional amino acids. Even if MMP-dependent functions are not being examined, this 
prevents assessment of correct folding by this means. The alternative of fusion at the C-
terminus would likely inhibit dimerisation of SFD-TIMP3. The small ubiquitin-related 
modifier (SUMO) fusion system offers some advantages in this respect as it is fused to the N-
terminus of the protein of interest and easily removed by SUMO protease to generate native 
protein without leaving any additional residues (Butt et al. 2005) and we have begun to 
explore this possibility in our laboratory. 
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While mammalian cell expression is the obvious alternative, and has been achieved for 
TIMP3 (Apte et al. 1995), protein yields are very low, probably as a result of binding of 
TIMP3 to glycoproteins on the cell surface and there are currently no reports of successful 
purification of SFD-TIMP3 from these cells. 
Another possibility that is being explored in our laboratory is the use of biolayer-
interferometry (Abdiche et al. 2008), using a BLItz machine produced by ForteBio.  This 
enables kinetic analysis of protein interactions in very small volumes.  Moreover, provided 
one of the proteins is available in purified form for immobilisation onto the chip, it is possible 
to get kinetic data from proteins expressed in a cell lysate.  We have successfully detected 




The original hypotheses of this project were: 
1. That all TIMP3 mutations found in Sorsby’s fundus dystrophy result in TIMP3 
dimerisation 
2. These TIMP3 dimers have a toxic effect on cells and trigger similar responses to 
those seen in age-related macular degeneration 
The first of these has been successfully addressed and demonstrates that TIMP3 dimers are 
almost certainly the toxic agent responsible for SFD. 
We have also found that these mutant forms of the molecule can trigger an inflammatory 
response and increase the susceptibility of retinal pigment epithelial cells to apoptotic death, 
both of which are features of age-related macular degeneration.  Additionally, mutation does 
not appear to impair the interaction between TIMP3 and EFEMP1 and accumulation of these 
proteins, is a common feature of SFD, ML and AMD. All of this is circumstantial evidence 
that TIMP3 plays a role in the pathogenesis of AMD, and while it has been shown that 
TIMP3 multimers are indeed observed in AMD (Crabb et al. 2002), this does not prove they 
are a causative agent.  However it is tempting to speculate that, if TIMP3 multimers cause 
SFD, then their presence in a phenotypically similar disease is unlikely to be coincidental.  If 
this is indeed the case, it may lead the way for new therapeutic strategies in the treatment of 
this currently intractable disease.   
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1. Preparation of buffers and solutions  
 
AGE-BSA solution 
AGE-modified albumin was prepared according to Zong et al. (2010) by mixing 50mg/ml 
BSA and 0.5M D-glucose in PBS (pH 7.4). The solution was sterilised using 0.2µm pore 
filter and incubated at 37°C for 2 months. Subsequently the solution was dialysed against 
0.2M sodium phosphate buffer (pH 7.4) followed by passing through endotoxin removing 
column (Detoxi-Gel, Pierce). Aliquots were made and AGEs protein concentration was 
quantified by BCA protein assay.   
 
Ammonium hydroxide (NH4OH) Solution  
To prepare 20mM ammonium hydroxide solution, 70µl of NH4OH stock solution was mixed 
with 50ml water in a fume hood. Then, the diluted NH4OH solution was sterilised using a 
0.2µm pore filter inside a tissue culture class II safety cabinet.  
 
Ammonium persulfate (APS)   
100mg of ammonium persulfate was dissolved in 1ml water to prepare 10% APS solution.  
 
Antibiotics for bacterial culture  
Carbenicillin or kanamycin was used for selection of transformed bacteria depending on the 
selection marker present in the plasmid. Carbenicillin (disodium salt) stock solution, at 
100mg/ml, was prepared in 70% ethanol and stored at -20°C. Kanamycin stock, prepared at 
50mg/ml in water, was sterilised using a 0.2µm pore filter and divided into aliquots that were 
stored at -20°C.  
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Antibiotics for mammalian tissue culture 
Hygromycin B or Geneticin (G-418 sulfate) were used to select stably transfected 
mammalian cells, depending on the resistance gene present in the vector. Geneticin stock 
solution was prepared at 50mg/ml in DPBS then sterilised by filtration and stored at 4°C. 
Hygromycin B was purchased as a sterile stock solution in PBS at 50mg/ml and kept at 4°C 
according to manufacturer’s storage instructions.  
 
Blocking buffer  
5% blocking buffer was prepared by dissolving 2.5mg skimmed milk powder in 50ml of 1X 
TBST buffer.  
 
Bovine serum albumin (BSA)  
Stock BSA solution was prepared at a concentrations of 2mg/ml and stored in 1ml aliquots at 
-20°C.   
 
Bromophenol blue dye  
Bromophenol blue stock solution comprised 1% (w/v) bromophenol blue and 10% (v/v) 
glycerol in water. 
 
5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal)  
20mg X-gal was dissolved in 1ml dimethylformamide to give a 2% w/v stock solution and 
stored at -20°C.   
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CAPS buffer (N-cyclohexyl-3-aminopropanesulfonic acid)  
A 10X CAPS stock solution was prepared by dissolving 22.1g of CAPS powder in 800ml of 
water. The pH was adjusted to 11 using 1M NaOH and the total volume was completed to 
1000ml with water, which was kept at 4°C. To prepare 1X CAPs buffer, 100ml of 10X CAPs 
stock solution was mixed with 100ml methanol and 800ml water.  
 
Carbonate-Bicarbonate buffer 
50mM carbonate-bicarbonate buffer (pH 9.2) was prepared by mixing 4ml of 0.2M sodium 
carbonate solution with 46ml of 0.2M sodium bicarbonate solution and 150ml water.  
 
Cell Tracker dye  
The cell tracker green CMFDA fluorescent dye (5-chloromethylfluorescien diacetate) was 
stored at -20°C and prepared according to the manufacturer’s instructions. The dye was 
warmed to room temperature, briefly centrifuged then dissolved in DMSO at a concentration 
of 10mM. For labelling cells this stock was diluted in serum free medium to give a final 
concentration of 2.5µM.  
 
Diethylpyrocarbonate (DEPC)-treated water (RNA extraction)  
RNase free water was prepared by adding 0.1% DEPC and mixing vigorously before leaving 
to stand for 1 hour at room temperature prior to autoclave. The sterilised stock solution was 
stored at room temperature. 
 
Hypotonic lysis buffers  
Three hypotonic buffers were prepared including Hypo, NP-40 and deoxycholate buffers. 
Whereas Hypo-buffer was prepared by mixing 10mM Tris-HCl and CaCl2 in water, NP-40 
buffer prepared by dissolving 0.25% NP-40 in Hypo-buffer. Deoxycholate buffer was made 
of 50mM Tris-HCl (pH 7.5), 0.1% sodium deoxycholate and water.  





0.5g IPTG was dissolved in 1ml water to give a 20% stock solution that was distributed in 
aliquots and kept at -20°C.  
 
LB Broth  
LB broth was prepared from LB High Salt granules (25g/litre water) as instructed by the 
manufacturer. The solution was sterilised by autoclaving and then stored at room 
temperature.  
 
LB agar plates  
LB agar plates were prepared from LB Agar High Salt granules (35g/ litre water) followed by 
autoclaving. Autoclaved LB agar was allowed to cool in a 50°C water bath and subsequently 
antibiotics such as carbenicillin (100mg/ml) or kanamycin (50mg/ml) were added. The agar 
was aseptically poured into 10cm petri dishes (approximately 15ml/plate). Plates were 
allowed to stand at room temperature for 1 hour to completely set and then stored at 4°C. 
 
Lysis Buffers  
Two lysis buffers were prepared including RIPA lysis buffer and single detergent lysis buffer. 
RIPA lysis buffer (radioimmunoprecipitation assay), consisted of 50mM Tris-HCL (pH 8), 
150mM NaCl, 1% Triton X-100, 0.1% SDS, 2mM EDTA, 50 mM NaF, 0.5% Na-
deoxycholate and 1 protease inhibitor tablet. The final volume of RIPA buffer was made up 
to 10ml and aliquots were prepared and stored at -20°C. Single detergent lysis buffer, a 
stock solution (total volume 10ml) consisted of 10mM Tris-HCl (pH 8), 1% Triton X-100, 1 
protease inhibitor tablet and water, prepared in aliquots (1ml each) and stored at -20°C. 
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6X Orange G (DNA loading dye)  
The stock dye was prepared by mixing 100mg orange G, 15ml glycerol and 35ml water.  
Aliquots were made and stored at 4°C.  
 
4% Paraformaldehyde (PFA) fixation solution 
1.2g PFA was dissolved in pre-warmed 30ml DPBS on a magnetic stirrer inside a fume hood. 
After cooling to room temperature the pH was adjusted to 7. The prepared stock solution was 
stored at 4°C and could be used for 1 week.  
 
Phosphate buffer saline (PBS) 
1 PBS tablet was dissolved in 100ml water to give a solution containing 137mM sodium 
chloride, 10mM phosphate buffer and 2.7mM potassium (pH 7.3-7.5).  
 
 
Recombinant human TIMP3 (rhTIMP3) 
A stock solution of 5ng/µl was prepared by dissolving 10µg rhTIMP3 in 2ml sterile water and 
storing at -20°C.  
 
S100B  
1mg S100B was dissolved in 1ml autoclaved water and subsequently aliquots were prepared 
(100µl each) and stored at -20°C. 
 
SDS sample buffer  
4X SDS and 2X SDS sample buffers were prepared for western blotting. To prepare 4X SDS 
sample buffer, 1g of SDS was dissolved in 2.5ml of 0.5M Tris-HCl (pH 6.8) and 4ml glycerol 
and then the total volume was made up to 10ml with water. Similarly 2X SDS sample buffer 
was made by mixing 4ml 10% SDS, 2ml glycerol and 2.5ml 0.5M Tris-HCl (pH 6.8), and 
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then 4mg bromophenol blue dye was dissolved in the mixture whose final volume was 
completed to 10ml with water.  
 
Sodium phosphate buffer  
A 0.2M stock buffer (pH 7.4) was prepared by dissolving 5.93g NaH2PO4.H2O and 23g 
NaHPO4 in 800ml water. The final volume was completed to 1000ml with water and the 
buffer was stored for up to 1 month at 4°C.   
 
Starving medium   
Two different starving growth media were prepared including 0.5% FBS supplemented 
EBM2 and 2% FBS supplemented DMEM/DMEM F12 and used for HUVEC and 
HEK293T/ARPE19, respectively.  
 
Stripping buffer  
The buffer comprised of 2% SDS, 100mM 2-mercaptoethanol and 6.28mM Tri-HCl (pH 6.7).  
 
50X Tris-acetate-ethylenediaminetetraacetic acid (TAE) buffer  
A stock TAE buffer was prepared at concentration of 50X by dissolving 242g Tris base in 
600ml water and 100ml 0.5M EDTA and 57.1ml glacial acetic acid. The volume was 
completed up to 1000ml with water and then stored at room temperature. Subsequently, 1X 
TAE buffer was prepared by mixing 20ml of 50x TAE with 980ml water. 
 
Tris buffered saline with Tween-20 (TBST)  
To prepare 1X TBST, a stock solution of 20X TBST was initially prepared by dissolving 
6.05g Tris base and 43.8g NaCl in water. Then, the pH was adjusted to 8 and the final volume 
was completed to 250ml. Subsequently, 1X TBST was made by diluting 25ml of 20X TBST 
in 475ml water and adding 500µl Tween-20. 




Vascular endothelial growth factor (VEGF) 
A 100µg/ml stock was prepared inside a class II safety cabinet by dissolving 10µg VEGF in 
100µl DPBS.  The protein was then stored in 5µl aliquots at -20°C. 
 
Water-saturated butanol  
Butanol was saturated with water by vigorously shaking 50ml butanol and 50ml water.  
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Ingredients 10% resolving gel 4% Stacking gel 
dH2O (ml) 4.85 6.36 
1.5 M Resolving gel buffer (ml) 2.5 - 
0.5 M Stacking gel buffer (ml) - 2.52 
4% Acrylamide/Bisarylamide (ml) 2.5 1 
10% SDS (µl) 100 100 
10% APS (µl) 50 50 
TEMED (µl) 5 5 
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3. TIMP3 splice mutant full gene sequence  
 
• Sequence: T3 exons + intron 4 splice mutant + cloning sites 
Range: 1 to 5429 
 
                                >NotI                                   
                                  |                                     
                  >SalI   >EcoRV  |   >HindIII 
                     |       |    |      | 
                    10       |20  |     30        40        50        60 
            GCCGCCGCCGTCGACGATATCGCGGCCGCAAGCTTGCCACCATGACCCCTTGGCTCGGGC 
            CGGCGGCGGCAGCTGCTATAGCGCCGGCGTTCGAACGGTGGTACTGGGGAACCGAGCCCG 
                           ______> 
                           ______> 
 
                    70        80        90       100       110       120 
            TCATCGTGCTCCTGGGCAGCTGGAGCCTGGGGGACTGGGGCGCCGAGGCGTGCACATGCT 
            AGTAGCACGAGGACCCGTCGACCTCGGACCCCCTGACCCCGCGGCTCCGCACGTGTACGA 
 
                   130       140       150       160       170       180 
            CGCCCAGCCACCCCCAGGACGCCTTCTGCAACTCCGACATCGTGATCCGGGCCAAGGTGG 
            GCGGGTCGGTGGGGGTCCTGCGGAAGACGTTGAGGCTGTAGCACTAGGCCCGGTTCCACC 
 
                   190       200       210       220       230       240 
            TGGGGAAGAAGCTGGTAAAGGAGGGGCCCTTCGGCACGCTGGTCTACACCATCAAGCAGA 
            ACCCCTTCTTCGACCATTTCCTCCCCGGGAAGCCGTGCGACCAGATGTGGTAGTTCGTCT 
 
                   250       260       270       280       290       300 
            TGAAGATGTACCGAGGCTTCACCAAGATGCCCCATGTGCAGTACATCCATACGGAGGCTT 
            ACTTCTACATGGCTCCGAAGTGGTTCTACGGGGTACACGTCATGTAGGTATGCCTCCGAA 
 
                   310       320       330       340       350       360 
            CCGAGAGTCTCTGTGGCCTTAAGCTGGAGGTCAACAAGTACCAGTACCTGCTGACAGGTC 
            GGCTCTCAGAGACACCGGAATTCGACCTCCAGTTGTTCATGGTCATGGACGACTGTCCAG 
 
                   370       380       390       400       410       420 
            GCGTCTATGATGGCAAGATGTACACGGGGCTGTGCAACTTCGTGGAGAGGTGGGACCAGC 
            CGCAGATACTACCGTTCTACATGTGCCCCGACACGTTGAAGCACCTCTCCACCCTGGTCG 
 
                   430       440       450       460       470       480 
            TCACCCTCTCCCAGCGCAAGGGGCTGAACTATCGGTATCACCTGGGTTGTAACTGCAAGG 
            AGTGGGAGAGGGTCGCGTTCCCCGACTTGATAGCCATAGTGGACCCAACATTGACGTTCC 
 
                   490       500       510       520       530       540 
            TAAGCTCTGGGGTCACTGGGGGAAGGAGGGGAGGTGCTGACTTGCAGCCCTAGAAACATC 
            ATTCGAGACCCCAGTGACCCCCTTCCTCCCCTCCACGACTGAACGTCGGGATCTTTGTAG 
 
                   550       560       570       580       590       600 
            AGCTCCCAATGCACTGGGTGCCAGGCCCTCGGCTGGGAAGGGTATGCATGTGTTAGGCCA 
            TCGAGGGTTACGTGACCCACGGTCCGGGAGCCGACCCTTCCCATACGTACACAATCCGGT 
 
                   610       620       630       640       650       660 
            GGGCAGAGGGGCAGGTCTGAGCAGATATAGTAAGGATTGTTGCCCCAGGTGGGGCAGTGA 
            CCCGTCTCCCCGTCCAGACTCGTCTATATCATTCCTAACAACGGGGTCCACCCCGTCACT 
 
                   670       680       690       700       710       720 
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            GGAAGGCAGGGAAGGAAGAATGCCTTTCTGCTGTAATCGGCTGCCTCCATGATGACCACT 
            CCTTCCGTCCCTTCCTTCTTACGGAAAGACGACATTAGCCGACGGAGGTACTACTGGTGA 
 
                   730       740       750       760       770       780 
            TGGAAGCTGCTGGGGCATGAGGGCTCTTGAGTCCCTGGCCCCACCTGGCAGTTCAAGGCT 
            ACCTTCGACGACCCCGTACTCCCGAGAACTCAGGGACCGGGGTGGACCGTCAAGTTCCGA 
 
                   >BamHI 
                     | 
                   790       800       810       820       830       840 
            GGAGGTATAGGATCCTGACACTGGCAGGTTCTCCCAAGTGGTTTCAAGTGGGCTCACCCT 
            CCTCCATATCCTAGGACTGTGACCGTCCAAGAGGGTTCACCAAAGTTCACCCGAGTGGGA 
 
                   850       860       870       880       890       900 
            GGTAGCTGACTCATCGCTAACCCCACCCCAGGTAGGCAAATGGGCCCAGGACTGCAGAGA 
            CCATCGACTGAGTAGCGATTGGGGTGGGGTCCATCCGTTTACCCGGGTCCTGACGTCTCT 
 
                   910       920       930       940       950       960 
            CCAGATGCTACAGAAGGTCTCTCTTTACCAGGCCCATCCCCCTGACCCAAGTATAGGGCC 
            GGTCTACGATGTCTTCCAGAGAGAAATGGTCCGGGTAGGGGGACTGGGTTCATATCCCGG 
 
                   970       980       990      1000      1010      1020 
            AAGGTGCAGCCTGCCTGCTGTGGGAGGAAGTTGGGCCATTCTCTCACTTCATCTTCAAAA 
            TTCCACGTCGGACGGACGACACCCTCCTTCAACCCGGTAAGAGAGTGAAGTAGAAGTTTT 
 
                  1030      1040      1050      1060      1070      1080 
            CAGTCCTGTGTGGTTTTAATTACTATGATCTCCATTCTGCAGATGAGAGCTCAGAGAACT 
            GTCAGGACACACCAAAATTAATGATACTAGAGGTAAGACGTCTACTCTCGAGTCTCTTGA 
 
                  1090      1100      1110      1120      1130      1140 
            TAAGTAACTAGCCCTAGGTCCCACAGTTCACTGAATCTGGTTTCCAACCTAGGGCAGCTA 
            ATTCATTGATCGGGATCCAGGGTGTCAAGTGACTTAGACCAAAGGTTGGATCCCGTCGAT 
 
                  1150      1160      1170      1180      1190      1200 
            GACTCCAAAGTTTATGCTCTAACCTTTCTAATTCCTCGATTCCCTAAAACAACTGAGATC 
            CTGAGGTTTCAAATACGAGATTGGAAAGATTAAGGAGCTAAGGGATTTTGTTGACTCTAG 
 
                  1210      1220      1230      1240      1250      1260 
            TCCCACCTGAGACGAAAAAGTCCTCTCAGTAGTCTAATTCTGCTACTTACTGGCTGTGTG 
            AGGGTGGACTCTGCTTTTTCAGGAGAGTCATCAGATTAAGACGATGAATGACCGACACAC 
 
                  1270      1280      1290      1300      1310      1320 
            ACCTGCAGCAAGTTACTTAACCTCTCAGAGCCTCCTAAAACTGTGATAAGAATTAAAGAG 
            TGGACGTCGTTCAATGAATTGGAGAGTCTCGGAGGATTTTGACACTATTCTTAATTTCTC 
 
                  1330      1340      1350      1360      1370      1380 
            AATAATATCAAAGCACTTATCAGAATGTCTGTTAGACAGCAGATGCTCAAGCTAGTGCTA 
            TTATTATAGTTTCGTGAATAGTCTTACAGACAATCTGTCGTCTACGAGTTCGATCACGAT 
 
                  1390      1400      1410      1420      1430      1440 
            TTTATATTATGATCACTGAGGGACTGATGTGGCTAGGCTTCCCATGCAGTGGCCCCAGGG 
            AAATATAATACTAGTGACTCCCTGACTACACCGATCCGAAGGGTACGTCACCGGGGTCCC 
 
                  1450      1460      1470      1480      1490      1500 
            tctgaatccaggctcggtagcctcaggcctgggcataccatggcagagtccatcaactgc 
            agacttaggtccgagccatcggagtccggacccgtatggtaccgtctcaggtagttgacg 
 
                  1510      1520      1530      1540      1550      1560 
            tgcctgttatctaattgcaagATCAAGTCCTGCTACTACCTGCCTTGCTTTGTGACTTCC 
            acggacaatagattaacgttcTAGTTCAGGACGATGATGGACGGAACGAAACACTGAAGG 




                  1570      1580      1590      1600      1610      1620 
            AAGAACGAGTGTCTCTGGACCGACATGCTCTCCAATTTCGGTTACCCTGGCTACCAGTCC 
            TTCTTGCTCACAGAGACCTGGCTGTACGAGAGGTTAAAGCCAATGGGACCGATGGTCAGG 
 
                                                         >KpnI 
                                                           | 
                  1630      1640      1650      1660      1670      1680 
            AAACACTACGCCTGCATCCGGCAGAAGGGCGGCTACTGCAGCTGGTACCGAGGATGGGCC 
            TTTGTGATGCGGACGTAGGCCGTCTTCCCGCCGATGACGTCGACCATGGCTCCTACCCGG 
 
                  1690      1700      1710      1720      1730      1740 
            CCCCCGGATAAAAGCATCATCAATGCCACAGACCCCTGAGCGCCAGACCCTGCCCCACCT 
            GGGGGCCTATTTTCGTAGTAGTTACGGTGTCTGGGGACTCGCGGTCTGGGACGGGGTGGA 
 
                  1750      1760      1770      1780      1790      1800 
            CACTTCCCTCCCTTCCCGCTGAGCTTCCCTTGGACACTAACTCTTCCCAGATGATGACAA 
            GTGAAGGGAGGGAAGGGCGACTCGAAGGGAACCTGTGATTGAGAAGGGTCTACTACTGTT 
 
                  1810      1820      1830      1840      1850      1860 
            TGAAATTAGTGCCTGTTTTCTTGCAAATTTAGCACTTGGAACATTTAAAGAAAGGTCTAT 
            ACTTTAATCACGGACAAAAGAACGTTTAAATCGTGAACCTTGTAAATTTCTTTCCAGATA 
 
                  1870      1880      1890      1900      1910      1920 
            GCTGTCATATGGGGTTTATTGGGAACTATCCTCCTGGCCCCACCCTGCCCCTTCTTTTTG 
            CGACAGTATACCCCAAATAACCCTTGATAGGAGGACCGGGGTGGGACGGGGAAGAAAAAC 
 
                  1930      1940      1950      1960      1970      1980 
            GTTTTGACATCATTCATTTCCACCTGGGAATTTCTGGTGCCATGCCAGAAAGAATGAGGA 
            CAAAACTGTAGTAAGTAAAGGTGGACCCTTAAAGACCACGGTACGGTCTTTCTTACTCCT 
 
                  1990      2000      2010      2020      2030      2040 
            ACCTGTATTCCTCTTCTTCGTGATAATATAATCTCTATTTTTTTAGGAAAACAAAAATGA 
            TGGACATAAGGAGAAGAAGCACTATTATATTAGAGATAAAAAAATCCTTTTGTTTTTACT 
 
                  2050      2060      2070      2080      2090      2100 
            AAAACTACTCCATTTGAGGATTGTAATTCCCACCCCTCTTGCTTCTTCCCCACCTCACCA 
            TTTTGATGAGGTAAACTCCTAACATTAAGGGTGGGGAGAACGAAGAAGGGGTGGAGTGGT 
 
                  2110      2120      2130      2140      2150      2160 
            TCTCCCAGACCCTCTTCCCTTTGCCCTTCTCCTCCAATACATAAAGGACACAGACAAGGA 
            AGAGGGTCTGGGAGAAGGGAAACGGGAAGAGGAGGTTATGTATTTCCTGTGTCTGTTCCT 
 
                  2170      2180      2190      2200      2210      2220 
            ACTTGCTGAAAGGCCAACCATTTCAGGATCAGTCAAAGGCAGCAAGCAGATAGACTCAAG 
            TGAACGACTTTCCGGTTGGTAAAGTCCTAGTCAGTTTCCGTCGTTCGTCTATCTGAGTTC 
 
                  2230      2240      2250      2260      2270      2280 
            GTGTGTGAAAGATGTTATACACCAGGAGCTGCCACTGCATGTCCCAACCAGACTGTGTCT 
            CACACACTTTCTACAATATGTGGTCCTCGACGGTGACGTACAGGGTTGGTCTGACACAGA 
 
                  2290      2300      2310      2320      2330      2340 
            GTCTGTGTCTGCATGTAAGAGTGAGGGAGGGAAGGAAGGAACTACAAGAGAGTCGGAGAT 
            CAGACACAGACGTACATTCTCACTCCCTCCCTTCCTTCCTTGATGTTCTCTCAGCCTCTA 
 
                  2350      2360      2370      2380      2390      2400 
            GATGCAGCACACACACAATTCCCCAGCCCAGTGATGCTTGTGTTGACCAGATGTTCCTGA 
            CTACGTCGTGTGTGTGTTAAGGGGTCGGGTCACTACGAACACAACTGGTCTACAAGGACT 
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                  2410      2420      2430      2440      2450      2460 
            GTCTGGAGCAAGCACCCAGGCCAGAATAACAGAGCTTTCTTAGTTGGTGAAGACTTAAAC 
            CAGACCTCGTTCGTGGGTCCGGTCTTATTGTCTCGAAAGAATCAACCACTTCTGAATTTG 
 
 
                  2470      2480      2490      2500      2510      2520 
            ATCTGCCTGAGGTCAGGAGGCAATTTGCCTGCCTTGTACAAAAGCTCAGGTGAAAGACTG 
            TAGACGGACTCCAGTCCTCCGTTAAACGGACGGAACATGTTTTCGAGTCCACTTTCTGAC 
 
                  2530      2540      2550      2560      2570      2580 
            AGATGAATGTCTTTCCTCTCCCTGCCTCCCACCAGACTTCCTCCTGGAAAACGCTTTGGT 
            TCTACTTACAGAAAGGAGAGGGACGGAGGGTGGTCTGAAGGAGGACCTTTTGCGAAACCA 
 
                  2590      2600      2610      2620      2630      2640 
            AGATTTGGCCAGGAGCTTTCTTTTATGTAAATTGGATAAATACACACACCATACACTATC 
            TCTAAACCGGTCCTCGAAAGAAAATACATTTAACCTATTTATGTGTGTGGTATGTGATAG 
 
                  2650      2660      2670      2680      2690      2700 
            CACAGATATAGCCAAGTAGATTTGGGTAGAGGATACTATTTCCAGAATAGTGTTTAGCTC 
            GTGTCTATATCGGTTCATCTAAACCCATCTCCTATGATAAAGGTCTTATCACAAATCGAG 
 
                  2710      2720      2730      2740      2750      2760 
            ACCTAGGGGGATATGTTTGTATACACATTTGCATATACCCACATGGGGACATAAGCTAAT 
            TGGATCCCCCTATACAAACATATGTGTAAACGTATATGGGTGTACCCCTGTATTCGATTA 
 
                          >EcoRI 
                            | 
                  2770      2780      2790      2800      2810      2820 
            TTTTTTACAGGACACAGAATTCTGTTCAATGCTGTTAAATATGCCAATAGTTTAATCTCT 
            AAAAAATGTCCTGTGTCTTAAGACAAGTTACGACAATTTATACGGTTATCAAATTAGAGA 
 
                  2830      2840      2850      2860      2870      2880 
            TCTATTTTGTTGTCGTTGCTTGTTTGAAGAAAATCATGACATTCCAAGTTGACATTTTTT 
            AGATAAAACAACAGCAACGAACAAACTTCTTTTAGTACTGTAAGGTTCAACTGTAAAAAA 
 
                  2890      2900      2910      2920      2930      2940 
            TTTCATTTTAATTAAAATTTGAAATTCTGAACACCGTCAGCACCCTCTCTTCCCTATCAT 
            AAAGTAAAATTAATTTTAAACTTTAAGACTTGTGGCAGTCGTGGGAGAGAAGGGATAGTA 
 
                  2950      2960      2970      2980      2990      3000 
            GGGTCATCTGACCCCTGTCCGTCTCCTTGTCCCTGCTTCATGTTTGGGGGCCTTTCTTTA 
            CCCAGTAGACTGGGGACAGGCAGAGGAACAGGGACGAAGTACAAACCCCCGGAAAGAAAT 
 
                  3010      3020      3030      3040      3050      3060 
            ACTGCCTTCCTGGCTTAGCTCAGATGGCAGATGAGAGTGTAGTCAAGGGCCTGGGCACAG 
            TGACGGAAGGACCGAATCGAGTCTACCGTCTACTCTCACATCAGTTCCCGGACCCGTGTC 
 
                  3070      3080      3090      3100      3110      3120 
            GAGGGAGAGCTGCAGAGTGTCCTGCCTGCCTTGGCTGGAGGGACACCTCTCCTGGGTGTG 
            CTCCCTCTCGACGTCTCACAGGACGGACGGAACCGACCTCCCTGTGGAGAGGACCCACAC 
 
                  3130      3140      3150      3160      3170      3180 
            GAGACAGCTTGGTTCCCTTTCCCTAGCTCCCTGGTGGGTGAATGCCACCTCCTGAGATCC 
            CTCTGTCGAACCAAGGGAAAGGGATCGAGGGACCACCCACTTACGGTGGAGGACTCTAGG 
 
                  3190      3200      3210      3220      3230      3240 
            TCACCTCTTGGAATTAAAATTGTTGGTCACTGGGGAAAGCCTGAGTTTGCAACCAGTTGT 
            AGTGGAGAACCTTAATTTTAACAACCAGTGACCCCTTTCGGACTCAAACGTTGGTCAACA 
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                  3250      3260      3270      3280      3290      3300 
            AGGGTTTCTGTTGTGTTTTTTTTTTTTTTTTTGAAATAAAACTATAATATAAATTCTCCT 
            TCCCAAAGACAACACAAAAAAAAAAAAAAAAACTTTATTTTGATATTATATTTAAGAGGA 
 
                  3310      3320      3330      3340      3350      3360 
            ATTAAATAAAATTATTTTAAGTTTTAGTGTCAAAAGTGAGATGCTGAGAGTAGGTGATAA 
            TAATTTATTTTAATAAAATTCAAAATCACAGTTTTCACTCTACGACTCTCATCCACTATT 
 
                  3370      3380      3390      3400      3410      3420 
            TGTATATTTTACAGAGTGGGGGTTGGCAGGATGGTGACATTGAACATGATTGCTCTCTGT 
            ACATATAAAATGTCTCACCCCCAACCGTCCTACCACTGTAACTTGTACTAACGAGAGACA 
 
                  3430      3440      3450      3460      3470      3480 
            CTCTTTTTTCAGCTTATGGGTATTTATCTTCTATTAGTATTTGTATCTTCAGTTCATTCC 
            GAGAAAAAAGTCGAATACCCATAAATAGAAGATAATCATAAACATAGAAGTCAAGTAAGG 
 
                  3490      3500      3510      3520      3530      3540 
            ACTTTAGGAAACAGAGCTGCCAATTGAAACAGAAGAAGAAAAAAAAAAAAAGCAGCAGAC 
            TGAAATCCTTTGTCTCGACGGTTAACTTTGTCTTCTTCTTTTTTTTTTTTTCGTCGTCTG 
 
                  3550      3560      3570      3580      3590      3600 
            AACACACTGTAGAGTCTTGCACACACACAAGTGCCCAGGCAAGGTGCTTGGCAGAACCGC 
            TTGTGTGACATCTCAGAACGTGTGTGTGTTCACGGGTCCGTTCCACGAACCGTCTTGGCG 
 
                  3610      3620      3630      3640      3650      3660 
            AGAGTGGGAAGAGAGTACCGGCATCGGGTTTCCTTGGGATCAATTTCATTACCGTGTACC 
            TCTCACCCTTCTCTCATGGCCGTAGCCCAAAGGAACCCTAGTTAAAGTAATGGCACATGG 
 
                  3670      3680      3690      3700      3710      3720 
            TTTCCCATTGTGGTCATGCCATTTGGCAGGGGGAGAATGGGAGGCTTGGCCTTCTTTGTG 
            AAAGGGTAACACCAGTACGGTAAACCGTCCCCCTCTTACCCTCCGAACCGGAAGAAACAC 
 
                  3730      3740      3750      3760      3770      3780 
            AGGCAGTGTGAGCAGAAGCTGATGCCAGCATGTCACTGGTTTTGAAGGGATGAGCCCAGA 
            TCCGTCACACTCGTCTTCGACTACGGTCGTACAGTGACCAAAACTTCCCTACTCGGGTCT 
 
                  3790      3800      3810      3820      3830      3840 
            CTTGATGTTTTGGGATTGTCCTTATTTTAACCTCAAGGTCTCGCATGGTGGGGCCCCTGA 
            GAACTACAAAACCCTAACAGGAATAAAATTGGAGTTCCAGAGCGTACCACCCCGGGGACT 
 
                  3850      3860      3870      3880      3890      3900 
            CCAACCTACACAAGTTCCCTCCCACAAGTGGACATCAGTGTCTTCTCTGTGAGGCATCTG 
            GGTTGGATGTGTTCAAGGGAGGGTGTTCACCTGTAGTCACAGAAGAGACACTCCGTAGAC 
 
                  3910      3920      3930      3940      3950      3960 
            GCCATTCGCACTCCCTGGTGTGGTCAGCCTCTCTCACACAAGGAGGAACTTGGGTGAAGG 
            CGGTAAGCGTGAGGGACCACACCAGTCGGAGAGAGTGTGTTCCTCCTTGAACCCACTTCC 
 
                  3970      3980      3990      4000      4010      4020 
            CTGAGTGTGAGGCACCTGAAGTTTCCCTGCGGAGTCGATAAATTAGCAGAACCACATCCC 
            GACTCACACTCCGTGGACTTCAAAGGGACGCCTCAGCTATTTAATCGTCTTGGTGTAGGG 
 
                  4030      4040      4050      4060      4070      4080 
            CATCTGTTAGGCCTTGGTGAGGAGGCCCTGGGCAAAGAAGGGTCTTTCGCAAAGCGATGT 
            GTAGACAATCCGGAACCACTCCTCCGGGACCCGTTTCTTCCCAGAAAGCGTTTCGCTACA 
 
                  4090      4100      4110      4120      4130      4140 
            CAGAGGGCGGTTTTGAGCTTTCTATAAGCTATAGCTTTGTTTATTTCACCCGTTCACTTA 
            GTCTCCCGCCAAAACTCGAAAGATATTCGATATCGAAACAAATAAAGTGGGCAAGTGAAT 




                  4150      4160      4170      4180      4190      4200 
            CTGTATAATTTAAAATCATTTATGTAGCTGAGACACTTCTGTATTTCAATCATATCATGA 
            GACATATTAAATTTTAGTAAATACATCGACTCTGTGAAGACATAAAGTTAGTATAGTACT 
 
                  4210      4220      4230      4240      4250      4260 
            ACATTTTATTTTGCTAAATCTTGTGTCATGTGTAGGCTGTAATATGTGTACATTGTGTTT 
            TGTAAAATAAAACGATTTAGAACACAGTACACATCCGACATTATACACATGTAACACAAA 
 
                  4270      4280      4290      4300      4310      4320 
            AAGAGAAAAATGAAACCCACATGCCGCCATTTTCCTGAATCAAATTCTGCAGTGGAATGG 
            TTCTCTTTTTACTTTGGGTGTACGGCGGTAAAAGGACTTAGTTTAAGACGTCACCTTACC 
 
                  4330      4340      4350      4360      4370      4380 
            AGAGGAAAATACTTCTAGGCAAGCAGCTAGACTGGTGAATTGGGGGAAATAGAAGGAACT 
            TCTCCTTTTATGAAGATCCGTTCGTCGATCTGACCACTTAACCCCCTTTATCTTCCTTGA 
 
                  4390      4400      4410      4420      4430      4440 
            AGTAACTGAGACTCCTCCAGCCTCCTCCCTATTGGAATCCCAATGGCTCCTGGAGTAGGA 
            TCATTGACTCTGAGGAGGTCGGAGGAGGGATAACCTTAGGGTTACCGAGGACCTCATCCT 
 
                  4450      4460      4470      4480      4490      4500 
            AAAAAGTTTAAACTACATTCATGTTCTTGTTCTGTGTCACTCGGCCCTGGGTAGTCTACC 
            TTTTTCAAATTTGATGTAAGTACAAGAACAAGACACAGTGAGCCGGGACCCATCAGATGG 
 
                  4510      4520      4530      4540      4550      4560 
            ATTTACTTCACCCCAAGTCCTGCTGCCCATCCAGTTGGGAAGCCATGATTTTCCTAAGAA 
            TAAATGAAGTGGGGTTCAGGACGACGGGTAGGTCAACCCTTCGGTACTAAAAGGATTCTT 
 
                  4570      4580      4590      4600      4610      4620 
            TCCAGGGCCATGGGAGATACAATTCCAAGTTCTCGCTTCCTCCTTTGGGCATCTCTTCTG 
            AGGTCCCGGTACCCTCTATGTTAAGGTTCAAGAGCGAAGGAGGAAACCCGTAGAGAAGAC 
 
                  4630      4640      4650      4660      4670      4680 
            CCTCCCAATCAAGGAAGCTCCATGCTCAGGCTCTCAGCTCTCGGGCCAGTGCTCTGCTCT 
            GGAGGGTTAGTTCCTTCGAGGTACGAGTCCGAGAGTCGAGAGCCCGGTCACGAGACGAGA 
 
                  4690      4700      4710      4720      4730      4740 
            GTCCAGGGTAGGTAATACTGGGAGACTCCTGTCTTTTACCCTCCCCTCGTTCCAGACCTG 
            CAGGTCCCATCCATTATGACCCTCTGAGGACAGAAAATGGGAGGGGAGCAAGGTCTGGAC 
 
                  4750      4760      4770      4780      4790      4800 
            CCTCATGGTGGCAACATGGTTCTTGAACAATTAAAGAAACAAATGACTTTTTGGAATAGC 
            GGAGTACCACCGTTGTACCAAGAACTTGTTAATTTCTTTGTTTACTGAAAAACCTTATCG 
 
                  4810      4820      4830      4840      4850      4860 
            CCTGTCTAGGGCAAACTGTGGCCCCCAGGAGACACTACCCTTCCATGCCCCAGACCTCTG 
            GGACAGATCCCGTTTGACACCGGGGGTCCTCTGTGATGGGAAGGTACGGGGTCTGGAGAC 
 
                  4870      4880      4890      4900      4910      4920 
            TCTTGCATGTGACAATTGACAATCTGGACTACCCCAAGATGGCACCCAAGTGTTTGGCTT 
            AGAACGTACACTGTTAACTGTTAGACCTGATGGGGTTCTACCGTGGGTTCACAAACCGAA 
 
                  4930      4940      4950      4960      4970      4980 
            CTGGCTACCTAAGGTTAACATGTCACTAGAGTATTTTTATGAGAGACAAACATTATAAAA 
            GACCGATGGATTCCAATTGTACAGTGATCTCATAAAAATACTCTCTGTTTGTAATATTTT 
 
                  4990      5000      5010      5020      5030      5040 
            ATCTGATGGCAAAAGCAAAACAAAATGGAAAGTAGGGGAGGTGGATGTGACAACAACTTC 
            TAGACTACCGTTTTCGTTTTGTTTTACCTTTCATCCCCTCCACCTACACTGTTGTTGAAG 




                  5050      5060      5070      5080      5090      5100 
            CAAATTGGCTCTTTGGAGGCGAGAGGAAGGGGAGAACTTGGAGAATAGTTTTTGCTTTGG 
            GTTTAACCGAGAAACCTCCGCTCTCCTTCCCCTCTTGAACCTCTTATCAAAAACGAAACC 
 
                  5110      5120      5130      5140      5150      5160 
            GGGTAGAGGCTTCTTAGATTCTCCCAGCATCCGCCTTTCCCTTTAGCCAGTCTGCTGTCC 
            CCCATCTCCGAAGAATCTAAGAGGGTCGTAGGCGGAAAGGGAAATCGGTCAGACGACAGG 
 
                                                           >XbaI 
                                                             | 
                  5170      5180      5190      5200      5210      5220 
            TGAAACCCAGAAGTGATGGAGAGAAACCAACAAGAGATCTCGAACCCTGTCTAGAAGGAA 
            ACTTTGGGTCTTCACTACCTCTCTTTGGTTGTTCTCTAGAGCTTGGGACAGATCTTCCTT 
 
                  5230      5240      5250      5260      5270      5280 
            TGTATTTGTTGCTAAATTTCGTAGCACTGTTTACAGTTTTCCTCCATGTTATTTATGAAT 
            ACATAAACAACGATTTAAAGCATCGTGACAAATGTCAAAAGGAGGTACAATAAATACTTA 
 
                  5290      5300      5310      5320      5330      5340 
            TTTATATTCCGTGAATGTATATTGTCTTGTAATGTTGCATAATGTTCACTTTTTATAGTG 
            AAATATAAGGCACTTACATATAACAGAACATTACAACGTATTACAAGTGAAAAATATCAC 
 
                                                      >XhoI   >NotI 
                                                         |      | 
                  5350      5360      5370      5380     |5390  |   5400 
            TGTCCTTTATTCTAAACAGTAAAGTGGTTTTATTTCTATCACACACTCGAGGCGGCCGCG 
            ACAGGAAATAAGATTTGTCATTTCACCAAAATAAAGATAGTGTGTGAGCTCCGCCGGCGC 
 
           >EcoRV          >AgeI 
             |               | 
             |    5410      5420          
            ATATCGGGCCCGCCGCCACCGGTGCCGCC 
            TATAGCCCGGGCGGCGGTGGCCACGGCGG 
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4. Pull-down vectors  














4.2 pHTC-EFEMP1-HaloTag  
  




4.3 pHTC-TIMP3-HaloTag  
  





4.4 pcDNA3-TIMP3 vector map  
 

































































































































































4.6 pcDNA3-SS-HaloTag-EFEMP1 vector map  
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5. Luciferase reporter vectors 




















































































5.4 pGL4-luc2p/NFKB vector map 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
